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"Although the physicians of all nations, from
the time of Hippocrates to the present, have, by
numberless researches and experiments, made trial
of everything in nature, from the most innocent
drug to the most virulent poison, both in the
mineral and vegetable kingdoms; yet the disease
still baffles the power of physic."
Burrows 17&7.
In the management of malignant disease two major problems re¬
main current and unsolved; the prevention of spread and recrudes¬
cence and the treatment of the advanced case.
The primary tumour may be eradicated by surgery or radiotherapy,
but the patient dies, often after an interval of many years, from the
effects of metastatic disease. The dissemination of viable malig¬
nant cells probably begins within a short period of the inception
of a tumour. Many of these cells fail to survive but those which
do may remain dormant for long periods before certain, little
understood factors, operate to restore their activity. If cancer
is to be controlled then means must be found for preventing dis¬
semination, or for destroying cells whioh have successfully estab¬
lished themselves in secondary sites. The concept of cancer as
a systemic disease requires the application of systemic therapy
■
and this is implied in the use of chemotherapeutic agents. This
1
same idea was expounded by Sir Astley Cooper in 1825 when he said:-
"It behoves medical men to direct their minds to
the trial of the numerous agents which chemistry
and botany have of late abundantly discovered
and simplified ...... and if the operation
be performed for this disease, the surgeon should
never trust solely to the knife, but he must en¬
deavour to alter the constitution which has not
only led to the complaint, but will surely regen¬
erate it, if it remain unchanged."
A few patients with advanced malignant disease may remain al¬
most symptomless and require no special treatment; the terminal
stage /
stage is short and pain and distress are absent or minimal. Others
present an impelling need for treatment; pain is severe and un¬
relenting; ulceration, bleeding,discharge and other distressing
symptoms produce the picture which to many is the epitome of
"cancer". Between these two extremes are the patients in whom
advancing disease results in progressive impairment of health, loss
of appetite and weight, disturbances of normal function and inevit¬
able death. When conventional means of treatment prove inadequate,
or cannot be employed because of the extent of the disease, the need
for effective agents, to control its progress and to relieve sym¬
ptoms, becomes urgent.
'Whetherthe treatment of cancer with the chemical agents at
'
present available is effective, can be considered ethical and can
be carried out without further jeopardising the patient's course,
remairPa matter of controversy. Some consider that cancer chemo-
2
therapy is unjustified, on the basis that good results are only
obtained in a small percentage of patients at the expense of pro¬
ducing severe toxic effects and often death in a large proportion
of those treated. It has also been stated that the use of cyto¬
toxic agents may speed the advance of certain tumours by reducing
3
the effectiveness of the host response to the tumour. The risk
of producing overwhelming intercurrent infection from severe
depression of the bone marrow is advanced as a further argument
against the employment of chemical agents in the management of
cancer. While it is accepted that the results of using
anti-cancer /
anti-cancer drugs are poor, a few dramatic and worthwhile responses
are nevertheless obtained and, in many cases, symptomatic relief is
afforded for at least a few months. The chemotherapy of oanoer is
very much where the chemotherapy of tuberculosis was twenty-five
years ago; the agents available were crude, their side-effects
severe and the outcome of treatment uncertain.
The problem of cancer is infinitely more complex than that of
tuberculosis, but the steady conquest of this and other diseases by
the advent and widespread use of effective ohemotherapeutic agents
is sufficient encouragement to continue the search for agents ef¬
fective against cancer. Whether or not such agents will be dis-
k
covered in the immediate future is uncertain, but as Walshe, in
18^6, said, "nothing can be more unphilosophical than to conclude
that a cure does not exist because it has not yet been found."
It, therefore, remains necessary for interested clinicians to ex¬
plore the use of those drugs currently available and to obtain a
detailed knowledge of their nature, range and duration of action,
indications and toxic effects. The majority of human tumours
cannot be cultured and since the laboratory animal can in no way
substitute for the clinical problems that present in the management
of human cancer, chemotherapy will remain a field in which clinical
investigation must precede laboratory confirmation. The behaviour
of two apparently identical tumours, in patients of the same age
and sex, may be entirely different. Pew observations in one patient
can be directly translated to the management of a tumour in another
patient. /
4.
patient. Only by the careful collection and collation of informa¬
tion obtained from a number of patients, treated over protracted
periods, is it likely that any advances in applied cancer theiao-
5
therapy will be made.
The management of advanced malignant disease by drugs is
complicated by the intangible human problems associated with this
6
disease. As William Osier said "... the practice of medicine is
an art, not a trade: a calling not a business: a calling in which
your heart will be exercised equally with your head." It is easy
for both doctor and patient to be biased in their assessment of
response to apy particular line of treatment and objective means of
assessment are essential. The burden of uncertainty must be
shared, often for many months, by patient, relatives and doctor alike,
while the effort is made to stave off an inevitable death.
Those undertaking the management of malignant disease by
chemotherapeutic agents require an optimistic outlook to overcome
the disappointments which follow their use. It is believed, how¬
ever, that worthwhile remission can be obtained in some eases and
it is these which should prompt the continued use of cytotoxins.
Their use requires selection, care, consideration, time and a
sympathetic awareness of the human problems involved. This study
is an attempt to illustrate these points.





"Here numbers of cases, however, mean little.
It is what is done with the few that actually
counts, and numbers, even though they add to person¬
al experience, may in reality prove a handicap to
the advancement of knowledge by absorbing the time
which might otherwise be spent in assuaging curiosity."
7
Harvey Gushing.
The aim of this investigation was to study, in depth, the
application of chemotherapeutic agents to the management of cancer,
in a small number of patients, carefully followed up to the time of
death or for a minimum of six months from commencing treatment.
The investigation was based on the following considerations
1. That the cytotoxic agents at present available have a
definite part to play in the management of malignant
disease.
2. That their clinical application and assessment must
frequently precede laboratory investigation.
3. That their effects on the metabolism of normal and malig¬




4. That the toxic effects of the agents at present available
can be minimised and need not contra-indicate their
use.
5. That the present methods of assessing response to the
cytotoxic agents are unsatisfactory.
6. That there are a number of problems, such as the effeots
on "immunity mechanisms" and red coll survival time
which justify study in relation to the use of cyto¬
toxic agents.
The results obtained farm the basis of this thesis.
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HISTORICAL REVIEW
"In criticizing the ignorance of the dark ages
or the middle ages, modern writers often forget how




To understand the present position of cancer chemotherapy and
to assess the effectiveness of the agents available, it is necessary
to review briefly the steps leading up to their discovery and use.
a) Early Concepts ' Arsenicals and Galenicals
The concept of treating cancer by chemicals is by no means
new. The efficacy of lead and arsenic in the control of certain
superficial cancers mis known to Paracelsus, Hippocrates and Galen.
Many of the remedies employed at this time, such as dried lizard
3kins, coal and extracts of hemlock, deadly nightshade and other
herbs, were entirely emnirical and the results rarely justified the
4,13,14. 15
extravagant claims. The use of pastes, ointments and escharotics,
containing varying proportions of arsenic, lead or zinc, was vigor¬
ously pursued by "quacks" who toured Europe and this country pro¬
claiming the wonders of their various cures, few of their extra¬




the use of these preparations can be found in the literature as late
16
as 1926,
b) Cancer as a Systemic Disease : the Alley-latin# Agents
The treatment of superficial, accessible tumours was well
established by the late 18th century, but the problems of managing
internal cancer by chemicals had to await the acceptance of cancer
as a systemio disease and the development of les3 toxic agents.
17 1
Hunter, Astley Cooper and others supported the belief that "cancer
is mare than a local disease" and that its control or "cure" re¬
quired the use of systemic remedies. It was not until the early
20th century, however, that systemic cancer chemotherapy became a
possibility with Shrlich's discovery of the sulphonamides and
salvarsan and the incidental observations that these drugs possessed
a cytotoxic effect.
The vesicant and haemopoietic effects of nitrogen mustard gas
in man had been noted in the First s/orld .Var. The possible appli¬
cation of mustard gas to the treatment of leukaemia and malignant
18
disease was investigated, in the laboratory, by Adair and others in
the 1930's but thi3 work was largely overlooked. Hot until the
Bari Harbour disaster in 1941, in which a troop ship, carrying one
hundred tons of nitrogen mustard gas, was sunk, was further intensive
study carried out. Many of the survivors of this incident demon¬
strated severe bone marrow depression particularly affecting the
white cell series and platelets. This effect was attributed to
the /
9.
the absorption of nitrogen mustard through the skin or from the
alimentary tract of those swallowing the contaminated sea water.
As a result of the subsequent researches, largely carried out in
19,20 21
secret by Oilman and Philips and by Rhoads and others in America,
nitrogen mustard was introduced in 1945 in the management of
leukaemia and malignant disorders of the reticulo-endotuelial
22,23
system. It was immediately recognised as a powerful, but highly
toxic agent which still has a part to play in the management of
certain malignant conditions, suoh as Hodgkin,s Disease and lympho¬
sarcoma.
c) Rational Research: the Anti-metabolites
Some of the most exciting steps in the search for anti-cancer
24
agents followed the observation by Paber, in 1947? that the pro¬
gress of acute leukaemia in children was accelerated by using the
folic acid conjugate pteroyl diglutamic acid. That folic acid was
present in large amounts in the cells of certain tumours,had been
known for some years. Folic acid could also bo antagonised in the
laboratory and by further research anti-folio acid agents were iso-
lated which could be used in clinical trials. The most effective
of these was amethopterin (methotrexate) and in 1948 Faber pub-
.
lished his first results in the management of acute leukaemia of
childhood using this agent. From this has developed the most fruit-
ful and most rational line of research in cancer chemotherapy. A
number of "anti-metabolites" effective against a wide range of
malignant /
10
malignant disorders has been discovered as a result of intensive
25
search. These agents, specifically designed to antagonise various
essential components of cell metabolism include the anti-purine,
6-mercaptopurine, the anti-pyrimidine, 5-fluouracil and the anti-amino
acid, azaserine. Although most effective in the management of the
malignant disorders of the haemopoietic and reticul©-endothelial
system, certain of the anti-metabolites are also of value in treating
solid tumours.
d) Serendipity and Smnirioal Research: the .antibiotics and Plant
Product??
It has been known for sixty years that colchicine ^ produced
depression of the bone marrow, but at clinically effective levels is
highly toxic. Largely as a result of empirical research, a number of
cytotoxic agents, derived from moulds and plants, have been dis-
covered in recent years. The work of Waksman and Woodruff (194°)
on the identification and isolation of Actinomycin from soil micro¬
organisms, paved the way for the isolation of agents possessing
cytotoxic activity of clinical value frcaa other varieties of mould
(Hithromycin; Mitomycin) and from plants such as the Periwinkle,
27 28
Vinca Rosea * (Vinblastine sulphate; vincristine sulphate). These
are most effective in malignant diseases of the haemopoietic and
reticulo-endothelial systems, but a few are of value in the manage¬
ment of solid tumours.
e) Present Position and Future Prospects
Gfreat strides have been made in the search for suitable cytotoxic
agents /
11
agents and the early days of arsenic, lead and coniua are now remote.
Despite this progress the ideal agents have^ot been found and their
immediate discovery cannot be anticipated. Those at present avail¬
able have a narrow range of activity, may produce severe and occas¬
ional fatal toxicity, are unpredictable in their effects and usually
produce remissions which are incomplete and short-lived. A few
dramatic and prolonged remissions, however, are obtained and in
chorion carcinoma occasional "cures" are reported. The use of drug
combinations, prophylactic chemotherapy and intra-arterial adminis¬
tration require further study.
Extensive research continues in America, this and other countries
for new agents. In the United States of America, the Cancer Chemo¬
therapy National Servioe Center organises and co-ordinates research
on a gigantic scale and it is estimated that fifty thousand chemical
31
substances are screened each year for anti-tumour effect. Of these,
only a very few reach the stage of concentrated research and only
one or two each year reach the stage of clinical trial. The likeli¬
hood of a new agent even then being more effective and less toxic
than those already available is slight. This continued research,
however, embodies the principle hope of these concerned in the
management of malignant disease; its control and final eradication.
In 1867, Langston Parker expressed the opinion that "we are at
the eve of a discovery for the arrest or perhaps the cure of cancer."
One hundred years later, this is still an overstatement, but the
possibility exists that current research will validate this view.
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TABLES I - VI
Pages 12 - 51
TABLE r
THE CHEMOTHERAPY OF CANCER
SYNOPSIS OF CASES TREATED
TOTAL = X07 : I «
Case Initials Age Sex Primary Tumour i rroup Total
No. Cases
1 J.G. 23 F Hodgkins Disease A
2 P.0*S. 39 M ft ft A
3 G.R. 26 M ft ft A
4 J.B. 19 M ft ft A 7
5 W.McG. 50 M ft ff A
6 G.C. 22 M ft ft A
7 R.P. 17 M tt »t A
8 A.A.W. 53 M Carcinoma of Lung B
9 J.C*G. 39 M Carcinoma of Larynx B
10 T.A.N. 43 M Carcinoma of Lung B
11 L.W.T. 50 M tt tl ti B
12 H.S. 36 M tt ft n B
13 J.P. 65 M ft If n B
34 A.M. 46 M ft tt n B
15 A.H.P. 32 M t* ft 11 B 15
16 E.J.W. 49 M ft l» n B
17 J.S.W. 50 M ff ft •1 B
18 A.McL. 43 F ft If •t B
19 A.L.F. 37 M It tf n B
20 R.J.C. 51 M ft It n B
21 M.W. 56 F ft ft it B
22 J.M. 61 M fl tt n B
23 T.W. 27 M Lymphosarcoma C
24 T.H.W. 47 M II C 3
25 D.T.W. 47 M If C
26 B.H.W. 38 M Leukaemia D
27 T.M.P. 18 M ft D 1,
28 M.C.C, 6 M tt D
29 L.F.C, 21 M ft D
30 H.E.V. 50 M Myeloma E 1
TABLE X (continued)
THE CHEMOTHERAPY OF CANCER:
Case Initials Age Sex Frimary Tumour Group Total
No. Cases
31 E.B. 48 F Carcinoma of Breast F
32 M.C. 36 F It tt tt F
33 D.B. 50 F tt tt tt F
34 F.M.P. 43 F ft ft tt F
35 M.G. 52 F ft ft tf F
36 D.N. 36 F ft tt tt F
37 F.H. 42 F tt ft tt F
38 M.M.D. 53 F ft tt ft F
39 M.P. 42 F ft tt ft F
40 F.S. 39 F tf tt ft F
41 B.S. 43 F ft ft tt F 22
42 I.F. 53 F tt tt It F
43 V.L. 67 F ft tt tt F
44 M.McD, 47 F ft tt ft F
45 L.B. 38 F It tt tt F
46 B.K. 42 F ft It tt F
47 M.G. 67 F tt ft Tt F
48 A.W. 63 F It tf ft F
49 M.O. 44 F tt tt tf F
50 M.S. 63 F ft ft tt F
51 M.K. 50 F ft tt tt F
52 s.o. 64 F tt It II F
53 J.M.H. 41 F Carcinoma of Ovary G
54 A.E. 39 F »f tt ft G
55 D.M. 46 F n tt It G 6
56 S.G. 42 F tt It ft G
57 M.C. 70 F it tt tt G
58 F.H. 60 F it tt tt G
59 D.H. 30 M Testicular Tumours H
60 T.T. 30 M ft tt H
61 B.A. 49 M ft ft H 5
62 A.J.I. 22 M ft tt H
63 M.W.F. 25 M ft ft H
64 H.F.S. 40 M Renal Carcinoma I
65 V.M.A. 49 F If tf I
66 J.W. 66 M tt ft I 5
67 J.C. 60 M ft tt I
68 H.S. 53 F tt tt I
TABLE T (continued)
THE CHEMOTHERAPf OF CANCER
Case Initials Age Sex Primary Tumour Group Total
No. Cases
69 W.K. 70 M Carcinoma of J 1
Bladder
70 T.P. 59 M Carcinoma of K 1
Prostate
71 J.R. 43 M Carcinoma of L
Adrenal Gland 2
72 O.K. 26 F w it It L
73 A.A.C« 45 K Carcinoma of M
Oesophagus 2
74 sr.A.p. 33 M If t» ft M
75 R.B.H. 42 M Carcinoma of N
Stomach
76 T.H. 58 M H H II N
77 W.M. 64 M If ft ft N
878 I.M. 69 F II If ff N
79 R.C. 66 M ft II rt N
80 E.C. 71 M H II it N
81 P.D. 63 M it »i it N
82 A.W. 58 F it if ft N
83 J.N.S. 32 M Carcinoma of 0
Colon and Rectum
84 I.L. 22 F ft If II ft 0
85 A.M.T. 52 M If It II ft 0
86 E.R.W. 50 M ft If II If 0
87 A.W.S. 53 M II If II II 0 9
88 E.M.H. 39 F II If It II 0
89 E.D. 35 F If If it n 0
90 P.W.N. 44 M ft If II K 0
91 R.G. 59 V If ft tl If 0
92 P.H.R. 62 F Carcinoma Of p
Pancreas
93 E.L. 48 F If ft II p 4
94 J.K. 65 M rt it II p
95 J.T. 59 M If t! II p
TABLE X (continued)
THE CHEMOTHERAPY OF CANCER
Case Initials Age Sex Primary Tumour Group Total
No. Cases
96 R.G.C « 52 M Malignant 0
Melanoma TL
97 M.S. 50 F ft ft Q J
98 J.S. 65 F If ft Q
99 C.J.B. 46 M Carcinoma of R
Unknown Primary
100 J.A. 24 M tt It ft R 4
101 J.McI. 54 F f» ff H R
102 J.W. 35 M •I ft If R
103 S.L.P. 37 M Others S
104 D.L.O. 42 M ft S
105 J.S.7/. 53 M tt S 5
106 M.M.A. 45 F « S






(i) Nitrogen mustard (Mustine)
(ii) Cyclophosphamide
(iii) Phenyl-alanine mustard (Melphelan)




















n PRINCIPAL AGENTS USED (continued)





















METHODS OF APPLICATION USED
1. Propl\ylaotic against spread or implantation
2# As an adjunct to radiotherapy or surgery
3. In advanced disease when other measures
already tried or not applicable
In each case anti-cancer drugs were used:*
(a) Singly or in combination
(b; In intermittent or continuous courses
TABLE IV
CHEMOTHERAPY" OF CANCER


















(c) Erythrocyte sedimentation rate
(d) Total white cell count
(e) Differential white cell count
(f) Platelet count
(g) Bone marrow examination
2# Biochemistry




(iv) Zinc sulphate turbidity
(v) Serum glutamic oxalic transaminase




(c) Serum uric acid
3. Radiolo;y
(a) Routine diagnostic investigations
(b) Chest
(c) Pelvis and spine
(d) Serial X-rays of metastatic sites



















3, Red-cell survival studies
12.
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Synopsis of Principal Agents Used.




a) NATURE AND SOURCE OF MATERIAL
A total of 107 patients (62 male and 45 female) with histo¬
logically proven malignant disease and all receiving cytotoxic thera-
py, were studied. Details of distribution by age, se;: and tumour
groups are contained in Table 1.
These cases were studied in the period July 1962 to September
1965, first at the Royal Air Force Hospital, Uxbridge, Middlesex
(July 1962-March 1964) and subsequently in the University Department
of Clinical Surgery and Royal Infirmary of Edinburgh (April 1964-
Septamber 1965). They represent approximately half of the cases
receiving cytotoxic therapy in the two centres during this total
period. The remainder did not fulfil the necessary criteria for
inclusion.
13.
b) PRINCIPAL Afc^S AVAILABLE
Of the many chemical agents now available for treating cancer
only a very few are of real value. These may be classified in
four main groups:
1, The Alkylating Agents,
2. The Antimetabolites,
3, The Antibiotic and Plant Products,
4. The Hormones.
A further group of drugs which do not fit into any of the




The alkylating agents are distinguished by their ability to
combine with reactive molecules, within the nuclei of cells,in such
a manner as to destroy normal cellular metabolism. It is believed
that this process of alkylation occurs through the medium of short
carbon chains which form abnormal linkages between the various
reactive sites, particularly those related to the nucleic acids of
the cell nucleus. In view of the important role played by the
nucleic aoids in cell reproduction, it is reasonable to assume that
interference with the formation of nucleic acids is the basic
action of this group of drugs. Exactly how alkyl tion operates to




The alkylating agents are among the oldest of the chemo-
therapeutic drugs in use in the treatment of malignant disease
and many of the earlier agents are still of value. They, there¬
fore, constitute the b&st-known group of anti-cancer drugs.
The drugs in this group closely resemble each other in their action,
side effects, and in the nature, degree and duration of response
obtained. The four important sub-groups are
I. The nitro.-cen mustards, of whioh the best-known
examples are nitrogen mustard itself (liustine),
cyclophosphamide and phenylalanine mustard
(melphelan).
II. The ethvlino amines, of which triotbylenethio-
phosphoramide (thiotepa) is the prototype.
IH. The sulnhonic acid esters, represented by Busulphan
(myleran).
IV. The epoxides. of which ethoglucid (epodyl) is the
principal agent of clinical value.
These preparations are particularly toxic to the bone marrow,
and, in varying degree, cause gastro-intestinal disturbances
such as nausea, vomiting and diarrhoea. Apart from a few ex-
t
oeptions, far example nyleran, which is much more toxic to granu¬
locytic than to lymphocytic precursors, the concept of a specific
agent for treating a specific tumour is not valid for this group as
a whole. If a tumour does not respond to one alkylating agent, it
is /
is unlikely that it will respond to another. If recrudescence of
the tumour occurs after satisfactory response to one agent, it is
unlikely that further remission will be obtained if another alkyla¬
ting agent is used.
In that the alkylating agents are cytotoxic, mutagenic and
most active against cells in the process of division, they may be
described as radiomimetic. This is, however, a meaningless term
f
since those tumours most likely, to be affected by radiothei»apy,
cryotherapy, or hormone therapy are also most likely to be af¬
fected by chemotherapy.
The duration of response to these agents is usually short
and frequently incomplete. They nevertheless represent the most
generally useful group of drugs for the treatment of solid tumours.
Their toxicity to bOne marrow and gastro-intestinal muoosa limits
the extent of this usefulness.
* « » -i i • j. 5,24,34,35,36.2. /antimetabolites
The antimetabolites constitute a group of anti-cancer agents
with the common property of accurately substituting for a normal
constituent of cell metabolism. By being incorporated in a counter¬
feit manner far normal constituents, they interfere with nucleo-
protein synthesis and, therefore, with cell division, again lead¬
ing to cell death. They may compote with a normal metabolite,
either by a greater affinity for the reactive molecules, or by
being present in greater amount. They may directly inhibit the
aotivity /
16.
activity of an enzyme essential to nucleo-protein synthesis or be
incorporated into abnormal molecules which in turn will lead to
interference with cell metabolism and death.
The antimetabolites represent the best example of rational
thought and research applied to the development of chemical agents
for the cure of cancer. Much ingenuity has been applied to the
design of new antimetabolites with the result that this has been
the most productive line of research. By various, often minor,
chemical modifications, substances have now been made available
which will compete with essential cellular metabolites, such as
folic acid, the purines, pyrimidines, and amino acids. Many other
specific antagonists are also available but thoy do not differ¬
entiate sufficiently between normal and tumour cells to be of
clinical use. Each of the four main groups of the antimetabolites
is represented by one better known agent. The anti-vitamins or
anti-folic acid agents by methotrexate, the antipurines by
6-mercaptopurino, the antipyrimidines by 5-fluorouracil and the
anti-amino acids by azaserine.
The antimetabolites are of greatest value in the treatment of
the leukaemias and malignant disorders of the reticuloendothelial
system. With the exception of 5-fluorouracil, they are of very
little value in the management of solid tumours. This drug is
peculiar in its action on well-differentiated gastro-intestinal
36
tumours, particularly those of the colon.
Apart /
17
Apart from their effects on the bone marrow, these agents,
as a group, commonly give rise to severe oral ulceration and
bleeding. They also cause nausea, vomiting, and skin rashes.
The length of remission obtained by the use of antimetabolites
varies from a few weeks to a few months but is seldom longer than
six months. The degree of remission may, however, be remarkable
and the rapidity of its onset dramatic.
26,27.
3. Antibiotics end Plant Products
In recent years, certain antibiotic and plant products have
been shown to possess varying degrees of anti-turnour activity.
A few of these agents have entered into clinical use and are of
a
value in the management of' narrow range of malignant disorders.
Of the antibiotics, the Actinomycins, particularly Actinomycin
37
D, have proved of greatest value. This agent, in combination with
radiotherapy, is effoctive in treating neuroblastoma of childhood
and rapidly growing sarcomas, such as rhabdomyosarcoma. Sinoe,
however, these conditions are uncommon, the applications of this
drug are limited.
27
Of the plant products, the alkaloids of the Periwinkle such as
Vinblastine sulphate (velbe) and Vincristine sulphate are the best-
known. They are of most value in the management of the malignant
reticuloses but also have a limited application in the treatment of
solid tumours.
Gastro-intestinal and haematological side effects are common,
despite /
18.
despite the fact that certain of them are used in very small doses.
Their mode of action is uncertain; they are grouped entirely on
the basis of their origin, and not on any common mode of action.
It is believed that they principally act as antimetabolites, again
interfering with essential enzymatic processes within the cell.




The use of oestrogens and androgens in the treatment of
advanced carcinoma of the breast and prostate is too well established
to require emphasis. These agents are frequently employed as
adjuncts to surgery or radiotherapy and if remission is obtained it
is of greater duration, more complete and freer of side effects than
the remission obtained with any of the other anti-cancer agents.
Despite this unique position, it is generally accepted than the
hormones are not included in the detailed discussions of cancer
chemotherapy. V/hile they will be discussed in context through¬
out this study, they are largely excluded from the analysis of the
results obtained by treating cancer by chemical agents.
In a similar manner, the steroid hormones, of great value in
the management of the leukaemias and malignant reticuloses will be
discussed in context, but are not considered in detail.
5. Miscellaneous Agents /
19.
5. Miscellaneous Agents
Many of the drugs in this group, such as arsenic, urethane
and lead, belong essentially to the history of cancer chemotherapy.
Colchicine, a powerful metaphase Inhibitor, has been combined with
an alkylating agent, similar to thiotepa, to form Thiocolciran,
This agent is of value in treating certain gastro-intestinal tumours
but causes considerable toxicity.
39
c) SYNOPSIS OF PRINCIPAL AGgKTo USED
1. ALKYLATING AGBHTS
5,20,21,22
a) Nitrogen Mustard (aethylbis (beta-ohlcrethyl)amine
hydrochloride. Mustine;
Nature and mode of action.- One of the earliest available
agents, nitrogen mustard, is a water-soluble, crystalline powder
which rapidly deteriorates after going into solution and must be
given immediately. It contains two active alkyl radicals which are
able to react with many cell constituents,producing abnormal cross-
linkages and preventing the chains of deoxyribonucleic add from
dividing,
Haemopoletic and other effects.- There is a progressive
and sometimes severe fall in polymorph, lymphocyte and platelet
count commencing within 24 to 36 hours of giving nitrogen mustard,
reaching a maximum between 10 and 15 days. The haemoglobin falls
by /
20.
by 10 to 20 points within 8 to 16 days. If no further treatment iB
given, these effects persist for three to ten days and then slowly
reverse. It has a powerful vesicant action on tissues, producing
.
induration and indolent ulceration at sites of accidental, extra-
vascular injection. Nausea and vomiting are common and occasion¬
ally severe.
Indications.- Of most value in the malignant disorders
of the reticulo-endothelial system and blood-fcanning tissues, it is
also effective against tumours of the breast, ovary end lung.
Doses and administration.- The recommended dose is 0.4 mg.
per Kg, of body weight, given well-diluted by intravenous injection
or continuous infusion. It can also be given by intra-cavitary
40
instillation to control serous effusions,when the dose used is be-
tween 15 and 30 mg. per Kg. of body weight. Treatment is best
accompanied by an anti-emetic such as chlorpromasine or promazine.
b) Cyclophosphamide (N.N-bis(B-Chlorethyl)-H. 0-proovlene-
ohosphorio acid ester caaoide monoto/urate 5ndoxanT"5,41
Nature and mode of action.- This agent, first synthe-
sised in 1957, is presented in the form of a water-soluble white
crystalline powder in 100 and 200 mg. vials and as 50 mg. oral
42
tablets. Arnold and Bourseaux (1958'' first reported on the action
of cyclophosphamide. This action depends on the attachment of a
phosphorus atom to the alkylating groups so that those are liberated
locally /
21.
in the tumour cells, at the 3ite of high phosphatase activity.
The general effect on normal tissues is thereby reduced.
Haemopoietio and other effects.- With small doses the
effects on the haemopoietio system are mild,while the platelets
.
remain unaffected by even high dosage. Prolonged treatment re¬
sults in progressive fall in white cell count and haemoglobin
which may take weeks or months to reach a maximum. These effects
can be dramatically produced, however, by the use of large dose
infusions. On withdrawal of treatment the effects on the haemo-
poietic system are reversed within 10 to 20 days and bone marrow
depression is seldom complete. Alopecia, a dry scaly skin,
brittleness of the nails, nausea and anorexia are the most import¬
ant additional effects. They usually disappear with dose re¬
duction or withdrawal of the drug.
Indications.- Cyclophosphamide is of particular value in
treating carcinomas of the breast, ovary and lung. It is also of
benefit in certain other tumours, including those of the gastro¬
intestinal and genito-urinary tracts.
.
Dosage and administration.- An oral dose of 100 to 150 rag.
daily is usually well tolerated. Single intravenous or intra¬
cavitary injections of 200 to 600 mg. produce little disturbance
although the higher dosage should be combined with an anti-emetic
such as chlorpromazine. When used by intravenous or intra-arterial
infusion /
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infusion a dose of 2.000 tag, over a period of 24 hours gives maximal
benefit •with minimal discomfort. The optimal maintenance dose
must be established by continuous monitoring of peripteral blood
count, but very large total doses may be given in some cases.
c) Phenyl-alanine Mustard (p-di(2 chloroetlyyl)amino-L-
phenvlalanine. Melphelon)
Nature and mode of action.- Tliis compound was first syn-
thetised independently by Bergel and Stock M 1953 in this country
and by Larioncar M 1955 in Russia. It is presented in 5 nig. tablets
for oral administration and more recently has become available as an
oily solution for intramuscular injection,in 2 ml. ampoules. By
combining phenylalanine with active alkylating groups, these are
released within the malignant melanoma cell by the incorporation of
phenylalanine in the production of melanin.
Haemopoietic and other effects.- The effects on the
haemopoietic system are marked. A severe reduction in white cell
count and haemoglobin occurs within 10 to 12 days of commencing treat¬
ment, persists for 14 to 21 days and only slowly reverses. Nausea,
vomiting and bucco-labial ulceration are also common.
Indications.- By its chemical nature this agent is de¬
signed for the treatment of malignant melanoma and is the drug of




Dosage and ackdnistration. - Five to 10 mg. should be
administered by mouth daily to a total dose of 50 to 100 mg. For
.
intravenous infusion or intra-arterial perfusion a dose of 25 to
50 mg. produces a good and occasionally dramatic response in a few
cases, but leakage of drug into the general circulation may cause
severe bone marrow and other effects#
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d) Mannitol Mustard (Degranol)
Nature and mode of action.- This substance is available
in 100 mg. ampoules for intra-venous or intra-arterial injection
and more recently has been produced in 100 mg. tablets for oral
administration. It acts both as an alkylating agent and. by virtue
of the mannitol fragment, as a metabolic blocking agent. This and
uracil-mustard are examples of dual antagonists.
Haemopoietic and other effects.- The effects of Degranol
on the haemopoietic system. are similar to those of nitrogen mustard,
but a marked, persistent and sometimes fatal marrow depression may
develop as late as 30 to 100 days after commencing treatment and
thus renders the use of this drug hazardous. uiorexia, nausea and
vomiting are also marked but can usually be controlled with anti¬
emetics.
Indications.- The use of mannitol mustard is indicated in




Dosage and administration.- The intravenous or intra¬
arterial dose is 2 to 3 mg. per Kg. of body weight to a maximum of
1,000 to 1,500 rag. This total dose may be given as a single intra¬
venous infusion over a period of 24 to 36 hours, but should be ac¬
companied by the use of sedatives or anti-emetics. An oral dose of
100 to 300 mg. per day may be continued for 10 to 30 days but constant
attention must be paid to the peripheral blood count. This agent may
also be administered by intra-cavitary instillation in a dose of
100 to 500 mg.
e) Chlorambucil (p-(di-2-chloreth.vl)anino-phenvlbutvric acid.
Leukeran j 47
Nature and mode of action.- This weak allylating agent is
xuuC 6"
available in 2,mg. tablets for oral administration. Chlorambucil
4:
was first synthesised by Everett, Roberts and Ross in 1953.
■
Haemoooietio and other effects.- This agent is much less
toxic than nitrogen mustard. Depression of white cell count and
haemoglobin usually occurs within 14 to 30 days of commencing treat¬
ment with leukeran and are controlled by reduction or withdrawal of
the drug; return to normal levels occurs within 10 to 20 days.
.
Gastro-intestinal effects are minimal.
Indications.- The use of this agent is largely confined to




Dosage and Administration.- The oral daily dose varies




Nature and mode of action.- Thiotepa is produced in 15 rag,
ampoules as a white crystalline water-soluble powder, suitable for
intravenous or intramuscular injection. It is the most effective
of a group of closely related compounds and its clinical use was
first reported by Shay and his colleagues in 1953. Its mode of
action is similar to that of nitrogen mustard and the other alkyla-
ting agents.
Haeraopoietic and other effects.- The haemopoietic effects
of thiotepa are again similar to those of nitrogen mustard but the
gastro-intestinal disturbances are usually less marked.
Indications.- Thiotepa is of greatest value in the man¬
agement of advanced carcinoma of breast and ovary particularly when
these are complicated by serous effusions. Good results have oc¬
casionally been observed in tumours of the gastro-intestinal tract.
Dosage and adrainistration.- An intravenous or intra¬
cavitary dose of 15 to 45 rag. nay be given on two or three occasions
at intervals of 7 to 14 days. A total dose of 90 to 120 rag. is





a) Methotrexate (h-aiaino-H1 °-;aethyl pteroylgdutamio acid.
Nature and mode of action.- The anti-folio acid agent,
methotrexate, is available as 2,5 sag. tablets for oral administration.
It is also available as a solution for intravenous, intra-arterial
or intracavitary use. % blocking the conversion of folic acid to
folinic acid it prevents D.N.A, synthesis and as such represents one
of the earliest and still most effective anti-metabolic agents.
Baemopoietic and other effects.- The action of this agent
is principally directed against the haemopoietic system and there¬
fore bone marrow depression may be marked. The range between thara-
peutic and toxic levels is narrow so that toxicity is usually pro¬
duced before evidence of remission is obtained. The most signifi¬
cant effects are, however, on the gastro-intestinal tract; nausea,
vomiting, diarrhoea and buccal ulceration occurring commonly.
Indications.- The principal indication for use of this
drug is chorion carcinoma in the female and this is one of the few
tumours in which chemotherapy may occasionally prove curative.^'"'
Methotrexate is also of value in the treatment of the acute leukaemias
and has been used in oertain gastro-intestinal tumours. In an
attempt to reduce toxicity, methotrexate has been given together with
its antagonist folinic acid.-^rtPis doubtful, however, whether this
technique /
27.
technique offers any real advantage.
Dosage and administration.- A daily dose of 2.5 to 5 ®£.
may be continued until a total dose of 100 to 200 rag. has been ad¬
ministered. When usee for intra-arterial or intravenous in¬
jection, infusion or perfusion, a single dose of 50 mg. has been
found of most value. Alternatively, daily doses of 10 to 20 mg.




Nature and mode of action.- This agent acta as an anti-
purine and is presented in 50 rag, oral tablets.
Haemopoietic and other effects.- The principal action of
this drug is again on the haemopoietio system and the range be-
tween toxic and therapeutic levels narrow. Gostro-intestinal
disturbances are, however, much less marked than with methotrexate.
'
Indications.- The principal indication far the use of
6-mereapto-purine is acute leukaemia. Remission usually begins
within 10 to 20 days of commencing treatment and treatment may be
continued for many months.
Dosage and administration.- An oral dose of 100 to
300 mg. per day may be tolerated for long periods before serious






This anti-pyriiaidine is available in solution form in vials
of 250 and 500 Big. It was first described by Heidelberger and his
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co-workers in 1957 and is suitable for intravenous and intra-arterial
use. It acts by blocking the methylation of deoxyui-aylic acid to
thymidylic acid which is an essential step in the formation of
desoxy-ribonucleic acid,
Haemopoietic and other effects.- Marked depression of
bone marrow function may develop within a short period of commencing
treatment particularly if 5.EM- is used in combination with, or
shortly after, another alkylating agent. Alopecia and skin pig¬
mentation occur in a few patients and gastro-intestinal symptoms -
nausea and vomiting, stomatitis and diarrhoea, may be moderate to
severe.
Indications.- 5-Eluouraoil i3 one of the few effective
agents against adenocarcinomas of the gastro-intestinal tract. It
is also valuable in the management of carcinoma of the breast and
'
ovary, and of tumours of the head and neck.
Dosage and administration.- A recommended dose of 15 mg.
per Kg. of body weight has been found, in practice, to be too high
and 12 mg. per Kg. of body weight is more suitable. A total dose of
1 G-, 3hould not be exceeded in 24 hours. Treatment is best
administered /
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administered by intravenous injection or infusion in intermittent
courses of 3 to 5 days at intervals of 6 to 12 weeks.
3. ANTIBIOTICS MB PLANT PRODUCTS
a) Vinblastine Sulphate (Velbe)
Nature and mode of action.- This agent, obtained from the
alkaloids of the Periwinkle (Vinoa Rosea) is presented as a cry¬
stalline powder, readily soluble in water, which should be adminis¬
tered Shortly after solution, but which will retain its activity
for up to 14 days if stored in a domestic refrigerator. Although
27
first investigated by Johnson, bright and Svoboda in 1959, its
mode of action remains uncertain, but probably resembles that of
the anti-metabolites.
Haemopoietio and other effects.- Moderate to severe de¬
pression of white cell count and haemoglobin level develop within
10 to 20 days of commencing treatment; depression persists for
5 to 15 days and then slowly reverts to normal. Castro-intestinal
symptoms are not marked but hallucinations, depression, occasional
paranoid states and neuritis accompany its use. Vinblastine
sulphate has a mild vesicant action and will produce indolent ul¬
ceration if injected extra-vascularly.
Indications.- The principal indications for its use are
malignant disorders of the reticulo-endothelial system, particularly
Hodgkin's Disease, but it is also valuable in treatment malignancies,
of /
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of the breast and ovary,
Dosage and administration.- Two-15 mg. nay be adminis¬
tered by single intravenous injections at intervals of 2 to 7 days.
This dose may be continued for many weeks before significant toxic
effects develop.
b) 2-Sthvl-Hydrnsine (S.P.I.)
This agent is not commercially available and is presented
in 2 mg. ampoules far intravenous or intra-artcrial injection. Its
mode of action is uncertain but again closely resembles that of the
anti-metabolites.
Haemonoietic and other effects.- These are similar to
vinblastine sulphate.
Indications.- The principal indication appears to be the
treatment of malignant melanoma, but it is also of value in the
management of Hodgkin's Disease.
Dosage and administration.- Single intravenous injections
of 200 to 400 og. may be given to a total dose of 1 G. in apy 24
hours. It is best administered in courses lasting 2 to 3 days at








Nature and mode of action.-. This agent, which is presented in
a
the form of'yellow powder, readily soluble in water, combines an
etlylene-imine with colchicine. In its mode of action it, there¬
fore, resembles both the alkylating agents and antimetabolites.
Haemopoietic and other effects.- Effects on the bone marrow
are minimal but gastro-intestinal disturbances particularly pain,
vomiting and diarrhoea are marked. Mild alopecia may occur in a
few patients.
Indications.- The principal indications for the use of this
drug are gastro-intestinal and breast carcinomas.
Dosage and administration.- Single intravenous injections of
10 to 30 mg. at intervals of 1 to 2 weeks may be continued for
many months. The total dose is determined by regular monitoring
of the peripheral blood count and by the incidence and severity of
gastro-intestinal disturbances.
d) METHODS OF APPLICATION OF iITTI-C/uIGIPl AGENTS
55,56,57,58,59,60,61,62.
1. Prophylactic Use
Manipulation of a tumour, however gently performed, results
-
in the dissemination of malignant cells along any of the recognised
avenues of spread. Only a very few of these cells survive to
form /
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farm metastases, but it would seem logical to reduce the risk of
spread by any means available. Cytotoxic agents have been shown
experimentally and under certain clinical conditions to reduce
the number of circulating malignant cells. IIow effective this is
in reducing the number of metastases that develop is unknown.
Nevertheless, it is considered that to use anti-cancer drugs as a
means of reducing spread or implantation of malignant cells, par¬
ticularly at the time of operation, is a justifiable technique.
The two principal ways in which cytotoxins have been used
prophylactically in this study are:
'
1) by a series of single intravenous injections
for a few days before, on the day of, and for
a few days after operation;
2) by infusing the operative area during the course
of the operation itself.
The first method has been used in such tumours as those of
the testis, rectum and colon and to "cover" biopsy procedures.
The second method has been employed in dealing with carcinomas
of the kidney and during the course of radical mastectomy for
carcinoma of the breast. In these case3, arterial cannulation
has been carried out and mannitol mustard or cyclophosphamide
slowly infused during and for a short period after the operation.
63,64,65,66.
2. Used as Adjunct to Radiotherapy or Surgery
Cytotoxic agents may be employed before, at the time of, or
following /
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following the application of standard surgical and radiotherapeutio
procedures. Their use in this context is incompletely defined but
there are four principal indications for adjuvant chemotherapy.
1- To potentiate the action of radiotherapy in certain tumours.
Actinomycin 3) in combination with radiotherapy, in the management
of Wilms* tumour in childhood, is possibly the best-known example
of adjuvant use. Certain alkaloids of the Periwinkle, e.g. vin¬
blastine sulphate, are regarded as powerful potentiators of ir¬
radiation. It is believed that the same effect can be obtained
from a smaller dose of irradiation when combined with vinblastine
as can be obtained with a larger dose of irradiation alone.
2. To prevent car delay recurrence and implantation.- Cyto-
toxins may be used in combination with radiotherapy or surgery in
an attempt to prevent or delay local recurrence, implantation,
and the appearance of distant metastases. An example of such use
is irrigation of the colon with a dilute solution of an alkylating
agent at the time of resection for carcinoma.
3. To control existing metastases.- Cytotoxins may be used
in an adjuvant sense to control metastases already present when
these cannot be included in the initial surgical or radiothera-
peutic fields. This constitutes the principal indication for
adjuvant chemotherapy.
4. To reduce tumour bulk and activity.- By reducing the bulk
and activity of tumour prior to surgery or radiotherapy, cytotoxins
may /
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may convert an unresectable tumour into a resectable one. The
reduction in size of certain head and neck and of alimentary tract
tumours are examples of 3uch use.
The effect of such combined therapy is difficult to assess.
Metastases may in some cases remain static for months or years.
The control of associated infection and oedema may result in
shrinkage in size of a tumour and thereby convert it into an oper¬
able form. The adjuvant role of cytotoxins is, nevertheless, im¬
portant and each of the above indications has been employed in this
study.
3. Used Alone in the Treatment of Advanced Disease
It is here that cytotoxins find their greatest use. This study
is principally concerned vdth that group of patients in whom all
conventional forms of therapy have already been used to their
maximum effect and are no longer applicable and in those in whom
the disease is already so far advanced at first diagnosis that
conventional methods cannot be employed. It is in this context
that conflicting views are expressed as to the value and justifi¬
cation of using potentially hazardous drugs when the outcome is
. 2
inevitable. For those patients who present with advanced malignant
disease and who are distressed by pain, discharge, bleeding, anorexia
and progressive inanition, any attempt to control these symptoms
seems justifiable. The behaviour of two apparently similar tumours
in/
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in patients of similar age and sex may be entirely different.
While certain tumours, such as those of breast and ovary, are much
more likely to respond to chemotherapy, no tumour, whatever its
site of origin, should be regarded as beyond the bounds of control
until cytotoxics have been used in sufficient amount for an ade¬
quate length of time. Certain treatment patterns are beginning to
emerge, but there are no hard and fast rules governing which drugs
to use in which cases, in what doses, by which routes and for what
length of time. It is the principal purpose of this study to
examine the effectiveness of cytotoxins in treating patients with
advanced malignant disease, to define, if possible, a group of
effective agents, and to determine approximate dose schedules for
a variety of tumours.
67,68,69.
Use of Agents Singly or in Combination
Many agents are effective when used alone, but there are
theoretical indications for using a combination of two or more
anti-cancer drugs in the treatment of any particular tumour.
% using a combination of agents, ideally from different groups,
it should be possible to simultaneously attack more than one meta¬
bolic pathway and, at the same time, to employ a smaller dose of
each agent. Effectiveness should be increased and toxicity re¬
duced. The concept that a combination of anti-cancer drugs is
preferable to using them singly appeal's valid in clinical practice
and has been frequently adopted in this study.
Use /
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Use In Intermittent Courses or as Continuous haintennnoe Therapy
Whether chemotherapy should be used in intermittent courses
over short periods of time, or as continuous maintenance, is still
a matter for controversy. It is the experience of all,that however
complete the initial remission, the tumour being treated will, with
few exceptions, inevitably escape control within a matter of weeks
35,43
or months. It is believed by some, that if a good response is
obtained, treatment should be stopped until relapse occurs when
another course of therapy is given in an attempt to obtain further
remission. Two, three or more courses of the same or of different
oancericidal drugs may, therefore, be administered at intervals of a
68,70
few weeks to a few months. Others believe that, if remission is
obtained, prolonged maintenance treatment at sub-toxic dose levels
I
should be continued to prevent or delay relapse. Both methods have
been employed in this study and are discussed in a later section.
e) ROUTfiS OP ADM IN13TR.t'i'ICII















7. Direct injection into tumour.
8. Intra-lyraphatic.
1. Topical application
The topical application of qytotoxins is limited to the man¬
agement of a few small superficial tumours, such as squamous epi¬
theliomas, and to the occasional control of ulcerating skin met¬
astases in such conditions as carcinoma of the breast. In some
measure, the use of cytotoxins in the oontrol of pleural and
peritoneal infusions and in the control of implantation at the time
cf surgery for colo-rectal and other tumours are camples of topi¬
cal application. It is probable, however, that a certain amount
of the agent is absorbed from the serosal surfaces thereby pro-
I
duoing a systemic effect.
'
2. %, Moutft
The administration of cytotoxic drugs by mouth is both con-
venient and effective. Only a few preparations are, however,
available for administration by this route. The majority of
these belong to the alkylating group of agents and the ones of
most value in the treatment of solid tumours are cyclophosphamide,
phenylalanine /
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phenylalanine mustard (melphelan) and chlorambucil (leukeran).
Methotrexate and 6-mercapto-purine are the only commonly used
anti-metabolites which are suitable for oral administration. Approx-
imately one-third to one-half of the orally administered dose is
absorbed by the gastro-intestinal tract, but little is known of the
sites of absorption and of the subsequent pathways to the tumour cell,
The principal advantage of oral administration is the ease with
which patients can be maintained on out-patient treatment. It is
also easier to disguise the exact nature of the treatment if this is
'
felt desirable. Many of the patients in this study have been main¬
tained for varying periods on oral maintenance therapy after an
initial intravenous or intra-arterial course of cytotoxics. Among
the disadvantages of oral administration, is the need to rely on
patients taking their tablets at the stated times. It is sometimes
difficult to persuade a patient to oontinue taking tablets which are
known to cause nausea, vomiting and other unpleasant effects.
3. Intramuscular Administration
This route of administration is of little value. Apart from
the occasional use of intramuscular thiotepa in the management of
cancer of the breast there are few indications for the use of this
38
route. When using androgenic or anabolic steroids, however, intra¬
muscular administration is of considerable importance.
4. Intravenous Administration
Many of the agents at present in use for the chemotherapy of
cancer /
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cancer can be given in an intravenous form. Certain preparations
can only be administered by this route and after suitable dilution.
The majority of the patients in this study have commenced treatment
on an intravenous regime and have either been maintained on inter¬
mittent intravenous injections,or on oral therapy,or on a combina¬
tion of both.
When given intravenously, cytotoxic agents may be administered
by continuous infusion over a short period of 24 to $6 hours or
over a longer period of 5 to 10 days. The most frequently em¬
ployed method, however, is a series of intermittent injections at
intervals of hours, days or weeks* Both of tloose methods may be
employed in the same patient and may be used concurrently.
In-patient treatment may, therefore, commence with a 24-hour con¬
tinuous infusion of a cytotoxic agent which is then continued at
intervals on an out-patient basis.
The advantages of intravenous administration are the certainty
of dose, the rapidly with which a large dose can be administered if
this is required and the assurance that the drug is being adminis¬
tered at the desired time intervals. The disadvantages include the
need for the patient to attend more frequently and the severe local
tissue destruction that occurs when certain of tho preparations,
e.g. nitrogen mustard, are injeoted axtravascularly.
43,71,72,73-
5. Intra-arterial Administration
Cytotoxic drugs may be administered intrc-ortorially by inter¬




principal advantage of this route is the administration of a large
■
dose of a cancericidal agent direotly to the tumour area. When
given by intermittent injection or continuous infusion, there is a
considerable leakage of the drug into the systemic circulation,so
that the total dosage which can be safely administered is the same
as could be given intravenously. By the mare elaborate method of
arterial perfusion, whereby a limb or the pelvis may be isolated
from the circulation and the venous and arterial supply routed
through an oxygenator, leakage of drug i3 less marked and a much
larger dose may be administered than wDUld otherwise be safe.
The systemic leakage'in this technique has, however, been variously
estimated as 20h to QOjt> of the administered dose, so that severe
side-effects may still develop. The principal indicationsfcr this
method are recurrent melanoma of a limb and the rare haemangio-
sarcomas that are associated with chronic lymphoedema.
Which-ever of the intra-arterial methods of administration is
employed, the technique requires additional time, skill and in¬
patient care and more elaborate equipment. Intermittent intra¬
arterial injections may be given under local anaesthesia, but usually
require general anaesthesia. The injection may bo given directly
by syringe over a period of 10 to 15 minutes and the needle or
cannula vdthdrawn. Alternatively, the cannula may be inserted into
a main artery supplying the tumour area and the drug administered
over a longer period of time (3-7 days) by means of a slow infusion
pump or by suspending the infusion bottle from a height. Other
complications /
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complications of intra-arterial administration include infection,
arterial thrombosis and occasionally massive haemorrhage. In this
study, the arterial route has been employed for local infusion of an
area at the time of operation, e.g. radical mastectomy and for
intermittent injection, particularly vdiere it has been possible to
isolate the main artery of supply, as in renal carcinoma.
40
6. Intracavitary Administration
The principal indications for this route of administration are
malignant, pleural or peritoneal effusions. Aspiration of an ef-'
fusion should be carried out to relieve symptoms, but it is not
necessary to aspirate to dryness before insfiliating cytotoxic drugs.
It is uncertain whether agents administered by this route act in a
cytotoxic manner or simply as sclerosing agents. It has, however,
been shown that a varying amount of the drug is absorbed into the
systemic circulation so that this may account for part of the effect
obtained. Despite these uncertainties, this is one of the most
satisfactory means of administering cytotoxic agents and their use in,
this manner is associated with few complications.
7. Direct In.ieotion into a Tumour
The administration of cytotoxic drugs directly into a tumour
is of limited value. Methods are now available for injecting solu¬
tions of cytotoxic drugs through intact skin to a depth of a few mm.,
but /
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but this has found little favour in the management of superficial
malignancies. In extensive chest wall recurrence of breast carcinoma.»
local injections of thiotepa may be of limited value, but usually
cause considerable necrosis and haemorrhage before tumour regression
is obtained. This technique has not been employed in any of the
cases discussed.
ROUTINE INVESTIGATIGNS
In addition to routine clinical examination, certain investi¬
gations must be carried out in every patient receiving cytotoxic
drugs. The investigations carried out in this study may be grouped
as follows.
1. Haematoloffy
a) Haemoglobin e) Differential white cell
b) Packed-cell volume count
c) Erythrocyte sedimentation f) Platelet count
rate g) Reticulocyte count
d) Total white cell count h) Bone marrow examination.
The haemoglobin, packed cell volume, erythrocyte sedimentation
rate, white cell count and differential white cell count and plate¬
let count were carried out in every case prior to commencement of
cytotoxic therapy. In many cases the reticulocyte count was also
estimated. These investigations were repeated at frequent and
often daily intervals during the course of cytotoxic treatment and
continued at weekly or two-weekly intervals while the patient
remained /
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remained under observation. Examination of the bone marrow was
carried out in the majority of patients prior to treatment and again
at intervals of 1 to 6 months after.
In the management of patients receiving anti-cancer drugs,
accurate, reliable and readily available haematological investi-
75
gations are essential. Treatment schedules must be based on
current blood counts and not on those obtained days or weeks pre¬
viously. It is also important to obtain absolute values rather
than percentages. A rapidly falling haemoglobin or white cell
count may be the first indication of severe toxic effects on the
bone marrow and serve as an indication that administration of the
drug must temporarily cease. A falling platelet count is of less
significance and treatment may be safely continued with smaller
amounts of drug,despite low platelet counts.
Examination of the bone marrow is of diagnostic value in
malignant disorders of the reticuloendothelial system and blood-
forming organs, but also allows accurate assessment of the toxic
effects being produced by the use of anti-cancer drugs.
2. Biochemistry




IV. zinc sulphate turbidity
v. serum glutamic oxaloacetic transaminase






c) Serum uric acid.
The toxicity of anti-cancer drugs is largely due to their
effects on normal, rapidly dividing cells particularly those of the
bone marrow, liver and intestinal tract. The possibility that these
agents may produce sufficient damage to cause jaundice is an indi¬
cation for the routine investigation of liver function by standard
tests such as serum bilirubin, alkaline phosphatase, zinc sulphate
turbidity, thymol turbidity, 3. G-.O.T. and S.GVP.T. These tests
were carried out before the administration of cytotoxic drugs,
within 7 to 14 days of commencing treatment and at intervals of
1 to 3 months thereafter.
frequent determinations of the plasma proteins were made and
the serum electrolytes estimated when they have otherwise been indi¬
cated. In addition, this study has included routine estimation of
serum electrophoresis and uric acid before and at intervals after th^
commencement of cytotoxic therapy. The significance of these will
be elaborated in the discussion.
These various tests must be carried out accurately and the
results should be available before treatment is commenced, changed of
continued,
3. Radiology




o) Pelvis and spine
d) Serial X-rays of metastatic sites
e) Follow-up X-rays of inoperable alimentary tract neoplasms.
In addition to the radiological investigations carried out to
determine the nature of the primary disease, and the extent of
known or suspected deposits, routine X-rays of the chest, pelvis
and spine have been obtained to establish the existence of otherwise
unsuspected metastases. Serial X-ray examination of known metas¬
tatic sites at intervals of one week to six weeks have also been
obtained. In addition, follow-up X-rays of alimentary tract neo¬
plasms, originally found inoperable, have been carried out in an at¬
tempt to assess response to treatment.
4. Bacteriology
a) Urine d) Wounds
b) Sputum e) Superficial tumours,
c) Blood
■
The possibility that cytotoxic drugs lower host resistance to
infection has been considered throughout this study. Repeated
bacteriological examination of urine, sputum and blood specimens for
pathogenic organisms have been carried out before and at intervals
after commencing cytotoxic therapy. Careful "bacteriological control
of all intercurrent infections, of infected wounds and of superficial




The use of photography in clinical cancer chemotherapy finds its
greatest value in assessing response to treatment vdiich produces a
change in the appearance of a superficial tumour dr in visible skin
and glandular deposits. Photography is also of value for recording
the occurrence and course of toxic effects, such as skin rashes,
buccal ulceration and cutaneous pigmentation.
6. Pathology
a) Histological.- The histological confirmation of malignancy
was obtained in every case prior to commencing treatment. In the
majority of cases the tissue for histological examination was ob¬
tained from the primary tumour. In others the tissue was obtained
from deposits in lymph glands, liver, skin or omentum. In these cases
the primary site was established at laparotomy, by X-ray examination,
or at autopsy. In four cases the primary site could not be deter¬
mined by appropriate investigation and in one was still not identified
at post-mortem.
A11 tumours in this series were histologically graded in order
that a final assessment might be made of the relationship between
tumour grade and response to cytotoxic therapy. It was hoped to study
in detail changes in morphology of a tumour following exposure to
76
cytotoxic therapy. Although it was possible in a few cases to obtain
serial /
47
serial biopsies for this purpose, in the majority it was only pos¬
sible to make this assessment on the basis of material initially
obtained from the primary tumour or its metastases and that ulti¬
mately obtained at post-mortem. As a result of rapid tissue autoly¬
sis and necrosis, much of thi3 post-mortem material proved valueless.
The assessment of morphological change is further made diffioult by
the lack of information on the changes which occur with time during
the natural history of untreated tumours and this aspect of the
study was largely abandoned.
Histochemical techniques to determine such tilings as changes in
cell ensyme content and activity with cytotoxic therapy, have not
been employed in th±3 study.
b) Macroscopic.- Post-mortem examination was obtained in
only 42 (54?0 of the JQ deaths in this series. It was hoped to
obtain a much higher percentage, but many patients died at home and
suitable arrangements far post-mortem examination could not be made.
In those cases in which it was carried out particular note was made
of the site and extent of the primary tumour, the sites and extent
of metastases and the presence of such features as obvious necrosis
or marked fibrosis. In those cases in which the primary tumour had
either been removed or found inoperable at laparotomy, interest was
concentrated on the extent of recurrence or extension at the primary
site. Careful note was also made of the existence of such features
as pericarditis, unsuspected pleural or peritoneal effusions and
changes in the adrenal glands, bone marrow and liver where these were
not /
not the site of overt metastases. An attempt was made in each case
to assess the approximate bulk of primary and metastatic tumour
present in each case. This was subsequently compared with the
nature and duration of cytotoxic therapy, with the occurrence of
toxic effects, intercurrent infection and other features, as a
clinical assessment of the concept that cytotoxic drugs may
occasionally act in a harmful manner by suppressing 'immunity
mechanisms". In a few cases post-mortem examination was of value
in correcting a previously wrong clinical diagnosis of site and
nature of primary tumour. In those cases not submitted to post¬
mortem examination, the nature of the primary tumour was established.
with confidence by clinical, X-ray and biochemical investigation,
'
in all but the four cases previously discussed.
g) LABORATORY RESEARCH INVESTIGATIONS
"
I. Lymphocyte Transformation
The in vitro transformation of lymphocytes by phyto-
haecegglutinin has proved of great importance in elucidating the
fole of the lymphocyte in antigen-antibody reactions and in the
body immune defence mechanisms. Certain malignant conditions,
particularly those involving the reticuloendothelial system,
react in some manner, a3 yet unknown, to alter the immune response
3
of the host, usually in favour of the tumour. By studying
lymphocyte transformation in in vitro culture it was hoped to
investigate /
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investigate the immune response of patients before and after the
administration of cytotoxic drugs.
The technique involved the separation of the buffy layer from
a 20 ml. sample of venous blood, the isolation of lymphocytes and
their culture in tissue culture media, Phytohaemagglutinin was
then added to the cultures and the rates and stages of transforma¬
tion following cytotoxic therapy compared with those observed be¬
fore treatment. The results obtained in this investigation were
limited by the sensitivity of the lymphocytes in vitro to even
minute dilutions of cytotoxic agent so that the cultures were reg¬
ularly arrested and cell disintegration produced. The technique
was abandoned.
II, Chromosome Changes
As a byproduct of this work, however, chromosome smears
were obtained by spreading cultures, arrested in metaphase by
colchicine, on slides frozen on carbon dioxide snow. It was found
that pleural effusions were most suitable for producing cell3 for
this purpose, but the facilities available did not allow accurate
description of the chromosome configurations encountered.
III. Red Cell Survival Studies ^
The development of anaemia is a common event in the coufse
of malignant disease. In some cases, however, the degree of anaemia
is out of proportion to the stage of the disease and cannot be attributed
to/
50
to blood loss or the effects of radiotherapy or chemotherapy.
The "anaemia of malignancy" may result from the action of a
haemolytic process, from maturation defects or from a reduction in
the life-span of the red cell. It was considered that a reduction
in the normal 100 to 120 day life-span of red cells may occur more
frequently in cancer than ha3 previously been thought and that
further reduction might follow the use of cytotoxic agents. Red
cell survival studies were accordingly carried out in ten patients
before and at some stage after the administration of cytotoxic drugs.
The technique consisted of "tagging" the red cells of a 20 ml.
51.
sample of the patients blood with radio-active chromium The
sample was then re-injected at a stated time and the dose of
radioactivity given was noted - usually 100 jic. Sight samples of
red cells (10 ml.) were taken over the following twenty-one days
51
and assayed for chromium activity. By this means it was possible
to calculate red cell survival tines.
In five cases the red cell survival time was abnormal before
treatment commenced, e.g. 40 days in Case No. 104, and was further
reduced by cytotoxic agents. In four cases, survival time was
normal initially and only minimal impairment followed cytotoxic
therapy. In the remainder, the results were normal throughout.
*
In the five oases showing abnormally low survival times,
radio-active scanning was carried out over the spleen to detect
evidence of abnormal breakdo?m of red cells in this site. Evidence
of increased breakdown was obtained in only one of these, Case No.2,
in /
51.
in whoa the spleen was grossly enlarged (Case No.2; Fig. l).
This demonstration that patients with malignant disease have, in
some cases, a loweredred cell survival time which can be further
reduoed by cytotoxic agents, is of significance in the causation
and management of the anaemia of malignancy. The use of routine
haematinie preparations in these cases is unsatisfactory and re¬
peated blood transfusions are required to maintain normal haemo¬
globin and red cell levels.
In the five cases demonstrating an initial reduction in red
cell survival time, three had urobilinogen in the urine and one of
these had a positive Coomb's te3t. In the remaining two patients
there was no evidence of abnormal haemolysis. Bone marrow studies
in these five cases showed varying degrees of hypoplasia of all cell
elements, but there was no gross deficiency in the erythroid series.
It would appear, therefore, that the survival time in these cases is
reduced partly as a result of circulating haemolysins, but may be
also due to an intrinsic defect in the structure or function of the
red cells, resulting in increased fragility and premature disinte¬
gration. The influence of cytotoxic agents on these mechanisms
requires further study.
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52.
RESULTS
The results obtained in this study have been detailed in
Table farm and are incorporated in Tables 1 to 33, inclusive.
The assessment of these results, when the tables are not self-
explanatory, is included in appropriate sections of the Discussion.
The difficulties of obtaining complete follow-up results in
patients with advanced malignant disease are self-evident. It is
considered, however, that sufficient data is presented to draw
worthwhile conclusions, although no attempt has been made to give
them statistical significance. It is to be noted that the de¬
tailed day to day results of the haematological investigations
I
have not been included, because of their enormous bullc. Repre¬
sentative examples have been plotted in graph form and are found in
relation to the case synopses, Tables 1 to 19, inclusive. Also
included in relation to the Case synopses, are the relevant clinical
photographs, arranged by Case number.
0 a No benefit or harmful
1 a Symptomatic relief only
2 a Good symptomatic and objective response
3 = Complete remission
chemotherapy of cancer
key to graphs of peripheral blood counts
graph a : total white cell count
polymorphs
lymphocytes
graph b ; haemoglobin
platelet count
abbreviations for cytotoxic agents






s set: appendix i
: 0
Table h
GROUP A : HODGKIN'S DISEASE
i
Case: J.G. 17/8/60 Age: 23 Sex: F
Diagnos: .s: HodgkLn* s disease. (Biopsy of axillary gland.)
History First noted painless glands in (L) axilla - July 196
symptoms, but found to have widespread lymphadenopat









(1) Radiotherapy: 3000r to (L) side neck;
3500r to (L) axilla
3000r to lumbar spine
3Q00r to (R) side neck}
2600r to (R; axilla
3400r to mediastinum
(2) Haematinics: ' Intermittently















(1) Chlorambucil: 580 m. orally (4 mg./dpy) 22
(2) Vinblastine 106 mg. by I.V.I. If









Clinically acute form of Hodgkin's disease when firs
Disease controlled by serial courses of radiotherapy
of neck, axillae, spine and mediastinum between Sept
December 1961. Chlorambucil 4 mg. daily to 580 mg.
above courses of radiotherapy. Readmitted with gener
January 1962 but marked regression of disease proces
vinblastine. Treatment suspended May 1962 when patie
pregnant - but aborted at 16 weeks. Further relapse
again responding to treatment with vinblastine. Inte
experienced mild backache, frequency of micturition,
and wheeziness but no further recurrence of disease
January 1964. Mediastinal recurrence treated with ra
out undue incident. At last review 12/3/64 was well
remission of disease. Symptoms well controlled by co


















Result: 2-3 for 3 years 8 months
Table 11 i
Case: 2 P.O»S. 5/3/62 Age: 39 S^: M
Diagnosis: Hod^kin's disease. (Biopsy of neck gland.)
History: Histologically proven Hodgkin's disease August 1957
radiotherapy. Remained symptom-free until March 1962
admitted with pain in back and (L) hypochondritis) trot




it family hi stay
Previous or (1) Radiotherapy: to neck and mediastinum - 1957. D
(2) Blood transfusions: total of 44 pints of whole
18,
(3) Antibiotics: including tetracycline.
erythromycin, ampicillin and chloram¬
phenicol in interrupted courses 11

















treatmen t: 1,000 mg. by I.V. drip 16,
1,000 rag. by I.V. drip 2%
1,000 mg. by I.V. drip 30y
(2) Vinblastine sulphate: 16 mg. by I.V.I. 16,
(3) Nitrogen mustard: 47 mg. by I.V.I. 2/l
(4) Vinblastine sulphate: 49.5 mg. by I.V.I. 21/
(5) Cyclophosphamide: 2.400 mg. orally 1/




Admitted in March 1962 with bepato-splenomegaly and
after five years* control of disease by radiotherapy
to initial course of mannitol mustard (2 x 1,000 rag.
relapse in October 1962 - main feature being massive
Short-lived remission following second 2,000 mg. cou:
mustard but severe depression of bone marrow functioi
complications. Reasonably well for 4 months and then
responding on this occasion to vinblastine. Degree OJ
demonstrated and repeated blood transfusions require<
enough for elective splenectomy and prednisone exhib:
1963 symptoms steadily progressive and only temporary
obtained to further therapy with cytotoxins singly al
Severe chest involvement terminally and died suddenly
Initial response to chemotherapy good but thereafter























Table 13 > (continued)
Autopsy
report:
Ri^it-sided heart failure due to pulmonary HodgkLn's
chronic bronchitis. Haemolytic anaemia due to hypers
gallstones. Generalised involvement of reticuloendot





Result: 2-3 for 34 months
Case tip, 2: Hod/frig's Disease
Pig, 1: Massive Splenomegaly : Hypersplenism
Table 1< k
Case; 3 G.R. 9/7/62 Age: 26 .Sex: M
Diagnosiis: Hodgkin's disease
Histar.v Accidentally noted swelling in (R) side of neck whil






(1) Radiotherapy: 4-.000r to (R) side neck) p/
3,500r to mediastinum )
(2) Marrow extraction: 12
(3) Marrow replacement: 14











(1) Nitrogen mustard: 30 mg. by I.V.I. 18
(2) Mannitol mustard: 1.000 mg. by I.V. drip 25
1,500 mg. by I.V. drip
in 24 hours 12,
400 mg. orally 8/
(3) Vinblastine sulphate: 71 mg. by I.V.I. 21
(4) Nitrogen mustard: 18 nv?. by I.V.I. 7/
(5) Cyclophosphamide: 2.100 mg. by I.V. drip 4/













Acute Hodgkin's disease with extensive involvement 0
Moderate response to initial course of nitrogen must
mustard (July, 1962) but mediastinum little improved
remission following radiotherapy (October, 1962) and
relapse. 4 month ranis si on following second course 0
and a course of vinblastine sulphate (Mareh-Mqy 1963
'
progressive mediastinal and pulmonary involvement no











Acute corpulmonale and respiratory failure due to me
obstruction secondary to Hodgkin's disease. Deposits




Result: 2-3 for 12 months
Table It
Case; 4 J.B. 17/8/62 Age: 19 Sex: M
Diagnosi s: Acute Kodgkin's disease. (Gland biopsy (r) pectora L region.)
History:
'
First admitted to another hospital on 34/7/62 with a
five-day febrile illness two months previously with
recovery. Vague general malaise, easy fatigue and la
Anorexia marked and progressive weight loss (l-g- ston
abdominal pain and diarrhoea for 1 week. Investigate














total of 31 pints of whole blood 18







(1) Vinblastine sulphate: 110 mg. by I.V.I. 4/
(2) Nitrogen mustard: 76 mg. by I.V.I. 4/
(3) Mannitol mustard: 1.500 mg. orally 11








Running high grade pyrexia on admission and not resp
prednisone. Within two weeks of commencing vinblastl
subjective and objective improvement was evident. Co
ment with gain in weight and control of fever; mark
prednisone, however, apparent. Moderate control unti
when readmitted with recurrent lymphadenopathy, anor
pyrexia. Marked, but short-lived remission of symptoi
course of nitrogen mustard. Thereafter course rapidl
with widespread adenopathy, high swinging pyrexia, p.
and weight loss. Symptoms only temporarily relieved
courses of mannitol mustard and Imuran. Deteriorated
coma on 29/6/63. Fulminating disease running rapid c
striae formation trunk and chest. Disease process on
















larked striae on trunk and chest - cortisone effect,
involvement of lymph nodes of neck, mediastinum and





Result; 1-2 for 10 months
Case iio. k
Fig. 1: Chest X-ray 23/7/62. Fig. 2: Chest X-ray 2^/9/62,
Fig. 3: Chest X-ray 27/13/62. Fig. 4-: Chest X-ray 22/l/63.
Case No. 4.
Fig. 5: Chest X-ray 2yy63.
Fig. 6: Chest X-ray 1/&63.
Table 1«P
Case: c. V.'.McG. 15/10/62 Age: 50 Sex: m
Diagnosj .s: Hodgkin's disease and carcinoma of lung.
Histology: Biopsy of gland (R) axilla on two occasions and tumour
removed at pneumonectony.
History Increasing malaise, weight loss and productive cough for 3 months.





(1) (r) pneumonectomy: 20/^/62
(2) Excision of glands (r) axilla: 25/10/62




(1) Nitrogen mustard: 20 mg. by I.V.I.
(operation cover) 22/10/62-24/10/62
(2) Mannitol mustard: 1.000 mg. by I.V. drip 31/10/62-4/11/62





First admitted 4 weeks after pneumonectomy - ill, pyrexial with
axillary and abdominal gland masses - Hodgkin's disease. Initial
good response to mannitol mustard, but recovery delayed by chronic
(R)-sided empyema requiring repeated aspiration and antibiotic
treatment. Short periods only out of hospital. Development of severe
epigastric pain prompted treatment with radiotherapy - temporary
remission only. Progressive symptoms and signs of Addison's disease.
Terminal stage short and died 24/3/63. Case of interest from
apparent presence of dual pathology but post-mortem examination
failed to confirm presence of Hodgkin's disease.
Autopsy
report:
Widespread deposits of adenocarcinoma from carcinoma (R) lower lobe
bronchus. Carcinomatous replacement of both adrenals. Involvement of
glands in chest, neck and abdomen by poorly differentiated adeno¬
carcinoma. No evidence of Hodgkin's disease in ary tissue examined.
(R) hemi-thorax partly filled by solid tumour with snail blood¬
stained effusion above it. Addison's disease.
Result: 2-3 for 6 months.
Table If
Case: 6 G.C. 9/4/62 Age: 22 Sex: M
Diagnosis: Hod^dn* s disease. (Biopsy of neck gland.)
History: Swellings in both sides of neck; first noted on (R)
previously and on the (L) one week previously. Dry,
cough for 2 months. Occasional night sweats - 2 mont








(l) Radiotherapy: 200r to mediastinum 25,
(course interrupted because of severe reactio:
3,000r to both sides of







(1) Nitrogen mustard: 30 mg. by I.V.I.
(2) ■ annitol mustard: 1,000 rag. by I.V. drip
2,000 mg. by I.V. drip
over 24 hours
(3) Chlorambucil: 250 mg. orally
184 mg. orally
(4) Hannitol mustard: 600 mg. orally
(5) Vinblastine sulphate: 86 mg. by I.V.I.















Presenting with acute HodgkLn*s disease affecting g
mediastinum. Rapidly became seriously ill. Initial
therapy (200r) produced rapid and severe oedema of nt
wall with gross swelling of neck glands - treatment
cytotoxins used alone. Marked improvement following
and discharged 5/6/62. Remained well until October 1
admitted with severe relapse - bull-neck, sweating,
masses in axillae and mediastinum. Further marked r
mannitol mustard but haemopoeisis severely depressed
Remained in remission for 5 months. Then widespread
disease on this occasion responding without incident
therapy. Further recrudescence of disease in October
control maintained to last review 17/2/64 with variou^
either singly or in combination.




















Case: 7 R.P. 8/1/64 Age: 17 Sex: 5
Plaranatot Acute Hodgkin* s disease, (Biopsy of axillary glanc )
History : Three week history of general malaise, pyrexia, swea
pain in the back and abdomen and loss of 2 st, in we
relevant previous or family history.
Lting, anorexia,
ight. No





(3) Aspiration of (L) pleural effusion: 300 ml, 2
(4) Prednisone: 40-60 mg./day orally 1
Cytotoxic
treatment:
(1) Nitrogen mustard: 20 mg, by I.V.I. 5








Gravely ill on admission with gross abdominal tendei
generalised tender lymphadenopattry. Initial rapid rf
nitrogen mustard so that by l$/l/6k he was apyrexial
tenderness was much less marked and all nodes were t
return of pyrexia, tachycardia, pleural effusion anc
I8/I/64 was demonstrating gross respiratory distress
condition was critical. Prednisone and cyclophospham
marked improvement which was maintained for 3 weeks,
again developed increasing, tender lymphadenopathy,
distension and tenderness, hepatosplenomegaly, pyres
effusion. Peripheral circulatory failure ensued and











he died in coma
Autopsy
report:
Widespread deposits of Hodgkin*s tissue in liver, sp
pancreas, and bone marrow. Gross involvement of lytni
areas. Bilateral blood-stained pleural effusions.
leen, kidneys,
h glands in all
Result: 1 for 4 weeks.
Ca.se Ho. 7
ilg. 1: Chest X-ray o/l/Q+. Fig. 2: Chest X-ray 11/1/64.
Table 2i
GROUP B : CARCINOMA OF LUNG
•
Case; g A.A.W. 24/11/61 Age; 53 Sex ; M
Diagnosa .s: Carcinoma of (R) lower lobe bronchus. (Biopsy of f




One week*s pyrexial illness with (R) sided chest pain and productive
cough five months prior to admission. Chest X-rey at that time (July,
1961) suggested an inflammatory lesion (r) base and patient treated
with antibiotics. Symptoms resolved, but two subsequent chest X-rays
revealed little change in (R) lower zone. Reported again in November
1961 with increasing anorexia, lassitude and productive cough.







(l) Antibiotics; July 1961 and intermittently
between 26/^62 and 21/5/63
\ a j AtiujL u ww px'iiucuivy t
(3) Chlorpromazine; 25 mg. B.I.D. orally 1






(l) Cyclophosphamide; 1.000 mg. by I.V.I. 1









Patient remained well for one year following radiotherapy with gain
in weight and only mild to moderate breathlessness on exertion.
Required inteimittent courses of antibiotics to control episodes of
productive cough. Readmitted lD/l/63 with hepatic metastases and
slow, general deterioration. Started cyclophosphamide 11/1/63.
Remained out of hospital and reasonably well for k months before
being readmitted following a brief haemoptysis. Thereafter became
listless, apathetic and deteriorated to death at home on 26/6/63.
Autopsy
report;
Not obtained - died at home.
Result: 3 for 1 year and 2-3 for 5 months.
Case No. 8; Carcinoma, of Lung
Pig. 1: Chest X-ray 27/?/60. Pig. 2: Chest X-ray 6 12/61.
Table 21
Case: 9 J.C.&. 22/9/62 Age: 39 Sex: M
Diagnosiis: Carcinoma of the larynx. (Biopsy of (L) vocal cord,)
Historyj Increasing hoarseness for 9 months; no pain cough 0
Had smoked 43 cigarettes a day for 15 years. Intrins









(1) Radiotherapy: 6.440r to primary lesion 2
(2) Laryngectomy: 2/8/63






(1) Cyclophosphamide: 4.225 mg. by I.V, drip 2






tnd Well for 7 months following radiotherapy and then debeneath (L) ear and increasing hoarseness. Direct la
II/7/63 revealed ulceration of posterior third of (L
biopsy confirmed active tumour. Complete laryngectom
2/8/63 with rapid recovery; discharged 31/8/63 aire
pharyngeal speech. Readmitted 7/IO/63 with a mass of
confluent glands in the (R) side of the neck and obv
around the tracheostomy stoma. l,OQOr to the neck gl
improvement. Following cyclophosphamide there wa3 an
shrinkage in size of neck glands, but effect short-1
episodes of respiratory distress occurred and the pa




) vocal cord and











Confluent mass of tumour tissue in neck,surrounding vessels and
tracheostomy stoma. Involved mediastinal lymph glands. Bilateral
pulmonary collapse and oedema. Death due to acute respiratory
failure secondary to collapse of lung and pulmonary oedema,
secondary to metastases in neck and thorax, secondary to carcinoma
of larynx.
Result: 3 for 7 months following initial radiotherapy,
0-2 for 3 months following chemotherapy.
SHE CKJMOmSAFY OF CXHC.,^
Case lip. 9: Caroinoaa of Jjcrynz
Fig. 1: Chest X-ray 3/12/62. Fig. 2: Chest X-ray 12/9/63.
Fig. 3: Chest X-ray IQ/7/63. Fig. 4: Chest X-ray Q/ll/63.
Table 2 c
Case; iq T.A.N. 22/13/62 Age: 43 Sex: M
Diagnosis: Carcinoma of the (L) lung with spinal metastases. (
spinal deposits at laminectomy l/ll/62.)
Biopsy of
History: First reported in July 1962 with pain in (L) lumbo-sacral area.
Recent loss of 1 stone in weight, but no other symptoms. Symptoms
considered orthopaedic in origin but little response to treatment.
By mid-October was virtually crippled by pain in back and in (l) leg.
Admitted to hospital where he developed bilateral foot drop and
disturbance of bladder function. X-ray of chest and lumbar spine now




(1) Physiotherapy: July-August 1962
(2) Bed rest and pelvic traction: October 1962
(3) Laminectomy and spinal decompression: l/ll/62
(4) Radiotherapy: 5.000r to lumbar spine 28/11/62-21/12/62
(5) Urinary antibiotics and antiseptics:
In repeated courses between 22/13/62 and 25/1/63
Cytotoxi
treatmenl1= (1) Chlorambucil: 210 mg. orally 29/11/62-12/12/62




Following decompression and radiotherapy, power improved
considerably and pain virtually cleared. Remained subject to
occasional severe muscle cramps and required an indwelling catheter.
Between 19/12/62 and 23/3/63 he was able to walk short distances
and spent a short period at home. Thereafter his condition began
to deteriorate; he required catheterisation and regular enanata.
On 15/2/63 he developed an influenzal illness, became much weaker
and bedridden. Glands appeared in neck and (l) axilla but lung
primary remained static. On 23/2/63 he began vomiting blood and this
recurred intermittently until death on 26/2/63. Case of interest





Result: 1 for 4 months
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Case No. 10: Carcinona of Luxv-:
Fig. 1: Chest X-ray 13/l/6l. Pig. 2: Chest X-ray 29/10/62.
Pig. 3: Chest X-ray 2l/l/63. Pig. 4: Chest X-ray 5/2/63.
4
Table 2,J
Case: x; L.W.T. 1/12/63 Age: 50 Sex: M
Diagnos: .s: Carcinoma of (l) lung with gangrene of (r) leg and j
osteo-arthropatly.
ulmonary
History First admitted to another hospital 22/10/63 with a £
of pain in (L) chest, dyspnoea, listlessness, conste
sweating and anorexia. Two weeks prior to admission
aching pains in wrists and ankles with swelling of t
Chest X-ray revealed mottled opacities (L) lower lot
effusion, Antibiotics produced no improvement and or
foot became pulseless and blue. Bronchogenic neople















(1) Antibiotics: Penicillin, erythromycin and
tetracycline in separate courses 5
(2) Blood transfusion: 4 pints packed cells 1
















Patient presenting with rapidly advancing carcinoma
initially regarded and treated as an infection. Demo
pulmonary osteo-arthropathy and developed gangrene o
? due to femoral artery thrombosis, which required m
amputation. No response to cyclophosphamide and died









Acute respiratory failure secondary to pulmonary oed
pneumonia, secondary to carcinoma of (l) lung. Recer
ventricle. Large bilateral pleural effusion. (L) lun
densely infiltrated with anaplastic squamous cell ca










Case: 12 H.S. 22/2/63 i£e: 36 Sex: m
Diagnosis: Carcinoma of (R) lung. (Pleural biopsy - 13/2/63)
History: Admitted to another hospital on 9/3/63 with a histor
malaise, anorexia, listlessness and weight loss over
9 months. Developed superficial venous thrombosis of
days prior to admission. Chest X-ray revealed a larg
side of chest. ? bronchogenic neoplasm. ? tuberculos
developed a massive (r) pleural effusion requiring a
Bronchoscopy was negative but pleural biopsy reveal£




















(1) Thiotepa: 45 mg. by intrapleural instillation 1
(2) Cyclophosphamide: 3.000 mg. by I.V.I. 1
2,700 mg. by mouth 2









Patient of Western extraction presenting with histor
pulmonary tuberculosis. Diagnosis of malignant disea
by pleural biopsy and treatment with cytotoxins coram
Intrapleural thiotepa resulted in gradual clearing 0
effusion so that aspiration has not been required fa
date. With the addition of systemic cyclophosphamide
general condition improved rapidly, he gained weight
returned to normal and remained continuously at work
At review 17/3/64 remained reasonably well but had a
had had three episodes of migratory thrombophlebiti














Result: 3 for 12 months
Case Ho. 12
Fig, 1: Chest X-ray 9/1/63. Fig. 2: Ghost X-ray 1/2/63.
Case No. 12.
KLg. 5* Chest X-ray Ify'l/Q-..
Table 21 >
Case: i; > J. P. 27/2/63 Age: 65 Sex: m
Biagnos:Ls: Carcinoma of (L) lung. (Biopsy of gland (L) side c f neck)
History Ilnergency admission in severe respiratory distress,
chronic chest trouble commencing in 1951 when had a
lobectany for proven carcinoma of the lung. Acute ea
respiratory symptoms two weeks prior to admission. I
in weight over previous three months with anorexia


















(4) Radiotherapy; 4.000r to primary )
?L) upper lobe ) 2








(1) Nitrogen mustard: 46 mg. by I.V.I. k
35 mg. by I.V.I.
(2) Cyclophosphamide: 1.500 mg. by I.V.I. 2











Patient in marked respiratory distress on admission,
improvement after one week's treatment with antibiot
spasmodics and physiotherapy. In view of desperate c
course of nitrogen mustard was given by I.V.I. This
considerable improvement so that the patient was abl
course of radiotherapy to primary lesion and neck gl
completion of this course improvement in condition m
stridor and distress relieved and radiologically les
regressed. Re-admitted 2 months later again in sever
distress. A further course of nitrogen mustard produ
minimal improvement and there was no significant res
phosphatide. Progressive respiratory distress to dea















Result: 1-2 for 6 months
■
■
Case Ho. 3.3: Carcinoma of Lung
Fig. 1: Chest X-ray 27/3/63. Kg. 2: Chest X-ray VV63.
Fig, 3: Chest X-ray 3Q/V63. Fig. 4: Chest X-ray 2C/8/63.
Table 2s
Case: 11h A.M. 25/3/63 Age: 46 Sex: M
Diagnos: .s: Metastasising bronchial adenoma (L) lung. (Biopsy
obtained at thoracotony)
of tissue
Ki story First reported January 1963 with persistent, chronic
cough troublesome for about 3 months, loss of one st
over the past six months and anorexia, ea^y fatigue
(L) shoulder pains for 1 month. Clinical examinatior
suggested a diagnosis of carcinoma of (l) lung; con














(1) (R) thoracotomy: Inoperable neoplasm 3
(2) Blood transfusion: Total of 13 pints whole
blood between 30/3/63 and 31/6/63
(3) Physiotherapy:







.0 (l) Cyclophosphamide: 3.000 mg. by I.V.I. 1





Slow recovery from thoracotomy and general condition
blood transfusion. Repeated attempts to aspirate (R)
produce fluid. Very little response to initial cours
phosphatide and patient remained weak, nauseated and
Moderate improvement following radiotherapy; requirin
transfusions. Home for two weeks 14/6/63-30/6/63 but
admission became dyspnoeic, cachectic, and unaffecte
treatment with oral cyclophosphamide. Collapsed ar











Extensive, invading tumour obliterating entire (L) p
Tumour necrotic with areas of calcification. Tumour
main stem bronchus. Marked mediastinal deviation. Th





proved to be a
Result: 0-1 for 4 months
.
■
Case No. IA: Carcinoma of Lung : Metastasising Adenoma
Pig. 1: Chest X-ray 2/7/6?. Fig. 2: Chest X-ray 25/3/63.
(6 months before patient
referred to hospital)
Fig. 3: P."'. X-ray of Lung to show
tumour calcification.
Case Ho. 14*
Fig. 4: Cut section of lung.
Fig. 5: Heart : Myocarditis and
Pericarditis.
Table 2h
Case: 15 A.H.P. 8/4/63 Age: 32 Sex: k
Diagnosis: Carcinoma of (L) lung with metastases in (L) 4th rib,





Gnawing pain and swelling in (L) pectoral region far 5 months.
Headaches, dizziness, diplopia, anorexia, nausea and occasional




(1) Local heat to (L) pectoral region ) 17/'






(1) Kannitol mustard: 500 rag. by I.V.I. 11/4/63-15/4/63
400 mg. by I.V.I. 24/4/63-29/4/63






Symptoms initially regarded as musculo-skeletal in origin and
diagnosis delayed for 4^ months. During this period symptomatic
treatment produced no benefit. Although chest pain temporarily-
decreased by cytotoxic therapy the patient pursued a rapid downhill
course with vomiting:, anorexia, and progressive cachexia. He became
ataxic, double vision persisted and developed nystagmus. Epilated.
Short periods of improvement in general condition between 26/4/63




Large tumour mass in (L) 4th rib anteriorly. Small area of tumour in
(R) main bronchus confluent with a mass of tumour replacing the
para-bronchial and tracheal nodes. Histology of tiinour showed muco-
epidermoid carcinoma. Multiple metastases in liver, cerebral cortex,
cerebellum and adrenals.
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Case; 1(5 E.J.W. 26/4/63 Age: 49 Sex: M
Diagnosis; Carcinoma of (L) lung with skeletal and hepatic metastases. Gross
biochemical disturbances, i.e. "functioning" tumour.
History; Six weeks' history of increasing cough, dyspnoea,wheeziness,
generalised muscle pains particularly in chest and back, anorexia,
lethargy, sweating attacks and weight loss. Had smoked 20-30
cigarettes a day for many years. No relevant past or family history.




concurrent electrolyte solutions: 30
treatmen t: (2) Antibiotics: Penicillin. 14 G. 25
(3) Blood transfusion: 4 pints whole blood 20





treatment: 2,600 mg. by I.V.I. 3q
3,600 mg. orally 2C
1,200 mg. by I.V.I. 17
2,500 mg. intrapleirally 2C
Total = 15.300 rag.




^atient extremely ill on admission with gross biochemical and
electrolyte disturbances secondary to carcinoma of the lung.
Symptoms and gross biochemical derangements were reversed for
6 weeks by cyclophosphamide, although marked depression of haemo¬
poiesis and alopoecia induced initially. At home for this period.
Readmitted 15/8/63 with massive hepatic and skeletal metastases,
pleural effusion, peripheral oedema and return of symptoms.
Transient response only to further cytotoxic therapy and died in
coma on IO/9/63 - 3 months from diagnosis. Case of especial interest




Primary carcinoma of (L) main bronchus. Widespread metastases in
liver, pleural cavities, lymph nodes and skeleton. Histologically an
oat-cell carcinoma of lung.
Result: 1-2 for 3i? months




DIAGNOSIS : OAT-CELLED CARCINOMA OF BRONCHUS
CASE NO. 16. J. W:
CYCLOPHOSPHAMIDE






1. CYCLOPHOSPHAMIDE : I. V. INFUSION
: IS V. INJECTION
: BY MOUTH.
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CASE NO. 16 PERIPHERAL BLOOD COUNTS
GRAPH B
CHEMOTHERAPY OF CANCER
DIAGNOSIS : OAT-CELLED CARCINOMA OF BRONCHUS

















1, CYCLOPHOSPHAMIDE : I. V. INFUSION
I. V. INJECTION
BY MOUTH.
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Caae No. 16: Carcinoma of Lung
Fig. 1: Chest X-ray 6/5/£>3> Fig. 2: Chest X-ray k/6/63.





Case; r; : J.S.W. 2/6/63 Me: 50 Sex; M
Dlagnoal* Carcinoma of (L) lung with cerebellar metastases,
deposit in cerebellum)
(Biopsy of
History: Found to have a (l) lower lobe bronchogenic neoplasm
"three-year" chest X-ray in January 1963. Had previa
October 1962 and again in November 1962 with a persi
productive cough. Symptomatic treatment only and no
(L) pneumonectomy was carried out in another hospita
Remained well until mid-March when he developed syrap
of a cerebellar lesion confirmed by posterior fossa














(1) Antibiotics: Penicillin by I.M.I. 1
(2) (L) pneumonectomy: 1
(3) Posterior fossa craniotomy: 1









(l)Cyclophosphamide: 3.000 mg. by I.V.I. 1








Patient admitted two weeks after posterior fossa era
condition fair; he was free of headache and had no a
respiratory symptoms. Completed a course of radiothe
posterior cranial fossa but complained of parietal h
became progressively more ataxic, confused and drow^
was sleeping most of the time, demonstrated gross me
and cerebration was grossly impaired. Improved a lit
home for 10 days. Cyclophosphamide was commenced on
thereafter condition gradually improved. By 2/9/63
cerebral conditions markedly improved and allowed ha
Readmitted 1 month later following an epileptic fit.
condition rapidly deteriorated, further epileptiform
















Result: 0-2 for 3i months
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Case: i£ A.MoL. 13/6/63 Age: 43 Sex: ] •
Biagnosis: Carcinoma of (r) lung with cervical gland and hepatic metastases.
(Bronchoscopy and biopsy of neck gland)
History: Five months history of persistent productive cough and aching
discomfort in (r) side of chest. Chest X»ray in March 1963 revealed
(R) lower lobe collapse but bronchoscopy reported negative and
treated gymptomatically. Reported again in June 1963 with glands in




(1) Physiotherapy: March 1963
(2) Gland biopsy neck: 13/6/63
" " | *
Cytotoxic
treatment:
(1) Mannitol mustard: 300 mg. by i.v.i. 13/6/63-15/6/63
(operation cover)
(2) Cyclophosphamide: 2.000 me. by i.v. drip 23/6/63-24/6/63




General condition fair on admission; large mass of hard fixed
glands in (l) side of neok and palpable mass in epigastrium.
Coiamenced cyclophosphamide on 23/6/63 and by 28/6/63 there was
definite decrease in size of neck glands. Patient claimed to feel
well. Thereafter steady improvement in general condition with
further shrinkage of glands and epigastric mass. Home 12/7/63.
Readmitted 27/7/63 with increasing jaundice for 6 days. Anorexia,
listlessness and weight loss now marked; increasing size of
metastases; jaundice increasing with marked pruritus. Epileptiform
episode on 6/8/63; recovered but by 19/8/63 was moribund,




Result: 2 for 3 weeks only
>'•-
Table £
Case: 1< ► a.L.F. 27/6/63 Age: 37 Sex: m
DiagnosJLs: Carcinoma of (R) lung. Anaplastic, giant-cell carcir





First reported on 25/4/63 with a 6 weeks* history of
gnawing pain in (R) side of chest posteriorly. Chest
December 1962 and on this occasion reported negative
arthritis of spine but symptoms persisted; psychiatr
sought. Finally mass in (r) posterior chest revealed
26/5/63. (R) thoracotomy in London 13/6/63 revealed
apparently chest wall tumour. Biopsy. In past histoi
had recurrent episodes of bronchitis 1955-1962 with













(2) Bed rest and pelvic traction: 2
(3) Cervical suspension: 1
(4) Analgesics: throughout
(5) Blood transfusion: 2 pints whole blood 1
(6) (R) thoracotomy; 1
(7) Radiotherapy: 6063r to primary tumour
(r) posterior thoracic area ) _
3,575r to lumbar spine )












(1) Cyclophosphamide: 7.100 mg. by I.V.I. 2






Patient admitted two weeks after (R) thoracotony. He
had obviously lost weight and his chest wall pain re
and severe. Thoracotomy wound well healed but palpab
to (R) scapula. Cyclophosphamide coiimenced 29/1/63 a
relief of pain (previously resistant to powerful ana
obtained in 24 hours; general condition also improve
radiotherapy to primary area, combined with cyclopho
wall pain further eased, but developed increasingly
dorso-lumbar area and also skin deposits. Back pain
analgesics or cyclophosphamide, only partly relieved
Patient by now addicted to pethidine and constantly
Developed further skin and axillary gland metastases
















Large tumour in upper lobe of (R) lung adherent to r
and invading upper thoracic vertebrae. Smaller raetas
lungs, glands of neck, axillae, mediastinum, and ing
invaded; skin deposits. Two amall hepatic metastase






Result: 0-1 for 3 months
.
*
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Case No. 19: Carcinoma of Lung
Table 2m
Case: 2C R.J.C. 7/10/63 A^e: 51 Sex: M
Diagnosis: Carcinoma of (L) lung path adrenal metastases. (Biopsy of
mass (L) main bronchus.)
History: Persistent productive cough for 8 months, increasing anorexia,
weight loss and exertional dyspnoea for 4 months. Admitted to
another hospital 16/7/63 where diagnosis of (L) bronchogenic
neoplasa established by chest X-ray and bronchoscopy. (L)thoracotomy




(1) (l) thoracotomy: 8/8/63
(2) Digoxin: 0.25 mg. - 1 mg. daily by mouth 7/10/63-2/1/64
(3) Cortisone acetate: 50 - 100 mg. daily
by mou th 7/10/63-2/1/64
9^fludrocortisone: 0.1 mg. daily by mouth 7/10/63-2/1/64
(4) Antibiotics: Tetracycline, ampicillin 7/10/63-30/12/63
Cytotoxic
treatment:
(l) Cyclophosphamide: 3,000 rag. by I.V.I. 16/10/63-5/11/63




On admission patient was deeply pigmented and was thought to have
Addison's disease secondary to adrenal metastases. He was
fibrillating and in congestive cardiac failure, "his responded to
intensive medical treatment and cyclophosphamide was commenced
10 days after admission. Thereafter general condition slowly
improved but an episode of acute left ventricular failure on 31/10^3
required urgent treatment. Rapid recovery. Chest infection 21/11/63
with Staph, aureus in sputum cleared with tetracycline and home for
1 month from 3/12/63. Readmitted 31/12/63 again in congestive cardiac
failure with clinical and E.C.&. evidence of pericarditis. Condition
rapidly deteriorated and patient died in coma on 3/1/64.
.Autopsy
report:
Large carcinoma of hilum (L) lung ?/ith infiltration of mediastinal
nodes. Collapse and infection distal to neoplasm. Extensive fibrinous
pericarditis and naemorrhaglc pericardial effusion. No liver
metastases and no glands involved other than those in mediastinum.
Adrenals were normal. Death due to cardio-respiratory failure
secondary to pericarditis secondary to carcinoma of lung.
Result: 1-2 for 2 months
C&36 Mo. 20: Ca il .o.u.. q„ Lury
Fig. Is Chest X-ray 22/7/63 Fig. 2: Chest X-ray 31/12/63
Fig. 3s Carcinoma of Lung : Addison's Disease
Table 2n
Case: 2] M.W. 2/8/65 Age: 56 Sex: F
Diagnosis: Carcinoma of (l) upper lobe bronchus with widespread metastases in
skin, bone and peritoneum. Anaplastic small-cell carcinoma.
History: First admitted to another hospital 2/8/65 with a 1 month history of
central chest pain and "lumps" in the skin. Also complained of
breathlessness, weakness and pain in (R) leg and inability to weight-
bear for 2 weeks. Haemoptysis three days prior to admission. Cough
for 1 month. Poor appetite and loss of 3 lb. in weight over 3 weeks.
N.B. 1 year previously had been treated in medical ward for (!•)-
sided pleurisy - followed up for 3 months. Smoked 20/day for many




(1) Stilboestrol: 15 mg. by mouth daily 12/8/65-26/8/65
(2) Blood transfusion: 1 litre of whole blood 4/1/66
(3) Analgesics: Ponstan throughout
Omnopon/morphine in increasing
dosage from 3/1/66
(4) Kxcision biopsy of skin nodules August 1965 - in another
hospital - and 29/10/65
Cytotoxic
treatment:
(1) Cyclophosphamide: 3.400 mg. by I.V.I. 26/8/65-30/9/65
1,200 rag. orally 9/9/65-23/9/65
(2) Thiocolciran: 170 mg. by I.V.I. 21/10/65-8/1/66
(3) Methotrexate: 50 mg. orally 21/10/65-10/1/66




Diagnosed as metastatic carcinoma but primary site was initially
uncertain and thought most likely to be breast. No response to short
course of stilboestrol and diagnosis revised to bronchogenic. Rapid
and dramatic response to cyclophosphamide, but short-lived and
required a single dose of radiotherapy to relieve pain from
metastasis in (R) fibula. Subsequently a further good but short¬
lived response to thiocolcirm and methotrexate. Treatment
interrupted by oral ulceration. Reasonably well far 3 months and
then required in-patient treatment for rapidly increasing pain in
chest and sicin metastases. Only transient benefit from further
chemotherapy and terminally required increasing analgesia. Died
6 months from initial diagnosis,19/2/66.
Autopsy
report:
Multiple subcutaneous nodules over trunk and limbs - sane ulcerated.
Large tumour mass in (L) upper lobe invading mediastinum. Lymph
gland and peritoneal metastases. Liver not involved. Histologically
an anaplastic snail-cell tumour of lung.
Result: Remarkable but short-lived response to cyclophosphamide during which
metastases melted away. Subsequent similar response to thiocolciran
and methotrexate but also short-lived. Subsequently treatment of
little benefit and pain required use of increasing doses of analgesic.
Oral ulceration after 2 weeks of thiocolciran and methotrexate but
treatment subsequently resumed without further trouble. 0-2 for 6mth.
Tt ble 2o
Case : 22 J.M. 29/3/65 Afie: 61 Sex: M
nosis: Carcinoma of lung with widespread metastases - thought initi




Hist ory: Three month history of intermittent, frank haeraaturia. Sin
onset of haematuria had steadily lost weight with progressiv
listlessness, dyspnoea, ankle swelling and anorexia, chronic
productive cough for 3 months. Carcinoma of (R) maxillary
treated by radiotherapy in June, 1963# Out-patient investi
had shown a large tumour of (L) kidney, thought to be a hype














(1) Radiotherapy: for carcinoma of maxillary antrum June 19
details no known.






(l) Cyclophosphamide: 1000 mg. by intra-arterial infusion (
renal artery 2/1/65.
400 mg. by I.V.I. 5/1/65 - 8/4/65








Clinically this patient was thought to have an advanced (L)
nephroma with widespread metastases. By selective arterial
catheterisation 1 G-, of cyclophosphamide was infused direct]
(L) kidney and tumour on 2/1/65. A further 400 mg. of cycl
ide was given by intravenous injection. Patients' general
condition was critically poor; following treatment deterior
continued, he developed a severe chest infection and progres











Bronchogenic carcinoma of (R) lower lobe bronchus with metas
to both lungs, liver, lymph-nodes, both kidneys and (L) adre
Pulmonary abscess formation and widespread bronchopneumonia.
tases
nal.
ISSi It: No benefit from cytotoxins, but small amount only given and




GROUP C : LYMPHOSARC OMA
Case: 23 T.w. 18/4/63 Age: 27 Sex: M
Biagnosi^: Generalised lymphosarcoma.
History: Perfectly well until October 1962 when he began to feel vaguely un¬
well, began to lose weight and noted that he was breathless on
exertion. Admitted to another hospital on 11/12/62 and noted to have
a (R) sided pleural effusion. The diagnosis was considered to be
tuberculosis and although this could not be substantiated a 4 month
course of anti-tuberculous chemotherapy was completed (including
prednisolone). Initially there was some improvement but continual
reformation of fluid in both pleural, cavities required repeated
aspiration. A full course of prednisolone was carried out between
13/3/63 and 21/4/63. No response to this treatment; condition








(a) Streptomycin - 90 G by I.M.I.
(b) Paainah 25 - 8 cachets daily
(c) Prednisolone - 5 mg. T.I.B. orally
5 tag. Q.I.B. orally
(2) Antibiotics: Penbritin 253 rag. 6-hourly
(3) Analgesics: increasing doses
(4-) Biuretics: orally












(l) Thiotepa: 80 mg. intrapleurally 2Q/4/63-29A/63
divided between two sides of chest
Clinical/
(2) Nitrogen mustard: 50 mg. by I.V.I.
(3) Vinblastine sulphate: 34 mg. by I.V.I.
(4) Cyclor hosphaaiae: 1,000 mg. by I.V.I.







Patient anxious, distressed, ill and dyspnoeic on adir
already been in hospital for 4 months, had been exter
investigated and, despite treatment, was progressive]
Diagnosis still in doubt at this stage but general or
lymphosarcoma. Decided to treat by aspiration of bott
to give cytotoxins intrapleurally and systemically ar
present patient for radiotherapy. Small glands first
side of neck on 22/4/63 and by 24/5/63 it was possibl
histological proof of lymphosarcoma by gland biopsy,
high doses of chemotherapy, dyspnoea decreased and re
frequent chest aspiration. General condition remained
hallucinations, massive swelling of (R) leg, distress
d./spnoeic. Further course of cytotoxins using velbe e
phosphamide produced some improvement and patient ref
therapy on 19/6/63. Was able to tolerate only a few d






















Confirmed presence of lymphosarcoma particularly invo
neck and mediastinum, assive pleural effusions.
lving glands of
Result: Only minimal and short-lived symptomatic relief obtai
toxins - and patient never left hospital.
0-1 for 5 months only.
ned from cyto-
Table 3b
Case; 24 T.H.W. IO/6/63 Ape; 47 Sex; M
Ida/ ;nosi s: Generalised lymphosarcoma. Neck gland biopsy.
History: First noted a swelling in (l) side of neck in May 1963. Admitted to
another hospital on 7/5/63 for investigation. No other symptoms
at that time and no other significant findings. Neck gland biopsy
revealed lymphosarcoma. No previous or family history of note.




treatmenIf (2) Radiotherapy: 4.200r to both sides of neck3,600r to mediastinum
(3) Radiotherapy; 3.950r to both groins 2£
Cytotoxi
treatmen b:
(l) Chlorambucil: 168 mg. orally (4 mg. daily) 12/9/63-24/IO/63





lymphosarcoma appearing as painless swelling of neck. Treated
initially by radiotherapy to necx and mediastinum. Completed course
without incident, but ejqperienced considerable soreness of throat
and lost 10 lb. in weight. Discharged home I6/7/63 with marked
regression of neck glands. No other findings. Remained in reasonable
health but easily fatigued for 1 month. Then found to have gland
masses in groins and iliac fossae. Commenced cytotoxins. Two months
later general health was improved with gain in weight; no sweating
or pruritis. Glands in groin remained enlarged and further radio¬
therapy to these sites in November 1963. Mild tinglings in hands
and feet at this time. At latest review, I8/3/63, was remaining in
good general health but persisting symptoms of neuritis in lower




Result: Cytotoxins commenced when disease becoming more widespread. Held in
check for 2 months and probably acting as good adjuvant to radio¬
therapy. Ultimate prognosis poor.
2-3 for 8 months to date.
Table 3c
Case: 25 D.T.W. 25/3/63 Age: 47 Sex: M
Diagno si s: Generalised lymphosarcoma. Neck gland biopsy.
Kistor.y: First reported to another hospital at beginning of March 1963 with
a painful swelling in (R) groin present for 2 weeks. Biopsy of the
swelling was attempted at that time under local anaesthesia but was
unsuccessful. Transferred to another hospital on 13/3/63. Now
had numerous soft glands in both axillae in (R) side of neck and
(R) groin. No other symptoms. Gland biopsy of neck established a
diagnosis of lymphosarcoma and patient was transferred for further
management. No previous or family history of note.
Previous or
concurrent
(l) Gland biopsy (R) side of neck: at another hospital 15/3/63
treatmem
ir
cment: (2) Radiotherapy: 5,0Q0r to (R) groin
4,00Or to both axillae
(3) Radiotherapy: 500r to abdomen
(4) Renal dialysis: one 6-hour dialysis on
Kolff twin-coil artificial
kidney
(5) Radiotherapy: 3t000r to base of skull
l,500r to lumbar 3pine
(6) Abdominal paracentesis: 600 ml.
(7) Prednisone: 20 tag ./day orally









fa) C.Vclophosphamide: 4,600 mg. orally







Diagnosis of lymphosarcoma established after initial difficulty in
obtaining biopsy. Marked regression of gland masses following first
course of radiotherapy in April 1963 and remained well for 2j
months. Then began to develop increasing listlessness, anorexia,
weight loss and abdominal distension. Readmitted 2/8/63 when abdomen
was found to be enormously distended with large intra-abdominal
gland masses, ascites and hepatomegaly. No significant peripheral
lymphadenopathy. Radiotherapy was given to the abdomen for three
days resulting in profound collapse and acute renal failure due to
hyperuricaemia. Dialysis was successfully carried out and by
13/9/63 he was fit for discharge. Two yreeks later he developed signs
and symptoms of an intra-cranial lesion and also severe pain in
sacro-iliac region and both legs. These responded to radiotherapy
combined with chemotherapy. By 4/11/63 was well and out of hospital.
Temporal epilation. Readmitted 1/12/63 ill with generalised severe
neuralgic pains, weakness and paraesthesia. Slight improvement with





Confirmed widespread lymphosarcoma. In particular the kidneys
showed widespread replacement by lympho cells leaving little
recognisable renal tissue. Probable cause of death was terminal
bleeding from gastrointestinal tract.
Result: 1-2 for 8 months. Cytotoxins used initially in conjun
radiotherapy. Response to the combined treatment was
degree but of short duration. Although a further cour
chemotherapy was given in the last few weeks of the i









GROUP D : LEUKAEMIA
>le M.B.
Ca se: 26 B.H.W. 20/6/62 Age: 38 Sex: M
Di Miosis: Chronic myeloid leukaemia.
Hi story: First reported on 18/6/62 with a history of increasing anor
general malaise, and loss of 3 stones in weight over a peri
6 months. "Spots" on upper lip for 1 week, feverishness, nai
vomiting, epistaxis and paraesthesiae in hands for 2 days,
symptoms referable to other systems. Malaria in 1943-44. Go
in 1952-53. No other previous or family history. Diagnosed


















whole blooTTransfused at intervals
between 21/6/62 and 25/6/63
(2) Antibiotics: Ca) Penicillin (oral) 250 mg. 4-hourly
18/6/62—
(b) Tetracycline, 250 mg. 6-hourly
22/6/62-
(c) Erythromycin, 250 mg. 6-hourly
21/6/63-





(l) Cyclophosphamide: 600 mg. by I.V.I. 13/6/63-








Disease already advanced when diagnosis made on clinical an
haeiaatological examination. Marked hepato-splenomegaly and
chest infection when first admitted. Treatment commenced wi
antibiotics and prednisone with rapid response. Discharge f
hospital after 5 weeks treatment and at this stage was well
marked reduction in size of liver and spleen. Remained well
work for 10 months. Was then readmitted with pyrexia, splen
and general malaise. Treatment with blood transfusion, incr
steroids and cyclophosphamide on temporarily checked downhi





















Widespread petechial haemorrhages and ecchymoses in axillae
groins. Pericardial effusion (150 ml.). Spleen enormously e
(3,150 gm.). Liver greatly enlarged (3,000 gm.). Evidence 0
agranulocytosis and marrow failure. Final diagnosis: chronii
myeloid leukaemia with terminal acute phase with infiltrate






Re suit: Cytotoxins only employed in terminal phases of illness and 1
no benefit. It is to be noted, however, that prednisone pro
10 month remission of symptoms.
?ere of
luced a
Case Ho. 26: Chronio Myeloid Leuizaenia
Fig. 1: Massive Splenomegaly
Tal
—xr£ £
Ca \e: 27 T.M.P. 27/5/63 Age: 18 Sex: M
Di ignosis: Acute monocytic leukaemia.
Hi itoiy: Admitted to another hospital on 15/5/63 with a 6 day histor.
fever, headache, anorexia and generalised aches and pains,
hospital continued to run a high-grade fever, developed gem
lymphadenopathy and splenomegaly. Became lethargic, apathet
confused. Progressive increase in size of glands. Transferr
further management on 22/5/63 and diagnosis of acute monocy
leukaemia established. Infective hepatitis 1 year previous!,














(1) Antibiotics: (a) Penicillin by I.M.I. 17/5/63-
(b; Penbritin, 250 mg. 6-hourly 18/5/63-
(c) Streptocycin, 1G daily 19/5/63-
(d) Tetracycline, 500 nig. 6-hourly
19/5/6>
(2) Blood transfusion: 1? litres of whole blood 13/6/63
(3) Gland biopsy (R) side of neck: 28/5/63










(1) Cyclophosphamide: 1.200 mg. by intravenous infusion
4/6/63-1
300 mg. orally 22/6/63-
2,000 mg. by intravenous infusion
28/6/63-
400 mg. by I.V.I. 9/7/63
Total - 3.900 rag.











Initially thought to have a severe infection ?septicaemia,
received massive antibiotic therapy. Rapid deterioration. E
ill on admission. Typical swelling of gums, widespread, dis
non-tender enlargement of all lymph gland groups. Commenced
treatment with prednisone on 3l/5/63;only minimal and short
response and accordingly cyclophosphamide therapy commenced
4/6/63. General condition improved after 5 days treatment b
developed an episode of nausea, vomiting and abdominal pain
gradually subsided. After further period of deterioration c
improved dramatically by 2/7/63 and improvement maintained
3 weeks. Then sudden deterioration with enlargement of all














Viidespread lymphatic involvement by leukaeraic process. Evid
terminal septicaemia in liver, spleen and bone marrow.
ence of
Ke 3ult: Transient benefit only from cyclophosphamide therapy. Total
was only 2 months and patient in hospital throughout. 0-1 f




Ca set 28 M.C.C. 7/6/63 Age: 6 Sex: M
Di gnosis: Acute nyeloid leukaemia.
Hi story: First diagnosed as acute myeloid leukaeraia in another hospi
November 1962 when he presented with a 6 week history of bn
arms and legs, progressive listlessness and apatty. He was
at that time by blood transfusion, prednisone and 6-mercapt
Remained reasonably well and at school until April 1963 whe
acute relapse occurred. This again responded to treatment b
transferred here on 7/6/63 because of rapidly weakening sta
this stage he was anaemic, listless and there was extensive















(1) Prednisolone: 30 rag,-15 rag. daily by mouth 7/11/62-
(2) Blood transfusion: 500 ml. 7/13/62
500 ml. 8/6/63
500 ml. 26/6/63
(3) Antibiotics: (a) Penicillin. 125 mg. 6-hourly





(l) 6-mercaptopurine: 500 mg. by mouth (25 mg. daily)
22/11/62
1,425 mg. by mouth (ranging from 50 mg












Initial progress as under "History". Within a few days of a
on 7/6/63 he became generally unwell with anaemia and risin
blood count. Condition improved with blood transfusion and
antibiotics but no further response to steroids. Accordingl
6-mercaptopurine was recommenced (50 mg. daily). Condition
improved and discharged hone 27/6/63. Thereafter remained
reasonably well and fully active until 28/7/63 when he was
readmitted as an emergency with severe (R) sided abdominal
grunting respirations, silent rigid abdomen and general app
of terminal state. Diagnosis of perforated viscus made clin
(steroid therapy induced) but collapsed and died before any











Large (R) axillary abscess - 80 ml. pus. Slight enlargement
lymph nodes, of liver and spleen. No perforation of viscus.
nodes, liver, kidneys, and spleen showed widespread infiltr
with leukaemic cells. Death essentially unexplained but tho






Re suit: Good objective response to 6-raercaptopurine combined with
prednisolone but no response to latter alone. Initial remis
maintained for 6 months and thereafter on3y short periods 0




Cae e: 29 L.F.C. V+/8/63 Age: 21 Sex: M
Diegnosis: Acute myeloid leukaemia.
His tory: First reported on 8/8/63 having noticed bleeding from his gi
brushing his teeth the previous day. Has also noticed a fine
around both ankles and present for 3 days. Over the previous
patient had noted occasional red blotches on arms and legs f
tendency to bruise more easily. No symptoms related to any












(1) Prednisolone: 100 mg.-60 mg. daily by mouth 9/8/63-3]
(2) Antibiotics: (a) Penicillin. 250 mg. by mouth 6-hourly
from 9/8/63














On admission his symptoms and good general condition belied
seriousness of his blood disorder. Despite prednisolone in 3"
dosage there was a progressive fall in Hb and platelets. Ren
well, however, until 29/8/63 when he became extremely ill w:
severe back and loin pain, bleeding from gums and mucous men
Clinic&lly retroperitoneal haemorrhage. Despite blood trans!
and intravenous cyclophosphamide his condition deteriorated,
restless, dyspnoeic and died with terminal generalised blee<














Res ult: No benefit from prednisolone. Cyclophosphamide exhibited to<























700000 10000 100 _
180000 9000 90 _
160000 8000 80 _
140000 7000 70 _
170000 6000 60 _
100000 5000 50 _
80000 4000 40 _
60000 3000 30 _
40000 7000 70 _
























































GROUP £ : MULTIPLE MYELOMATOSIS
Cai ®: 30 H.E.V. 22/2/63 Age: 50 Sex: M







torv: First admitted to another hospital 23/1/63 with signs and 33
of a (R) basal pneumonia which had failed to respond to usiu
measures. At this time was complaining of cough and haemopti
anorexia, marked exertional dyspnoea and loss of 1^- stones :
weight over previous 9 months. In previous history patient
recurrent bouts of pneumonia since December 1961 requiring
patient treatment. On present occasion was thought to have
carcinoma of lung but investigation established a diagnosis
multiple myeloma and patient transferred for further manager


















(1) Antibiotics: in repeated courses between December 1961
March 196 3 - usually tetracycline or peni
(2) Blood transfusion: 5p litres of whole blood
between IO/2/63 and











(l) Cyclophosphamide: 6.100 mg. by I.V.I. 24/2/63-'









Multiple myelomatosis presenting in typical way with recurr«
episodes of pulmonary infection usually clearing with antib:
and physiotherapy. On admission 22/2/63 was extremely ill w:
dyspnoea and cyanosis from extensive consolidation of (r) 1<
lobe. Thought to have (r) pleural effusion, but two attempt
aspiration were unsuccessful. 3 weeks after admission, howei
chest was beginning to clear as the result of treatment wit!
antibiotics; cyclophosphamide and physiotherapy, 2 months
admission appetite had returned to normal with gain of a fen
in weight. Chest was now clear and blood picture satisfactoa
ing transfusion and prednisone. Discharged home 24/4/63* re*
i6/5/63 with recurrent chest symptoms end involvement now ol
upper lobe. Symptoms and signs resolved rapidly on this occ
and discharged on cyclophosphamide and prednisone 29/5/63*
improvement by 20/6/63 with chest entirely clear on X-ray. 1
well until IO/7/63 when readmitted as an emergency to a loci
hospital in extremis with diarrhoea and vomiting. Died in p<






















Death considered due to pneumonia and acute (r)-sided heart
Confirmed myelomatosis but no extra-osseous myeloma deposits




Re anit: Short period of control with prednisone and cyclophosphamide
sudden unexpected death suggests the possibility of septica
1-2 for 5 months.
i, but
imia.
Case No. 50: Multiple Myelomtoais
Fig. 1: Chest X-ray 13/12/6l. Fig. 2: Chest X-ray 8/12/62,
Fig. 3: Chest X-ray 21/2/63. Fig. 4: Chest X-ray 15/1/63.
Case No. 30
Fig. 5: Chest X-ray 20/6/63,
Table 6a
GROUP p : CARCINOMA OF BREAST
Case: 31 E.B. 9/1/62 ARe: 48 Sex:
history:
Carcinoma of (L) breast with widespread skeletal metastases.
(L) radical mastectomy for Stage II carcinoma 1955, followed by
postoperative radiotherapy. Well until September 1958 when developed
pain in (R) chest. X-ray March 1959 showed a pathological fracture
of (R) 9th rib. Complete relief from deca-durabolin. Then developed
further rib and humeral deposits. Bilateral oophorectomy and two-
stage adrenalectomy carried out without incident. Good response
until September I960, then given radiotherapy for re-activation of
metastasis (L) humerus. Pathological fracture (l) humerus October
1961 but otherwise well until January 1962 when admitted with severe




(1) (L) radical mastectomy: Jul,'/ 1955
(2) Radiotherapy: 4,100 r to internal mammary
nodes
4,050 r to (L) supraclavicular) 2/8/55-5/10/55
nodes
3,250 r to anterior axilla J
(3) Rurabolin: 25 mg. weekly x 4 by I.M.I. I'arch 1959
(4) Bilateral oophorectomy and two-stage adrenalectomy: June 1959
(5) Radiotherapy: 2,000 r to (l) humerus 23/9/6Q-3Ao/60
(6) Cortisone acetate: 75-150 mg./day orally from
time of adrenalectomy
(7) Durabolin and dianabol:
(8) Radiotherapy: 2,800 r to lumbar spine
2,400 r to (L) humerus
(9) Radiotherapy: 3,600 r to lumbar spine
AO) Analgesics: Wide variety at various times






(l) Cyclophosphamide: 18,000 mg. orally
3,000 mg. by I.V.I.
12,600 mg. orally










When readmitted in January 1962 was virtually bedridden due to
back pain from metastases in lumbar spine; marked weakness in lower
limbs. Commenced intravenous cyclophosphamide, rapidly experienced
relief of back pain but developed severe electrolyte disturbances,
became hypotensive and required high dosage of cortisone to restore
balance, 3y 5/2/62 required antibiotics and barrier nursing because
of very low W.B.C. (600/ccm). Marked alopecia 22/2/62 but feeling
well and pain-free. Discharge home on 24/2/62 on maintenance dose
of oral cyclophosphamide. 1 month later was fully mobile and
Symptom-free. Remained well far a total of six months and then
readmitted with further severe low back pain but no other gross
findings. Further radiotherapy to spine August 1962 but symptoms
greatly aggravated and treatment stopped. Further response to
anabolic steroids and cyclophosphamide. Remained reasonably well
for further 6 months and then readmitted in constant severe pain
from spinal metastases. Marked weakness and loss of sensation in
lower limbs. Analgesics not controlling pain. Further dramatic
response to cyclophosphamide, pain relieved and power improved in
lower limbs. Hair regrowth. Home for further 2 months. Readmitted
for review 20/8/63; general improvement continued but required
radiotherapy for a new area of pain in mid-dorsal region. Started
on vinblastine sulphate while on radiotherapy. Well enough to go
home on 2</l0/63 and at home far 2 months. Thai readmitted with
severe pain in neck aid back - reactivation of widespread skeletal
metastases. Now developed bladder and bowel symptoms, chest
infection, congestive cardiac failure and finally died, after a
distressing terminal phase, on 2/1/64.
Autopsy
report:
Widespread hepatic and skeletal metastases from carcinoma of breast;
relatively little lymph gland spread and lungs not involved. Bone
marrow hypoplasia.
Result: Remarkable and sustained regression on cyclophosphamide. Further
long remissions obtained from repeated course of cyclophosphamide
and altogether was at home for 16 of the 24 months on treatment.
.
t
Case Ho. 51: Carcinoma of Broast
Fig. 3: Nock X-ray VV59. Fig. 4: Nock X-ray 5/12/63.
Case No. 31
Fig. 5? (l») Humerus X-ray Pig. 6: (L) Humerus X-ray
V9/60. 2/10/S3.
Case No.31.
Pig. 9: Lumbar spine X-ray Fig. 1°' Lumbar spine X-ray
3/6/59. 3/IO/63.
Pig. lit Pelvis X-ray VV59. Fig. 12: Pelvis X-ray 3/IO/63.
Table 6b
Case: 32 M.C, 9/8/62 Age: 38 Sex: F
Diagnosis t: Carcinoma of (L) breast Stage IH. Anaplastic infiltrating duct
carcinoma.
History: Painless, non-tender lump in (L) breast for 1 month. ]






(1) Radiotherapy: 5.969r to tumour area (L) breast as pre-operative
procedure 16/8/62-27/9/62
(2) Bilateral oophorectomy: 30/8/62





(1) Cyclophosphamide: 300 mg. by intra-arterial infusion via
(L) internal manmary artery
during operation




Large carcinoma of (L) breast treated by initial course of radio¬
therapy to maximum dose, followed by radical mastectomy. Operation
carried out under cytotoxic cover. Postoperative course complicated
by delayed wound healing and by necrosis of tips of (R) first and
second toes. ? pressure effect. Discharged well on 16/12/62.
Readmitted to another hospital as an emergency on 20/3/63 and died
the same night. Had been well until 1 week before admission when
became increasingly breathless, developed swelling of feet and
ankles, was jaundiced and in peripheral circulatory failure on
admission. Said to have an enlarged liver and left pleural effusion.
Autopsy
report;: Post-mortem not carried out.
Result: Patient given cytotoxins prophylactically. Total treatment prolonged
and sudden unexplained deterioration 3 months after leaving hospital.
? septicaemia. ? myocarditis or cardiomyopatty-.
Ta ©o
Ca l§: 33 D.B. 31/10/62 Age: 50 Sex: F
Dignosis: Carcinoma of (L) breast. Stage I, Infiltrating duct carcino &&«
Hi story: Lump in (L) breast noted six months previously. Slight pain
breast. Periods still normal. No other significant symptoms
in
•







gatment: (2) (L) radical mastectomy: 18/12/62
(3) Bilateral oophorectomy: 5/l/63
(4) Radiotherapy: 4.400r to (L) axilla and
(L) neck 17/1/63-















Uninterrupted post-operative recovery but developed an indo
ulcer (L) antecubital fossa at site of injection of cytotox
effects from course of radiotherapy. Remaining free of evid









Re j lult: Cytotoxin given by intermittent intravenous injections as "
for operation period. Unable to assess result, but ulcer fr




Case; 3k ■ P.M. P. 4/2/63 A£e: 43 Sex: F
Diagnosis: Carcinoma of (L) breast Stage I. Intralobular duct carcinoma.
History: Small lump first noted in (L) breast 2 months previously. No pain or





(l) (L) radical mastectomy: 6/2/63
CytotoxL
treatmen
c (1) "annitol mustard: 500 rag. by I.V.I.
(100 mg. x 5) 4/2/63-8/2/63






Small carcinoma of (L) breast treated by radical mastectomy alone
but under cytotoxic "cover". Developed oedema of (L) arm which





Result: Cytotoxins used prophylactically as operation cover,
result not possible to assess.
No effects and
Table 6e
Case; 35 M.G. 8/2/63 Age: 52 .Srac: F
Diagnosi s: Carcinoma of (L) breast with hepatic and skeletal metastases.
Liver biopsy - infiltrating carcinoma and malignant cells in bone
marrow.
Histor.v: (L) radical mastectomy for Stage I carcinoma of breast 5 years
previously in another hospital. No post-operative radiotherapy.
Remained well thereafter and considered fVee of recurrence of
disease. At laparotony for suspected chronic duodenal ulcer in
January 1963, however (in another hospital) was found to have
malignant glands in porta hepatis and numerous small hepatic
metastases. Main complaints had been gnawing epigastric pain for








(1) Laparotomy: at another hospital - malignant glands
at porta hepatis, small hepatic metastases.
Pyloroplasty performed but no biopgyj. 22/1/63
(2) Laparotomy: findings as above. No intra-abdominal
primary. Biopsy of liver deposit. 12/2/63
(3) Radiotherapy: to metastases lumbar spine.
Dose not known. November 1963
(4) Chlarpromazine: 25 mg. B.I.D. on same days as
(5) Durabolin: 25 mg. by I.O*^-eelciy^om 9/1/64
Cytotoxic
treatment
• (1) Mannltol mustard: 3p0 mg. by I.V.I.
(operation cover) (100 mg. x 3) 11/2/63-13/2/63
(2) Cyclophosphamide: 1.000 mg. by I.V.I. 27/2/63-7/3/63




Apparently free of recurrence 5 years after radical mastectomy for
Stage I carcinoma (L) breast. Long history of ulcer dyspepsia and at
laparotomy for these symptoms 22/1/63 was found to have metastatic
malignant disease. Second laparotomy carried out shortly after first
to establish diagnosis. Slow postoperative improvement. Small
pleural effusion clearing with physiotherapy. Started on cyclo¬
phosphamide orally after initial I.V. course. Discharged home
19/3/63 and remained extremely well until November 1963 when
required radiotherapy for back pain from metastases. Further period
of reasonably good health until January 1964 when readmitted for
reassessment. Widespread skeletal metastases but almost free of
symptoms. Chemotherapy suspended because of low W.B.C. but continued
out-patient review and well at last review March 1964. Marked but







Result: Cytotoxic cover over second operation with inannitol m
Remarkably good subjective and objective response to
maintained for 8 months. Further symptom-free period
radiotherapy to spine. Although increasing evidence o







Case; 3^ D.N. 1/3/63 Age: 36 Sex: P
Dia/nosi s: Carcinoma of (L) breast Stage I. Intraduct carcinoma.
Histor.v: Lump in (L) breast first noted 1 month previously. Associated with
slight tenderness and milky discharge from nipple. Lump had
decreased a little in size since first found. No other significant
symptoms. No previous or family history of note.




treatment: (2) (L) radical mastectomy: 4/
(3) Blood transfusion: 2 pints whole blood 5/
Cytotoxic
treatment:
(l) Manidtol mustard: 400 mg. by I.V.I.




Small mobile tunour excised by biopsy. Uncomplicated
operation. On oral iron for 1 month. No radiotherapy,








Result: Cytotoxins used as operation cover. Not possible to assess result.
N.B. Attempt to perfuse cyclophosphamide at time of radical
mastectomy failed.
Table $,<?
Case: 37 P.H. 17/6/63 Age: 42 Sex: F
Biasno si s: Carcinoma of (l) breast with neck gland metastases. Biopsy of neck
gland - metastatic carcinoma consistent with breast origin.
History: (L) radical mastectony for Stage I carcinoma of breast 1958 in
another hospital. Free of recurrence until February 1963 when she
noticed swelling in (L) side of neck. Ho other symptoms at that time.
Reported to doctor in April 1963 and biopsy of neck glands carried




(1) (l) radical mastectomy:
(2) Biopsy glands of neck:
(3) Bilateral oophorectomy
(4) Radiotherapy: 5980r to (L) supraclavicular
area and (L) side of neck 1/7/63-8/8/63















(l) Mannitol mustard: 300 mg, by I.V.I.
(operation cover) (3 x 100 mg.)
(2) Cyclophosphamide: 800 mg. intrapleurally
(2 x 400 mg.)
(3) Thiotepa: 60 mg. intrapleurally (4 x 15 mg.)










Appearance of neck gland metastases five years after radical
mastectomy for Stage I carcinoma of (L) breast. Biopsy of neck gland
under cytotoxic cover followed by bilateral oophorectony in June
1963. Completed course of radiotherapy to neck glands in August 1963
with marked shrinkage of glands. Remained well for 3 months and,
although free of symptoms, was then found to have a malignant pletral
effusion (l) November 1963. Intrapleural and systemic chemotherapy
commenced November 1963 with gradual control of effusion. At last
review on 27/2/63 the effusion had cleared, patient well and no
evidence of other metastases.
Result: Cytotoxins employed initially as "cover" for neck gland biopsy.
Subsequently required for control of malignant pleural effusion
after radiotherapy to neck glands. Good control of effusion for 3
months to final review. No side effects.
Table 6'h
Case: 38 M.M.D. 17/6/63. Aj^: 53 Sex: P
11a/;nosis: Carcinoma of breast (R) Stage I. Muco-epideraoid carcinoma.
History: Small, painless lump first noted 3 weeks previously,







(1) Excision biopSLV of lump (r) breast: 18/6/63
(2) {R) radical mastectomy: 22/6/63
(3) Blood transfusion: 2 pints whole blood 22/6/63
Cytotoxit
treatmenl
(l) Mannitol mustard: 450 mg. by I.V.I.




Small primary tumour treated by radical mastectomy; no postoperative
radiotherapy. Uncomplicated recovery. Remaining well and free of




Result: Cytotoxin given as operation cover and result cannot be assessed.
No complications. N.B. Attempt to perfuse cyclophosphamide via
(R) internal mammary artery at time of operation failed.
Table $1
Case: 3J M.P. 19/8/63 Age: 42 Sex: F
Diagnosis: Carcinoma of (r) breast Stage II. Infiltrating duct carcinoma with
involvement of axillary glands.
History: First noted large, painful red swelling in upper outer part of (r)
breast 2 years previously. Regarded as mastitis and treated with
penicillin followed by short-wave diathermy. 2 months after onset
symptoms and signs largely resolved but firm nodular mass remained.
Residual mass was kept under observation and subsequently a
discharge from the nipple was noted. Patient finally reported in
August 1963 with small swelling in (r) axilla present for 3 weeks.
Mass in breast now much larger and harder.





treatment: (2) Wide excision biopsy of mass in (R) breast: 28j
(3) (R) radical mastectomy: 29/8/63
(4) Radiotherapy: 6.000r to (p.) chest wall, axilla
and supraclavicular region 1/
(5) Blood transfusion: 2 pints whole blood 29j
(6) Penicillin: for wound infection
Cytotoxic
treatment:
(l) Mannitol mustard: 500 mg. by I.V.I.
(100 mg. x 5) 26/8/63-30/8/63




Remarkable delay in establishing diagnosis despite patient being
continuously under review. Tumour advanced before treatment
commenced. Postoperative course complicated by necrosis of axillary
flap, wound infection and wound dehiscence in its middle two-thirds
protracted healing preventing commencement of radiotherapy until
1/10/63 - delay of 5 weeks. Discharged home 7/11/63. Remaining well




Result: Cytotoxins given as operation "cover" and final result cannot be
assessed. Further oral mannitol mustard given because of delay in
commencing radiotherapy. Cytotoxins may in part have been
responsible for delayed wound healing but no other side effects.
Table 6'.i
j
Ca3e: 40 F.S. 20/8/63 Ae£: 39 Sex: t
Diagnosis3: Carcinoma of (R) breast Stage III. Poorly differentiated carcinoma
of breast with invasion of axillary glands.
History: First seen at another hospital on 4/7/65 with a mass in (R) breast
noted 2 months previously. Examination at that time revealed a hard,
irregular tumour in lower medial quadrant of breast, fixed to skin
and with clinical3y involved glands in axilla. Simple mastectony was
carried out on 8/7/65 and patient referred for further treatment.







(1) Simple mastectomy: 8/7/63
(2) Radiotherapy: 6,000r to (R) axilla, chest wall
and supraclavicular region 16/9/63-21/10/63
(3) Blood transfusion: 1 pint whole blood postoperatively
(4) Completion of (R) radical mastectomy: 27/8/63
C.ytotoxi<
treatmentE:
(1) Cyclophosphamide: 200 mg. by internal mammary
artery perfusion 27/8/63
(2) Mannitol mustard: 500 mg. by I.V.I.




Incomplete initial treatment for locally advanced carcinoma of
breast. Uninterrupted postoperative recovery, primary wound healing.
Completed radiotherapy without incident. Remaining well and free of




Result: Cytotoxins given as prophylactic measure and final assessment not




Case; 4] B.S. 3/9/63 Age: 43 Sex: F
Lia/:nosi i3: Carcinoma of (L) breast. Stage I. Infiltrating duct 0arcinoma.
History: First noted stabbing pain in (L) breast 2 months previously - on
examining breast patient felt a small lump in upper inner quadrant.
Lump increased in size but no discharge from nipple. Generalised
tenderness in (L) breast and (L) axilla. Had previously experienced
symptoms of fibrocystic disease in (L) breast over period of 2 years.
No other symptoms and no previous or family history of note.










(2) (L) radical mastectomy: 7/
(3) Radiotherapy: 5.000r to (L) axilla, chest
wall and supraclavicular area







(l) Mannitol mustard: 300 mg. by I.V.I.




Small primary tumour. Primary wound healing but recurrent effusion
beneath flaps requiring repeated aspiration. Initially worried about
being pregnant; initially tests equivocal, subsequently negative.





Result: Cytotoxin given as operation "cover" and final result cannot be
assessed. No side effects. N.B. Failed to attempt to infuse
(L) internal mammary artery with cyclophosphamide at time of
operation.
Table $1
Case: 42 I.P. 19/11/63 53 Sex: P
Diagnosis: Carcinoma of (R) breast Stage II. Infiltrating duct carcinoma.
History: Mass in (r) breast noticed 1 year previously - not reported and
found by own doctor during examination for a certificate of medical
fitness. No pain in breast and no nipple discharge. No previous
history but one relative had died of breast cancer.





(r) internal mammary artery 23
(2) Radiotherapy: 4.400r to (R) axilla, chest wall





(1) Cyclophosphamide: 400 mg. b.v I.V.I. 22/11/63-24/11/63
(2 x 200 mg»)






Long delay before tumour of breast found during examination far
other reasons. Postoperative course cexplicated by delsyed wound
healing and formation of large eschar. Postoperative radiotherapy
therefore postponed for 3 weeks but course ultimately completed
without incident. Discharged 7/2/64 and was remaining free of




Result: Cytotoxins given as operation "cover" and final result cannot be
assessed. Delayed ?/ound healing thought more lively due to use of
diathermy than to cytotcadLns.
Table 6'm
Case: 43 V.L. 28/11/63 Age: 67 Sex: F
Diagnosiis: Carcinoma of (R) breast Stage I. Intra-duct carcinoma•
History: Accidentally noted small lump in (R) breast 1 month previously.
No pain in breast or nipple discharge. Menopause 6 years previously
No previous history of note but distant relative died of cancer of
breast.




treatment: (2) (R) radical mastectomy: with cannulation of(R) internal mammary artery 30
(3) Blood transfusion: 2 pints whole blood 30
Cytotoxic
treatmentu
(l) Cyclophosphamide: 200 mg, by internal




Small tumour; some initial doubt over histology and hence delay in
definitive operation. No postoperative radiotherapy. Uncomplicated









Case: 44 M.McD. 9/12/63 •Age: 47 Sex: F
Diagnosis: Carcinoma of (L) breast Stage H. Invasive intra-duct carcinoma with
involvement of glands.
History: Small lump in upper outer quadrant of (L) breast for 3 months, with
associated pain, tenderness and swelling in breasts, particularly
the (L), for same period. No nipple discharge. Periods scanty and
irregular for 3 months. No other relevant symptoms.
N.B. 2 years previously a small lump had been removed from (L)
breast; reported as intra-duct carcinoma but no further action taken




(1) Excision biopsy of Imp (L) breast: under
cytotoxic"c over" 27/11/63
(2) (L) radical mastectomy: under cytotoxic
"cover" 28/11/63
(3) Bilateral oophorectomy: under cytotoxic
"cover" 17/12/63
(4) Radiotherapy: 5,000r to (L) axilla, chest wall
and supraclavicular area 2/l/64-2l/l/64
(5) Blood transfusion: 1 pint of whole blood 28/11/63




(1) Mannitol mustard: 600 mg. by I.V.I.
(6 x 100 mg.) as operation
"cover" 27/11/63-2/12/63
(2) Cyclophosphamide: 600 mg. by I.V.I. (3 x 200 mg.)




Small primary tumour (L) breast with invasion of axillary lymph
glands. Uninterrupted recovery from radical mastectomy and bilateral
oophorectomy. No effects from cytotoxins. Remained well and free of
evidence of recurrence of disease at last review March 1964.
Autopsy
report:
Result: Cytotoxins given as operation "cover" and final result cannot be
assessed. No untoward effects produced.
Tab Le 60
Ca £! ^-5 L.B. 18/3/63 Age: 38 Sex: F
Piignosis: Carcinoma of (L) breast with widespread bone, skin and cere
metastases. Anaplastic carcinoma.
sral
Hi story: Radical mastectony for Stage II carcinoma of breast 6/4/62
8 months post-parturn. Admitted 28/12/62 with 6-week history
headaches and vomiting. Re-admitted 18/3/63 with severe pai













(2) Radiotherapy: 6.000r to (L) chest wall and
axilla - post-operative
(3) Radiotherapy: 3.700r to skull 8/1/63-2
l,230r to pelvis 8/1/63-1
(4) Testosterone proprionate: 100 rag. daily by I.M.I.
24/2/63-
(5) Prednisone: 30 mg. daily by mouth reducing to
20 mg. daily by mouth 20/3/63-
;otoxic
iatment:
(1) Perfusion of internal mammary and axillary
arteries at operation - cyclophosphamide 200 mg« 6/4/
(2) Cyclophosphamide: 2,600 rag. by I.V.I. 31/3/63-
22,800 mg. by mouth 16/4/63-
Total - 25.6 G.











First evidence of skin and skeletal metastases developed 7
after mastectomy. Headaches, facial pain, nausea and voraiti
cranial and bone metastases, incompletely relieved by radio
to skull and hormone therapy. Complete relief of all sympto
marked tumour regression with cyclophosphamide. Regression









Widespread bone, skin and glandular metastases from breast









Case Mo. 45: Carcinoiaa of Breast
Chest X-ray 30/k/63. Pig. 2: Chest X-ray 0/l/63,
Pig, 3i Skull X-ray 20/12/62. Pig. 4: Skull X-ray 22/9/63.
Case No.45.
Fig. 5: (L) Shoulder X-ray Fig. 6: (L) Shoulder X-ray
1$V63. 1S/S/63.
Fig. 8: Lumbar spine X-ray
1W63.
Fig. 7: Lumbar snine X-ray
29/12/62.
Case No.45.
Fig. 9: Pelvis X-ray 29/12/62.
Fig. 10: Pelvis X-ray U/Q/63.
Tal >le 6p
Ca se: 46 B.K. 15/3/64 Age: 42 Sex: F
Di ignoais: Local recurrence of carcinoma (R) breast. Anaplastic carcinoma.
Hi 5tory:
"V
Radical mastectomy was carried out in another hospital in M
for anaplastic Stage II carcinoma of (R) breast. No post-op
radiotherapy given but radiation menopause induced in May 1
Remained well until November 1963 when she noticed a small
over (r) anterior chest wall. Gradual increase in size of s
with mild aching discomfort over it. Rapid increase in size
local tenderness over 1 month. No other symptoms. Pulmonary















(2) Radiation menopause: elsewhere May 196£
(3) Bilateral oophorectomy: 10/3/64






(l) Cyclophosphamide: 2.000 mg. by intra-arterial infusion
(r) internal mammary artery 10/3/64-









Clinical examination revealed a 3" x 3" mass of recurrent t
beneath the medial skin flap end 1" from the mid-line. Ther
evidence of metastases elsewhere. Rapid and dramatic respon
intra-arterial infusion of cyclophosphamide with loss of te
discomfort after 24 hours and marked reduction in size of t
after 6 days. Regression continued until tumour had virtual
disappeared within 3 weeks. Slow recurrence of lesion with
discomfort, moderate hair loss and decline in general condi













Re suit: 2-3 for 7 months.
Table 6q
Cage: 47 M.G. 3/9/65 Age: 67 Sex: F






Stage iv carcinoma of (r) breast treated by radiotherapy in
Recurrent disease in October 1959 controlled by stilboestr
September 1961. This slow increase in size of local tumo
axillary gland involvement. Bilateral ovariectomy 4/3/64
slight benefit. Also given prednisone and testosterone,
slowly spreading disease patient remained reasonably well
until I/9/65 when she was re-admitted complaining of incre
breathlessness, lisfLessness and chronic non-productive coug












(l) Radiotherapy: for Stage IV carcinoma of (R) breast 1958 -
details not known.
tre atment: (2) Hormone therapy: (a) stilboestrol - October 1959-Septe|mber ISt
then losing effect.
(b) bilateral ovariectomy - 10/3/64
(c) testosterone proprionate and prec
from I/7/64 - 22/10/64, thereafter
dnisone
r testof
erone continued alone until 1/9/6
(3) Aspiration of pleural effusion: 1000 ml - 3/9/65
700 ml - 13/9/65
600 ml - 4/13/65
Cyt otoxic
tan atment:
(l) C.yclophosphamjde: 1300 mg. intr&pleurally
400 mg x 2
300 mg x 1
200 mg x 1
3/9/65-18/31/65
1800 mg, by I.V.I.
400 mg x 2
300 mg x 2
200 mg x 2
9/9/65-21/10/65
300 mg. by mouth
100 mg x 3




Xlhen re-admitted on 1/9/65 was found to have a large (r)
effusion. Area of locally recurrent ulcerated tumour (R)
wall 5 cm x 5 cm.. Single large gland (l) axilla, glands
(R) side of neck and in groins, ribs invaded. Pleural ef
aspirated and cyclophosphamide commenced intrapleurally and








T£j ible 6q( continued)
aspiration on 13/9A>5«, No obvious change in local tumour
gland masses during this time. Patient remained reasonab
and active, but stopped oral cyclophosphamide after only 3
because of nausea and vomiting. Was making good progress
collapsed end died suddenly at home 25/11/65 one hour afte










Med et home. No post-mortem, but clinically death due t
myocardial infarction
0 acute
Resuit: Pleural effusion controlled for 2 months to time of sudden
but no obvious effect on recurrent and metastatic tumour m




«i ' ■":T : '
Ti ible 6r
SMe: 48 A.W, 9/3/65 Age: 63 Sex: P
Diegnosis: Carcinoma of (R) breast with (L) pleural effusion
Ki£ tory: Stage III carcinoma of (R) breast treated by radical mastec
followed by radiotherapy in another hospital in 1962. Gla
recurrence (r) axilla treated by excision on 14/6/64. Sev
herpes zoster in distribution of (L) 10th nerve, 2 years pr
and still complaining of severe post-hepatic pain resistent
therapy. Found at review in February 1965 to have (L) pie
effusion; started stilboestrol, but with no effect, Sefe
consideration of cytotoxins on 9/3/65 because of increasing

















(2) Excision gland (R) axilla: 14/6/64.
(3) Hormone Therapy: Stilboestrol - 1 mg. b.i.d. from 16/2
10/6
(4) Aspiration of Pleural Effusion: 1100 ml. - 11/3/65
1300 ml. - 13/11/65
1200 ml. - 15/12/65





(l) Cyclophosphamide: 1800 mg. intrapleurally 11/3/65-15/









Large (L) sided pleural effusion present when patient first
in chemotherapy clinic. Main complaint, however, was of s
constant pain in (L) lower chest present for two years and
relieved by ary kind of analgesic - warch 1965. Treated t
aspiration of pleural effusion and instillation of cyclophc
Effusion controlled for 8 months, during which time patient
general condition remained good. Continued, however, to c
of unrelenting pain in (L) side although metastatic bone or
tissue lesion never established. In November, 1965 reacc\J
of effusion requiring further aspiration. Partial control
cytotoxins intrapleurally and intravenously, but condition
deteriorated. Admitted to a medical ward in March 1966 me
social problem, but thereafter declined to death at home or


















Died at home- no post-mortem obtained.
& (D toult: Although pleural effusion controlled for 8 months with anal
of cyclophosphamide, but pain never relieved. Terminal il
long drawn-out and little further benefit from cytotoxins.





Tal le 6 s
Cas« >: 49 m,0, 12/3/65 Age: 44 Sex: F
nosis: Carcinoraa of breast with widespread metastases and gross asc
Hepatic metastases.
ites.
Ser¬ Stage III carcinoma of (L) breast treated by simple mastectc
radiotherapy in I960, Radiation menopause in July 1963 foi
recurrent tumour in (L) axilla and chest all* Temporary c
of disease with disappearance of recurrent nodes (l) axilla,
Further recurrences in skin of chest wall and (r) breast in
1964 with gross ascites and bilateral pleural effusions, f
known to have rheumatic heart disease and significance of
uncertain. Dramatic response to prednisolone which was mai
until December 1964 when admitted to a medical ward with grc
palpable masses in abdomen and recurrent tumours in (R) bret
















tretI|••ff of ft) breast. Details not known.(2) Radiation to ovaries: July 1963,
(3) Digoxin and diurectics: intermittently from January 196
(4) Steroids: Prednisolone: 15-30 rag. daily by mouth 16/6/6
(5) Abdominal paracentesis: Two occasions in July 1964 - de
known, 4+ litres - 14/V^





(l) Cyclophosphamide: 1000 mg, by I.v* infusion over 24 hou
34/3/65
rs
200 mg. by I.V.I. 19/1/65







Patients' general condition was poor when cytotoxic therapy
commenced on 14/3/65, but it was hoped to control her rapidl
accumulating ascites and to lessen severity of symptorns.Wide
tumour masses were present in abdomen and elsewhere. Patie
remained listless and anorexia began to deteriorate by 25/3/











ResuIt: Insufficient dosage given at too late a stage to obtain apy
benefit, 0 far 2 weeks.
Ta )le 6t
Ca 561 50 M.S. 15/12/64 Age: 63 Sex: F
Dl( ignosis: Carcinoma (R) breast with widespread deposits in bone, live
adrenals and glands. Poorly differentiated scirrhous carcin
breast.
oma of
Hi 3tory: First seen as out-patient in December 1964 with thrombophle
(R) arm. No other symptoms at that time and no evidence of
malignancy. Again seen in September 1965 with swelling of (
palpable glands in (L) supraclavicular area and distended v
(R) breast. Bronchoscopy, chest X-ray, negative, but biopsy
gland revealed anaplastic carcinoma. ? bronchogenic or brea
Admitted to ward for investigation and treatment 9/9/65. No
complaining of subcostal and back pain, swelling of abdomen
ankles. N.B. No primary breast lesion found but evidence of
















(2) Radiotherapy: Lumbar spine. (R) axilla, dorsal spine a






(l) Cyclophosphamide: 1.800 mg. by I.V.I.







Although general condition was good at commencement of cheir
symptoms were marked and disease already widespread. Primar
not known at this stage. Symptoms less marked within 1 week
starting treatment and after 1 month was able to do housewo
without pain. Appetite normal. Remained well until 5/11/65
re-admitted with severe pain in (L) hip and back due to col
of L.V.3* General condition remaining good and given radiot
to spine and (L) supraclavicular areas. Following radiother
general condition deteriorated; no further chemotherapy was
and patient died in hospital on 5/1/66 - 1 year from first

















Primary tumour not detected in life but P.M. revealed 2x1
scirrhous carcinoma of (R) breast, widespread deposits in v
liver, adrenals and lymph glands with microscopic deposits
(R) pulmonary embolism with thrombosis in (R) femoral ana i





Re 3ult: Initial response to cyclophosphamide was rapid and symptoms
for 2 months. Recurrence of severe back pain from vertebral
No further benefit from radiotherapy. 1-3 for 3j? months. No





Ca se: 51 M.K. 8/8/63 and 13/4/65 Me; 50 Sex: P
Di Carcinoma of (R) breast with skin, glandular, pleural, ske
and hepatic metastases. Poorly differentiated carcinoma
Letal
>f breast
His tor,y: Radical mastectomy for stage three carcinoma of (R) breast
1963, Previous ovariectomy in 1941 and hysterectomy 1958
Local chest wall recurrence January 1964 and at same time
a pre-malignant rectal polyp subsequently treated by diath
excision* Skin recurrences treated by radi otherapy April
but further recurrences chest wall and (R; axilla by July,
gradual appearance of skeletal metastases (R) hip, (R) ill
ribs between September and December 19b4« Further radiot
to recurrences December, 1964. Re-admitted 20/1/65 with
(L) leg chest and back} (R) pleural effusion, commenced
with steroids 22»/l/65 and pleural effusion aspirates, Co
reasonable for two months and then re-admitted because of

















(1) Radical Mastectomy; Stage III carcinoma of breast 1







(3) Excision of rectal polyp; 13/2/64 and 16/11/64
(4) Radiotherapy; (a) to (R) chest wall April 1964
(b) to chest wall, (R) acilla, (R) hip
(L) 9th rib, December 1964.
(5) Hormone therapy: (a) testosterone mg. 100 by I.M.I, d
21^/1/^5-1/2/63 then 100 mg. week
(b) cortisone acetate 100 mg. b.y mou







(1) Thiotepa: 48 mg. b.y I.V.I. 12/8/63-15/8/63 (4x12 rng
(2) Cyclophosphamide: 2.100 mg. by intrapleural insiillat
13/4/65-8/10/65.
8000 mg. by mouth IO/6/65-8/IO/65









When treatment with cytotoxins commenced in April 1965 the
had already received surgery, radiotherapy and hormone the
an attempt to control advancing metastatic uisease. Main
due to pleural effusion and anaemia. Symptoms rapidly isa
intrapleural cyclophosphamide subsequently controlled reas
well with oral therapy and occasional pleural aspiration,
alopecia. General condition remained good, required occa
blood transfusion and iron therapy to maintain haemoglobin
Managed at home for 6 months and was then re-admitted to w
of breathlessness, weakness end upper abdominal pain. No
able to manage at home. Symptoms improved and discharged














Ta3 >le 6u (continued)
to a mental hospital. General condition slowly deteriorat






Carcinoma of (R) breast with metastases to regional lymph n
pleura, lungs, pericardium, liver, suprarenal glands and bo:
Polypoid tumours of rectum - carcinoma in situ. Effusion
serous cavities with large collection in (R) pleural and coi






las ilt: Case of interest from "propl^ylactic" use of thiotepa at tim
mastectony and rapid recurrence of tumour. Symptomatic ca
for 7 montus with cyclophosphamide. Moderate alopecia and






Ca le: 52 S.O. 28/8/64 Age: 64 Sex: F
Di<gnosis: Carcinoma of breastj skin nodules and pleural effusion. CI
neoplastic cells in pleural fluid.
imps of
Hi story: (R) radical mastectomy for carcinoma in 1947 • Local skin re
in flaps on 4 occasions treated by radiation or local excis:
Remained in good general health, however, until July 1964 w
reported with increasing breathlessness found to be due to .
(R) pleural effusion, and further skin nodules. The effusio












satment: (2) Excision of recurrent skin nodules:
on 4 occasions between 1949 and 1963.












(l) Thiotepa: 45 rag. intrapleural 28/8/64-








Despite repeated appearance of small nodules in mastectomy
the patient's general condition remained good for 17 years
following operation. Then developed a large (R) pleural eff
which responded to a short course of thiotepa and did not r
aspiration for the last 15 months. She remained remarkably \
active until 3/12/65 (18 months after appearance of pleural
effusion) when readmitted to ward with anorexia, vomiting a
ascites. Remained well for a further short period following












Died at home - no post-mortem obtained.
Re;3ult: Nineteen year survival following radical mastectomy for car
(R) breast. Complete control of pleural effusion for 15 mon
cytotoxins and.no side effects. 2-3 for 15 months.
cinoma of
ths with
G-RQUP & : CARCINOMA OF OVARY
Table Is.
Case: 53 J.M.H. 26/6/62 Age: 41 Sex: F
Diagnosis: Mucus-secreting adenocarcinoma of ovaries with peritoneal and neck-
gland metastases. Initial biopsy of gland (L) side of neck.
History: Increasing lassitude and epigastric "fullness" after meals for 1 yea:
Swelling in (L) side of neck for 6 months, frevious health normal bu
treated for a "mental illness" in 1950. Biopsy of gland in (L) sidi
of neck 5 weeks previously in another hospital - mucus secreting





(1) Laparotomy: large soft tumours replacing 11/7/62
both ovaries, peritoneal metastases and in
stomach wall - partial gastrectomy and biopsy
of ovarian masses.
(2) Radiotherapy: 4.500 r to (L) side of neck 11/3/63-1/4/63
(3) Blood transfusion: 2x2 pints of whole blood
on 11/7/62 and 25/8/62
Cytotoxi<
treatmenl
E (1) Thiocolciran: 60 mg. by I.V.I. 9/7/62-14/7/62
operation cover
260 mg. by I.V.I. 8/8/62-26/10/62
(2) Cyclophosphamide: 9.900 mg. orally 5/11/62-28/2/63
3,000 mg. by I.V.I. 30/4/63-8/5/63




Fatient presented with malignant glands in neck thought to be from
primary lesion in stomach or colon. Laparotony and subsequent
histolo ical examination confirmed ovaries as the primary site.
Laparotomy carried out under cytotoxic "cover". Post-operative course
complicated by recurrent abdominal distension and development of a
chronic subphrenic abscess. Some initial response to cytotoxins and
home for short periods. Experienced recurrent bouts of depression,
abdominal pain and backache requiring repeated re-admission. Short¬
lived response to radiotherapy and cyclophosphamide but terminal




Permission for post-mortem not obtained.




Case: 5*V A.E. 7/8/62 Age: 39 Sex: F
Diagnosis: Carcinoma of ovary with widespread omental and peritoneal deposits.
Biopsy of omental deposit, ovary and Fallopian tube.
Histor.y: Perfectly well until last month of her first pregnancy (May 1962)
then experienced nausea and vomiting thought to be due to hiatus
hernia. Noted post-partum to have ascites - ? tuberculous.
Laparotomy at another hospital in July 1962 revealed carcinomatosis
peritonei from primary lesion of ovaries. Biopsy only carried out.
Previous or (l) Anti-tuberculous chemotherapy:
concurrent
treatment:
Streptomycin and P.A.S. for brief period June-July 1962
(2) Laparotomy: Biopsy of omentum, ovary and
Fallopian tube Jul,, 1962
(3) Radiotherapy: 3.3Q0r to whole abdomen and
pelvis 10/8/62-13/9/62
(4) Laparotomy: Subtotal hysterectomy, bilateral
oophorectomy with removal of
omentum 25/9/62
(5) Blood transfusion: 14 pints whole blood
between 21/8/62 and 23/7/63




(1) Thiocolciran: 130 mg. by I.V.I. 14/8/62-28/10/62
20 mg. intraperitoneally 29/10/62-4/11/62
(2) Cyclophosphamide: 13.500 mg. orally 17/1/63-30/5/63
4,650 mg. by I.V.I. 3/7/63-12/9/63
(3) Thiotepa: 45 mg. intraperitoneally 11/5/63




Thought initially to have tuberculous ascites but no response to
short period of anti-tuberculous chemotherapy and at laparotomy July
1962 found to have carcinomatosis peritonei. Following a course of
radiotherapy to the abdomen and I.V. thiocolciran a subtotal
hysterectomy and oophorectomy was carried out. Postoperative course
was stormy but cytotoxic therapy continued and patient was discharged
home on 21/11/63. Progress thereafter was rapid and weight increased
by 1 stone. Further weight gain by January 1963 but appetite
decreasing and masses palpable in abdomen - commenced cyclophos¬
phamide. Good clinical response for 4 months and then readmitted May
1963 with backache, ascites, increasing abdominal masses and
cystitis. Slow progressive downhill course with ascites requiring
aspiration on 3 occasions. Herpes Zoster in June 1963. Increasing






Peritoneal cavity almost obliterated by dense adhesic
multiple seedling metastases. Snail subphrenic absce:
grossly involved by metastases. Invasion posterior
by residual tumour. Few pleural but no pulmonary mete
significant metastases elsewhere.




Result: Good subjective and objective response maintained for




CASE NO. 54 PERIPHERAL BLOOD COUNTS
















200000 10000 100 _
180000 9000 90 _
160000 8000 80 _
140000 7000 70 _
120000 6000 60 _
100000 5000 50 _
80000 4000 40 _
60000 3000 30 _
40000 2000 20 _
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-Adenocarcinoma of ovary with peritoneal metastases. Biopsy of
omental deposit and pelvic mass.
Admitted to another hospital 21/11/62 with history of diarrhoea and
bilateral £xoin pain for 6 days and increasing abdominal distension
for 3 days. Influenzal illness one month previously. Laparotony
5/12/62 revealed mass (R) ovary and tube with omental nodules
? metastases. 2 litres of ascitic fluid removed; biopsy of pelvic
mass. No other procedure. Transferred 14 dgys postoperatively -
no significant symptoms.
(1) Laparotomy: Mass (R) ovary and tube.
1 omental metastases. Ascites.
Biopsy only




thickened omentum but no other
peritoneal masses. Ascites.
Biopsy only






(5) Chlorpromazine« folic acid, 3^ and iron:
December 1962-January 1963
(6) Paracentesis: Repeated aspiration of ascites 23/9/63-28/10/63
(1) Cyclophosphamide: 26,700 mg. orally
(2) Thiotepa: 50 mg. intraperitoneally








Tumour could not be excised at secondary laparotomy (8/1/63) which
was carried out after 2 weeks of oral cyclophosphamide therapy.
Following laparotomy a radical course of radiotherapy was given to
pelvis and abdomen and cyclophosphamide was continued. Complete
remission was maintained for 8 months. During this time almost
complete alopecia required a wig but subsequent strong regrowth of
hair while still on treatment. Readmitted 23/9/63 with ascites,
palpable mass P.V., but no other evidence of spread. Ascites
aspirated and thiotepa instilled intraperitoneally. No significant
benefit with increasing abdominal discomfort, nausea and. vomiting.
Developed pain and swelling (L) leg - massive thrombosis. Condition
static for short period on velbe and then deteriorated to death on
27/11/63.
Table 7c (continued)
.Autopsy 3 litres ascitic fluid. No discrete peritoneal nodules but whole
report: peritonei® appeared to be infiltrated by malignant tissue. No
obvious liver nodules but involved microscopically. Malignant mass
in pelvis binding: down and embedding bladder, ovaries and uterus.
No metastases outside the abdomen.
Result: Complete objective and subjective remission for 8 months then only
intermittent subjective response for further 2 months.
Table 7d
Case; 5£ S.G. 30/8/63 Ape: 42 Sex: F
Diagnosis: Papillary-cystadeno-carcinoma of ovary. Biopsy of omentum.
History: Increasing (r) sided abdominal pains for 3 months with awareness of
a lump in (r) abdomen and increasing malaise. Constipated and marked
urinary symptoms; no menstrual symptoms. N.B. Previously complained
of (R) sided abdominal pain at intervals for 8 years; variously
investigated in 3 other hospitals and finally referred to a
psychiatrist who found a large, tender mass in (R) side of abdomen!
Examination under anaesthesia on 23/8/63 revealed large masses in




(1) Laparotomy: Peritoneal cavity obliterated by
grossly thickened omentum infiltrated
by tumour. Pelvis and upper abdomen
"frozen" with adhesions and tumour
deposits. 2 litres of bloodstained
glairy fluid. Biopsy of omentum only. 26/8/63
(2) Blood transfusion: 4 pints whole blood 16/9/63




(l) Cyclophosphamide: 3.200 mg. by I.V.I.
and I.V. drip 5/9/63-13/9/63




Rapid refilling of abdomen with viscid, glairy fluid following
laparotouy. Became dehydrated, drowy and in gross electrolyte
imbalance. Marked peripheral oedema. No improvement from cytotoxins,
developed bedsores and ran a downMil course to death on 18/10/63.
.Autopsy
report:
Confirmed laparotomy findings of peritoneal cavity "frozen" by
adhesions and widespread tumour deposits. Liver, lymph gland in
abdomen involved. Pelvic and abdominal viscera ensheathed and
obscured by large amounts of tumour tissue. Bilateral pleural
effusions but no metastases outwith the abdomen. Histology confirmed
primary cystadenocarcinoma of ovaries.
Result: No benefit from cytotoxins
CASE NO. 56 PERIPHERAL BLOOD COUNTS
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Case; 57 m.C. 24/6/65 Age: 70 Sex: P
Diagno si b: Carcinoma of ovaries with ascites and omental deposits. Papillary
adenocarcinoma.
History: Laparotomy on 17/3/65 in another hospital for a 1 year history of
increasing abdominal distension and constipation. Clinical diagnosis
of ovarian malignancy made. When first seen here three months post¬
operatively general condition was good and only complaint was of





(1) Laparotomy: removal of uterus and appendages;
biopsy of omental deposit - in
another hospital 17/3/65
(2) Blood transfusion: 1 litre 5/11/65
1 litre 31/1/66
(3) Abdominal paracentesis: 5 litres 12/12/65
5 litres 29/1/65
2^ litres 5/3/66
(4) Diuretics: Neo Naclex and lasix from 7/IO/65
Cytotoxic
treatment:
(1) Thiotepa: 60 mg. intraperitoneally at time of operation
(2) Cyclophosphamide: 2.200 mg. by I.V.I. 24/6/65-26/8/65
2,200 mg. orally 9/9/65-13AV65




Patient with advanced ovarian malignancy when first diagnosed. Well
for 8 months and at home. Then developed rapidly re-accumulating
ascites, nausea, anorexia, occasional epistaxis and mild to moderate
alopecia. Platelet count low throughout possibly due to initial
thiotepa. Slow but progressive deterioration over last three months
of illness during which time only small amounts of oytotoxins were
used and repeated aspiration of ascites was necessary despite




Died at home - no post-mortem.
Result: Good subjective and objective response maintained for 8 months then
slow deterioration. Low platelet count throughout with occasional
mild epistaxis. Mild to moderate alopecia after 3 months of cyclo¬
phosphamide. 2-3 for 8 months.
Table 7f
Case: 5*3 E.H. 29/6/64 A^e: 60 Sex: P
Diagnosis: Carcinoma of (R) ovary with peritoneal metastases and
Pleomorphic anaplastic carcinoma of ovary.
ascites.
History: Emergency admission thought to have intestinal obstruction. Histoiy
was of increasing abdominal distension with backache for 1 week,
mild general malaise and mild anorexia for 6 weeks. No symptoms
referable to specific ^ystea^s. "Pleurisy" two years previously but
no other past histoiy of note. Married but no children; no other




(1) Laparotomy: large amount of ascitic fluid;
widespread deposits from apparent
primary in (R) ovary. Biopsy only. 7/7/64
(2) Low-salt diet and diuretics: from 11/7/64
(3) Blood transfusion: I? litres of whole blood 4/9/64
(4) Aspiration of (U) pleural effusion: 3 litres 3/9/64
1 litre 6/9/64
700 ml. 21/10/64
(5) Prednisone: 20 mg./day by mouth from 2l/l0/64
Cytotoxic
treatmenl
t (1) Thiotepa: 90 mg. intraperitoneally
(3 x 30 mg.) 11/7/64-20/7/64
(2) Cyclophosphamide: 2.600 rag. by I.V.I. 13/7/64-29/7/64
(3) Thiotepa: 60 mg. intrapleural (4 x 15 mg.) 3/9/64-19/9/64
(4) Cyclophosphamide: 300 mg. intrapleural 21/10/64




Presented with obvious ascites and a clinical diagnosis of ovarian
malignancy was made on d«y of admission. Diagnosis confirmed at
laparotony and treatment commenced with cytotoxins, low-salt diet
and diuretics. Marked diarrhoea following intraperitoneal thiotepa
and diuretics. Settled and apart from superficial wound breakdown
progress was satisfactory. Remained well for 1 month then developed
(R) pleural effusion which required repeated aspiration. Epilation
was marked and from second month general condition steadily-
deteriorated. Anorexia was main complaint with intermittent bouts
of vomiting and diarrhoea, listlessness and weight loss. Died at
home 16/11/64, 5 months from diagnosis.
.Autopsy
report:
Died at home - post-mortem not obtained.
Hesuit: Cytotoxins given in 2 courses with an interval of 5 weeks between.
Initial course for intra-abdominal metastases and control of ascites.
This was effective and ascites did not require further aspiration
over 5 months. Second course given for pleural effusion but this
much less effective. Side effects from initial course were marked
with diarrhoea and alopecia. 1-2 for 5 months.
Table §a
GROUP H : TESTICULAR TUMOURS
Case: 59 D.H. 5/10/62 Age: 30 Sex: ft
Diagnosis: Teratoma of left testis (intra-abdominal). •
History: First reported 4/10/62 with a two-week history of frequency of
micturition, lassitude and cramp-like pain in (R) leg, worse on




(1) Radiotherapy: 976r to midline of pelvis
between 29/10/62 and 2/11/62
(2) Laparotony and removal of large left testicular
tumour, intra-abdominal and freely mobile
on cord 12/11/62
(3) Radiotherapy: 3.476r to para-aortic glands 26/11/62-2/1/63
(4) Blood transfusion: 2 pints whole blood 12/11/62
Cytotoxic
treatment:





Large abdominal mass arising from pelvis tentatively diagnosed as a
testicular tumour and confirmed at laparotomy. Cytotoxins used as
prophylactic cover two days before operation, on day of operation
and two days after operation. Completed radiotherapy without





Result: 3 P. for 15 months to period of follow-up.
Table 8b
Case; 6 0 T.T. 7/6/63 Age: 30 Sex: M
Diagnosis: Terato-carcinoma of left testis,with pulmonaiy metastases.
Histology: terato-carcinoma with chorio-carcinomatous elements.
History; Pain, swelling and tenderness of left testis for 5 weeks. Aching





(1) Left orchiectomy: 11/6/63
(2) Radiotherapy: 5.000r to abdominal gland
fields 3/7/63-5/8/63
3,550r to deposit left upper
chest 29/13/63-20/12/63
3,000r to left hilum and
mediastinum 31/12/63-27/1/64
(3) Blood transfusion: 3 pints whole blood 15/8/63
(4) Bone marrow extraction: modest yield only 12/8/63
Cytotoxi c (1) Mannltol mustard: 500 mg. by I.V.I. 10/6/63-34/6/63
treatment: operation cover
(2) Vinblastine sulphate: 38.5 mg. by I.V.I. 13/8/63-16/9/63
(3) Methotrexate: 12.5 mg. by mouth 13/8/63-17/8/63
~ "
60 mg. by I.V.I. 18/8/63-29/8/63
115 mg. by mouth 30/8/63-28/9/63
Total = 187.5 mg.
Clinical
OQ
Uncomplicated recovery following (L) orchiectomy. Carried out under
cytotoxic cover. Completed postoperative radiotherapy without
incident. Small haemoptysis 6/8/63 and chest X-ray revealed a small
metastasis in left upper lobe. Commenced cytotoxic therapy on
13/8/63 after bone marrow extraction and storage. Remained
reasonably well with occasional small haemoptyses and transient
chest pains. Metastasis in (L) upper lobe remained static but
further metastases developed at (L) hilum - both areas of metastasis
being treated by radiotherapy with gradual resolution of the lesions,
At last review 13/2/64 was remaining well with normal weight and






Result; 3 P. for 6 months to period of follow-up.
Table 8c
Case: 6;L B.A. 17/7/63 Age: 49 Sex: 1
Diagnosis: Seminoma of left testis, with widespread skeletal, pulmonary and
lymph node metastases.
History: (L) orchiectomy carried out in Singapore for histologically proven
seminoma on 10/9/62. Postoperative radiotherapy to (L) inguinal
region and para-aortic chains. Remained well until 8/4/63 when he
developed a metastasis in his (r) ischial tuberosity. by 17/5/63
had developed a cauda equina lesion and pulmonary metastases.
Lesions treated by radiotherapy with temporary improvement. Patient
developed haemoptysis in June 1963 and received further radiotherapy
to the mediastinum. Increasing bone and mediastinal lesions with








(1) Radiotherapy: 2.67Qr to para-aortic glands end
3,150r to left inguinal region 25/9/62-6/11/62
(2) Radiotherapy: 4.200r to posterior sacral area
l,950r to mediastinum 21/5/63-21/6/63
l,100r to right pubic region 9/7/63-11/7/63
(3) Blood transfusion: total of 13 pints
"between 18/7/63 and 29/8/63
(4) Antibiotics: Erythromycin 28/8/63-3/9/63
Penbritin
(5) Prednisone: 30 mg./dav by mouth 22/7/63-2/8/63
Cytotoxi
treatmen I, (1) Cyclophosphamide: 3.200 mg. by mouth over3 weeks prior to admission
4,600 mg. by I.V.I. 1/8/63-7/9/63




General condition was very poor on admission; improved by blood
transfusion, prednisone and diet. Severe pain in (R) hip and leg
controlled for 6 weeks by cyclophosphamide but course interrupted by
recurrent haematemesis. Pulmonary metastases demonstrated regression
and by 3/9/63 was feeling well with good appetite and free of pain.
Sudden, rapid deterioration with pyrexia and falling blood count;




Result: 2-3 for 2 months
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Case. No, 6l: Testicular Nunour-■oGrainoma
Fig. 1: Chest X-ray 12/0/6$.
Fig. 2: Chest X-ray 20/0/6$.
Table gd
Case: 62 A.j.i. 17/9/63 Age: 22 Sex: M
Diagnosis: Terato-chorio-carcinoma of (R) testis - with skin, lung and lymph
gland metastases.
Hi story: Admitted 17/9/63 for incision of a supposed abscess (infected
haematoma) over (L) upper arm said to have resulted from a motor
cycle accident 6 weeks previously. Lesion recognised clinically as a
skin deposit from an enormous tumour of the (R) testis. Patient
admitted to a progressive, painless swelling of (r) testis for
17 months after initial acute symptoms were thought to be due to
epididymo-orchitis. Also complained of increasing malaise for
previous few months, anorexia, and loss of 2-g- stones in wt. with




(1) Physiotherapy: for leg injury following motor cycle accident.
(2) Antibiotics: Penbritin. 250 mg. 6-hourly from 27/9/63
(3) Blood transfusion: Total of 24 pints whole
blood between 19/9/63 and 16/12/63




(1) Mannitol mustard: 100 mg. by i.v.i, as
operation cover 19/9/63
(2) Methotrexate: 50 mg. by I.V. drip over 72 hr. 19/9/63-21/9/63
(3) Cyclophosphamide: 3.800 mg. by i.V.i. 28/9/63-2lAo/63
(4) Methotrexate: 30 mg. by mouth 25/10/63-6/11/63
(5) Cyclophosphamide: 2.000 rag. by I.v.i. 13/11/63-8/12/63




Patient demonstrated widespread malignant disease on admission but
removal of the primary tumour was considered reasonable to prevent
further dissemination from source and to provide histological con¬
firmation of tuaour type. Uncomplicated postoperative course despite
commencement of cytotoxins on day of operation. Within 5 days of
methotrexate infusion was feeling generally improved with return of
appetite and disappearance of pain in (R) upper arm. Commencing
regression of skin metastases and abdominal glands by 28/9/63 and
improvement maintained for 3 wks. Thereafter developed deep vein
thrcrab0sis in (L) leg and increasing skin and abdominal glandular
metastases. General condition fluctuating but over-all deterioration
with intermittent gastro-intestinal bleeding, vomiting and rapid
increase in size and number of metastases. Died 24/12/63.
Autopsy
report:
Terato-chorio-carcinoma of (r) testis with large necrotic ulcerating
deposit over (L) humerus and similar but smaller lesions over (L)
clavicle and sternum. The lungs were heavily infiltrated with
massive involvement of mediastinal and retroperitoneal glands. There
were multiple petechial haemorrhages throughout G-.I. tract but liver
free of metastases. Death due to progress of disease and broncho¬
pneumonia.
Result: 0-1 for 3 months
Table 8e
Case: 6.5 M.W.F. 5/11/63 Age: 25 Sex: M
Diagnosi s: Bnbryonal-cell carcinoma of (R) testis, with pulmonary metastases.
History: Four months' history of painless swelling of (R) testis. Chest X-ray
taken at time of first reporting revealed a mass in the (L) hilum




(1) (r) orchiectomy: for malignant tunour of
testis, under cytotoxic cover 11/9/63
(2) Radiotherapy: 2.038r to both lung fields ll/ll/63-27/11/63





(1) Manmitol mustard: 300 mg. by I.V.I. 10/9/63-12/9/63
(2) Methotrexate: 50 rag. by I.V. drip I6A0/63
(3) Cyclophosphamide: 2.600 mg. by I.V.I. 16/10/63-1/11/63
3,200 mg. by I.V.I. 23/12/63-12/1/64




Although pulmonary metastases were present at first diagnosis
removal of the primary tumour was carried out to reduce further
dissemination. In view of widespread nature of disease and poor
general condition cytotoxic therapy was continued with methotrexate
and cyclophosphamide intravenously. General condition improved and
some regression of pulmonary metastases produced. Radiotherapy
commenced on H/ll/63 when evidence of new metastases seen on chest
X-ray. Following initial treatment general condition deteriorated,
lost 10 lb. in weight and became nauseated and anorexic. Further
glands in abdomen treated by radiotherapy. General state poor
despite combining radiotherapy with vinblastine, but at last review




Result: 1-2 for 5 months
Table 9<
GROUP Ii RENAL CARCINOMA (HYPERNEPHROMA)
a
Case: i% H.F.S, 3/10/63 Age: 40 Sex: M
Diagnos:Ls: Hypernephroma (R) kidney: pulmonary metastases.
History First reported 29/8/63 with increasing breathlessnej
cough, intermittent pyrexia, anorexia and weight los
over the previous 8 months. At laparotomy (at anoth<
19/9/63 a (L) hypernephroma was found and removed. 1











(1) Laparotomy: (L) nephrectomy 1







(1) Cyclophosphamide: 1.300 rag. by I.V.I. 2
2,000 mg. by I.V, drip 3
2,100 mg. by I.V.I. <
(2) Vinblastine sulphate: 38 rag. by I.V.I. 1
(3) Cyclophosphamide: 1.800 mg. orally 1










Originally thought to have carcinoma stomach and byj
discovered at laparotomy. Noted to have small metast
lower lung fields but radiotherapy given to (L) rens
of local extent of ttmour. General condition remains
but cytotoxic therapy commenced on 17/12/63 because
size of pulmonary metastases. Remained in good healt
to work for 4 months. Weight steady and appetite fai
hair. Thereafter slow deterioration and at last revi
pulmonary metastases were steadily increasing in si2
he complained of a persistent, productive cough and
ernephroma only
ases in (R)











Result: 2-3 for 6 months
Table 9
&r0up I : RENAL CARCINOMA (HYPERNEPHROMA)
(continued)
b
Case; ( >5 V.M.A. 28/5/63 Age: 49 Sex P
Biagnos Is: Hypernephroma (r) kidney: extensive local recurren
skeletal metastases.
se, pulmonary and
History > (R) nephrectonjy for histologically proven bypernephi
hospital August 1962 for 10-month history of backacl
and (R) loin pain. Found in May 1963 to have lung ai
metastases and was in considerable pain. Thereafter
severe pain in (r) loin, hip and thigh, numbness and















(2) Radiotherapy: 400r to abdominal mass ]
Course interrupted because of falling W.B.C.








(1) Cyclophosphamide: 2.400 mg, by I.V.I, and
I.V. drip ]
6,200 mg. orally 2









111 and extremely distressed on admission with an er
the (R) side of the abdomen, extensive pulmonary met
metastases in (R) femur. Severe intractable pain, ur
form of analgesic. Maintained pain relief with cycle
clearing of pulmonary metastases. Minimal change in
mass. Required repeated blood transfusion to maintai
Complete epilation - wig fitted. Three months after
condition began to deteriorate, and abdominal mass i













Emaciated. Large mass in (R) loin extending into (l/
mass fixed to retroperitoneal structures. Liver gros
widely infiltrated by tumour deposits. 2j x 2 cm. tu
(R) lung but no other obvious metastases in lung. Mi






Result: 1-2 for 4 months
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Case No. 65: Renal Carcinoma
Fig. 1: Chest X-ray 29/5/63. Fig. 2: Chest X-ray 21/6/63.
Fig. 3 • Chest X-ray 12/$/63.
• 1
T able 9c
se: 66 J.w. 9/3/65 A£e: 66 Sex: M
£i agnosis: (R) i\ypernephroma. No histology obtained.
Acmitted as a tranafer from a medical ward with a 4-month
nausea, vomiting, anorexia, diarrhoea and the loss of 1 st
weight. Thare had been one brief episode of haematuria 3
previously, but no otner urinary symptoms. Had previous!,
under care of cardiology unit since September 1962 followi
episode of Eyocardial infarction and congestive failure,
to be severely hypertensive ani on treatment for this. I
gymptoras thought to be due to cardiovascular state or its















eatraent: ft] Aldomet 250 mg. t.i.d.Bigoxin 0.25 mg. b.i.d.
C,ytotoxic fl) Cyclopnosphamide: 3,000 mg. by intra-arterial injection
treatment: (R) renal artery (3 x 1,000 mg.)
600 rag. by I.V.I.







Patient with known severe hypertensive heart disease pre3e
unusual history of nausea, vomiting and diarrhoea due to a
hypernephroma of (R) kidney. Symptoms initially ascribed t
condition and to medical treatment. Operation was not co
feasible and despite the lack of histological proof, it wa
to try the effects of cytotoxins. Given by intra-arteria
intravenous injection, cyclophosphamide produced a rapid a
relief of principal symptoms. Patient remained well and
for 5 weeks, but was then re-admitted to a medical ward wi
















Re £ult: Rapid and coraple te relief of vomiting and diarrhoea with c
phosphamide, but little significant effect on tumour itsel
Benefit lasting 5 weeks only, but side effects limited to




Case Ho. 66: Renal Carcinoid.
fig.l: Inferior vena cavagram: Pig.2: Inferior vena cavagram:
tumour invasion: A.P. tumour invasion: lateral
view. vim/.
Pig. 3: Arterial infusion of
cyclophosphamide 16/V65.
Case No. 66,
Fig. 4: Arterial infusion of Pig. 5' Second arterial infusion
cyclophosphamide 16/3/65, of cyclophosphamide ?5fo/6$.
Pig. 6: Second arterial infusion of
cyclophosphamide 25/h/6^.
Pig. 9s Chest X-ray: (L) ventricu¬
lar aneurysms 12/k/65.
Case No* 66.
Pig. 7: Third arterial infusion Pig. 8: Third arterial infusion
of cyclophosphamide of cyclophosphamide
12/1/65, 12/1/65.
Ta >le 9di.
Ca ie: 67 J.C. 10/ll/62 and 15/6/64 Age: 60 Sex: K
Di agnosis: Hypernephroma (R) kidney - massive local recurrence and pul
metastases. Typical renal carcinoma.
monary
Hi story: First admitted 10/L1/62 as a transfer from a medical ward w
3-month history of intermittent gnawing pain in (r) loin. A
had revealed a tumour of (R) kidney. At operation on 13/ll/
large hypernephroma was found extending along renal vein an
inferior vena cava with invasion of peri-renal tissues. Exc
known to be incomplete. Remained well, relatively symptom-f
at work until 3/10/63 when a palpable mass was felt beneath
By 15/1/64 patient was himself aware of the mass but had fe
symptoms. At review on 9/5/64, however, was experiencing
considerable local pain with pain and paraesthesiae down ba
(R) leg. Given 1 week1s palliative radiotherapy 13/5/64 to
but with relief of leg symptoms only. In view of severe loc


















(1) (r) nephrectomy for large carcinoma of (r) kidney. Exci
known to be incomplete. 13/11/62
(2) Radiotherapy: to (R) renal area - details of dosage no
13/5/64-
(3) Analgesics: Various - from April 1964.








(l) Cyclophosphamide: 3.030 mg. by I.V.I, and I.V. infusio
20/6/64-










At the stage of starting cytotoxic therapy the patient was
complaining of severe pain in relation to large tumour mass
side, despite a palliative course of radiotherapy 5 weeks p
He had lost weight following radiotherapy and appetite was
beginning to return. 10 days after starting cyclophosphamid
was definitely less marked, but had had some mild haematuri
Reduced need for analgesics. 1 month later was virtually f
pain in tumour, but leg pain and paraesthesiae had returned
larger and pulmonary metastases extending. Oral cyclophosph
increased, but no further benefit and general condition ste















Died at home. No post-mortem obtained.
Re suit: Definite pain relief from use of cytotoxins but maintained
6 weeks only, N.B. Cystitis from ? cyclophosphamide but no






Ca se: 68 H.S. 29/9/65 i^e: 53 Sex: P
Dii■tgnosis: Hypernephroma of (r) kidney. Typical renal carcinoma.
Hi story: First admitted to another hospital in September 1965 with a
swelling which she had noticed in (r) side of her abdomen f
previous 6 weeks. Denied any other symptoms at this time. N
previous or family history of significance. Investigations,
including aortography, established a diagnosis of (r) hyper











(l) Laparotomy: in another hospital. Extensive, invading h
nephroma of (R) kidney. Inoperable. N.B. C,







(l) Cyclophosphamide: 1.500 mg. by intra-arterial infusion
(R) renal artery, i.e. per
femoral puncture and seldi





1,400 mg. by I.V.I. 4/13/65-
4,200 mg. by mouth 18/13/65













Patient presented with an enormous mass in (R) side of abda
was curious3y free of other symptoms. At laparotomy the mas
to be an extensive inoperable hypernephroma. It was conside:
proper to treat this tumour with cytotoxins and on 3 occasi
cyclophosphamide was infused via the (R) renal artery. At tl
time intravenous and oral therapy were continued. Over a pe
5 months the mass in (R) side of abdcraen slowly increased i
but the patient remained active, reasonably well and entire:
of pain. She became mildly anaemic by mid-January and there
gradually deteriorated with occasional vomiting and increas.
lethargy. Re-admitted to original hospital on 3/3/66 with v
weakness and depression. Hb 64/. Vomiting settled but two 1



















Massive carcinoma of (R) kidney infiltrating abdominal wall
anteriorly end laterally with penetration into colon. Ketas
both lungs. Massive haemorrhage into colon due to penatratii
carcinoma. Large areas of necrosis in primary tumour.
;ases to
ig
Resrnlt: Cytotoxins exhibited over period of 5 months. Probably litt.
on tumour until later stages. No significant side effects.
1-2 far 5 months.
Le effect
1
Case No. 68: Renal Carcinoma
Fig. 1j Arterial infusion of
Cyclophosphamide 28/2/6$,
Fig. 2: Second arterial infusion
of Cyclophosphamide 6/2/66.
Ta
GROUP J : CARCINOMA OP BLADDER
>le
Ca. se: 69 W.K. 12/2/64 Age: 70 Sex: M
Di gnosis: Carcinoma of base of bladder vdth local infiltration, gland
hepatic metastases. Undifferentiated infiltrating squamous
ular and
carcinoma.
Hi 3tory: First treated in February 1962 for a (L)-sideS renal cyst g
rise to aching discomfort in (L) loin. For the next 12 mont
patient complained of increasing frequency, supra-pubic pai
dysuria and nocturia. Symptoms subsequently attributed to a
infiltrating carcinoma of base of bladder although initiall
prostate had been thought the site of origin. No response t
treatment vrflth oestrogens and not considered suitable for r
therapy since site and extent of tumour could not be define















(1) Hormone therapy: (a) Honvan - 300 mg./day 25/3/65-
(b) Stilboestrol - 90 mg ./day18/4/65-
(2) Antibiotics: Various - for recurrent urinary tract inf
(3) Uretero-colic anastomosis: Widespread deposits in live
abdominal glands; hard infiltrating tumour bladder n
pro state. 28/6/65










(1) Cyclophosphamide: 1.000 rag. by I.V. infusion over 24 b
13/6/65-










Despite treatment with antibiotics and hormones, patient's
remained unchanged. Persistent, severe supra-pubic and (L)
abdominal pain resulted in patient being virtually bedridde
Cytotoxins started in hope of relieving severity of pain ar
supporting proposed uretero-colic anastomosis. Within 10 da
starting treatment pain relief was virtually complete, but
and incontinence persisted. Uretero-colic anastomosis carri
without incident on 28/6/65, but general condition remained
No further cytotoxin therapy given and patient survived in













Died in Nursing Home and post-mortem not obtained.
Re suit: Although cytotoxins given for only short period and in mode





GROUP K : CARCINOMA OF FROSTATE
le Ha
Ca 1§: 70 T.P. 6/9/62 and 27/8/63 Ape: 59 Sex: M
Di« ./gnosis: Carcinoma of prostate with skeletal metastases.
Hi itory: First admitted 6/9/62 with 1-month history of backache, con
and marked weight loss. (Had previously been investigated i
hospital in 1957 for weight loss and general malaise but cai
found.) Now presented with clinically obvious carcinoma of
with widespread skeletal, metastases, particularly in lumbar
















(2) Steroids: (a) Hydrocortisone 500 mg. I.Y.I. 30/7/63
(b) Cortisone acetate 100 mg. IM. 1x2 1
(c) Cortisone acetate 25 mg. t.i.d. orally
from 2/8
(3) Oestrogens:
(a) T.A.C.E. 12 mg. t.i.d. ty mouth 15/8/63-
(b) Ethinyloestradiol 0.6 mg./day from 29/8/63





(l) Cyclophosphamide: 2.500 mg. by I.V.I. 11/9/63-








Marked remission of symptoms following bilateral orchiectorn
with healing of skeletal lesions. Remained well and at work
30/7/63 when he was admitted to another hospital with sudde
of severe backache, fatigue, lethargy and dehydration. Exam
at this stage revealed a waay pallor (although Hb 78/), pre
senility, dehydration, a firm, irregular prostate and a lar
mass occupying hollow of sacrum. X-rays revealed extensive
reactivation of metastases. Transferred for further managera
On admission was unfit for any further surgery althou$i bow
almost obstructed from tumour mass in pelvis. Started
cyclophosphamide II/9/63 and general condition improved by
White blood count and platelets then dropped to very low le
patient barrier-nursed. By 21/9/63 was weak and deteriorati
Small melaena 22/9/63 - transferred and same day collapsed
severe hypotension. Despite I.V. hydrocortisone and blood




















Oedema and early decomposition of face and trunk. Large ble
deep red blobs in skin. Abdomen distended and early gangren
changes of scrotum. Pronounced hiss of escaping gas on refl
scalp. Culture of CI. Welchii and gram negative colifoims f
exudates and tissues. Death due to ?gram negative septicaen






Re suit: Cytotoxins exhibited late in disease process. Produced prof
marrow depression within one week of commencement and patie




Case No. 70: Carcinoma of Prostate
Fig. Is Chest X-ray 2^8/62. Fig. 2: Chest X-ray 10/3/63.
Fig. 3 5 X-ray of pelvis 28/8/(52.
Table 1%
ORCUP L : ADRENAL CARCINOMA
i
Case: 7 1 J.R. 13/2/62 Age: 43 Sex; H
Dia^jio s: -s: Adrenal carcinoma. (Mediastinal, bone and skin raetas
(Biopsy of abdominal mass.)
tases.)
History, Laparotomy August i960 for history of persistent bac
loss and anorexia over previous 3 months. Biopsy of
irremovable retroperitoneal mass above (L) kidney re
adrenal carcinoma. Lesion treated by irradiation wit
Mediastinal metastases were also treated by irradiat
later. Remained well and at work until February 1962
admitted with increasing listlessness, dysphagia, we















(1) Radiotherapy: 5.700r to primary tumour 2
4,300r to mediastinal metastases
(2) Analgesics:
(3) Blood transfusion: total of 14 pints 9
(4) Haematinics:
(5) Radiotherapy: 3.967r to mediastinum *)
5,240r to (L) buttock ? 2






treatmer|. (1) Nitrogen mustard: 40 mg. by I.V.I. 540 mg. by I.V.I. 1
(2) Cyclophosphamide: 1.000 mg. by I.V.I. 2
1,000 mg. by I.V.I. 1
1,000 mg. by I.V.I. 2
18,300 mg. orally 5
1,000 mg. by I.V.I. 1
10,600 mg. orally S
1,500 mg. by I.V.I. 1
2,700 mg, orally I
1,000 mg. by I.V.I. 2
550 mg. orally 1



















When admitted in February 1962 patient was unwell wl
weight loss, dysphagia and a palpable mass in (L)
two weeks of starting chemotherapy with nitrogen mu
phosphamide there was a marked improvement both objc
jectively and the patient returned to work on l8/4/£
for 4 months and was then readmitted following an e;
an epileptiform convulsion. No obvious lesion on e:
discharged after a few days, on continued treatment,
was readmitted with similar symptoms to those in Feb:
now had pain in (l) tibia also. Again made a rapid
response to cyclophosphamide intravenously. Discharg
11/3/63# Thereafter, however, periods of remission
18/7/63 ^nptoms were again severe. Further rediothe
mediastinum, buttock and (L) knee and symptoms stop
well for 6 weexs but in severe pain thereafter in
knee. Again responded dramatically to cyclophosphami
for 1 month only. Thereafter relentless downhill coij:
17/12/63, Case of especial interest from point of vj
response to cyclophosphamide intravenously on at lec












ere short and by












Death from acute pulmonary oedema secondary to care
secondary to carcinoma ? from (l) adrenal. Widesprej
deposits with considerable necrosis. Glands of media
abdomen widely infiltrated. Both kidneys embedded ir




a mass of tumour
nals.acre
Result: 2-3 for 18 months
Table 13 )
Case; 72 O.M. 17/9/62 Age: 26 Sex: F
Diagno sis; Carcinoma of adrenal gland with pulmonary metastasei
(Biopsy of abdominal mass.)
History •• One year increasing weight loss, listlessness and b:
exertion. Increasing abdominal pain, vomiting, fevei
for 6 months - following birth ofsecond child. Init:
have a polycystic (L) kidney and recurrent pyelitis












(1) Blood transfusion: at birth of second child J
Also total of 7 pints whole blood (
(2) Laparotomy: Large tumour mass confluent with i
upper pole of (l.) kidney found and resected
(3) Radiotherapy: 5,766r to (L) kidney region :










(1) Maimitol mustard: 400 mg. by I.V.I. 1
operation cover
(2) Thiotepa: 7.5 mg. intra-abdominal -at operation
(3) Cyclophosphamide: 1.000 mg. by I.V.I. 2
2,400 mg. orally f
N.B. Refused to take further cyclophosphamide
because of fear of hair falling
(4) Methotrexate: 50 mg. by I.V. drip












Following operation and radiotherapy patient gained
of abdominal pain and felt generally well. Remained
28/2/63 when pain recurred in (L) hypochondrium and
revealed metastases in (T,) lower lung- fields and in
Readmitted and cyclophosphamide commenced. Allowed t
experiencing aching pain in (L) hypochondrium. Readn
with severe back pain, anorexia, vomiting and weight
metastases in lung, liver and spine. Thereafter deve
weakness of legs, bladder dysfunction and finally ps















Resuit; 3 for 2 months
'
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Case No. 72: Adrenal Carcinona
Pig. 1: Chest X-ray 10/1(^62. Fig. 2: Chest X-ray 12/10/62.
Tal
GROUP M : CARCINOMA OF OESOPHAGUS
t>le 13a
Ca £* 73 A.A.C. it/U/62 Age: 45 Sex: M
Dii gnosis: Carcinoma of oesophagus - middle third. lymph node, lung an
metastases. Anaplastic squamous cell carcinoma.
1 liver
Hi story: First admitted to another hospital 24/10/62 with a 1-month
of increasing dysphagia. Able to swallow fluids only. Anore
general malaise and listlessness for same period. Occasiona
vomiting of recently taken food. Loss of 1 stone in weight
3 months. Congenitally absent (R) kidney diagnosed July 196












(1) Oesophagoscopy: obstruction at 22 cm. - could not be p
? extrinsic lesion. 30/10/62
(2) Biopsy gland (L) axilla: 9/11/63
(3) Oesophagoscopy: malignant lesion of oesophagus
just above aortic arch - biopsy 2
(4) Laparotomy and insertion of Mousseau-Barbin tube
- inoperable carcinoma of oesophagus 6/12/62
All above carried out at another hospital.
(5) Antibiotics: penicillin 250 mg. 6-hourlv by mouth from
(6) Diuretics: Hydrosaluric K - from 28/12/62









(l) Cyclophosphamide: 1.000 mg. by continuous infusion
27/12/62










Advanced carcinoma of oesophagus when first presented. At t
operation was already complaining of severe pain in (R) hip
Numbness and weakness (R) buttock - thought to have metasta
pelvis and sacrum. Dehisced wound on 5th post-operative day
Thereafter developed urinary retention and required an indw
catheter. Developed anaesthesia of perineum 14/12/62 and al
X-ray evidence was lacking, was considered to have a cauda
lesion. Also bilateral chest signs. Allowed home for Christ
re-admitted on 27/12/62 with continuous, severe pain in (R)
and perineum since previous day - unrelieved by repeated an
Now showing evidence of weight loss with swelling of feet ai
ankles. Bedsore. Started cyclophosphamide 27/12/62 and by n
was pain free. Remained virtually pain free thereafter, but
condition gradually deteriorated with increasing chest infe





















Wasted. Large bedsore over sacrum. Bilateral pleural effusi
metastatic deposits in lungs. Middle third of oesophagus re
carcinoma with invasion of regional lymph nodes and also th
abdomen. Few small deposits in liver. Deposits in sacrum. D






Rej jult: Dramatic and sustained relief of pain with cyclophosphamide
effect on course of disease, 0-1 for 3 months.
but no
s
Case No* 73: Carcinoma of Oesopha/aia
Fig. 1: Barium swallow: Fig. 2: Chest X-ray 26/10/62.
Carcinoma of oesophagus
26/10/62.
Fig. 3: Chest X-ray Vll/62. Fig. 4: Chost X-ray l/l/6.5.
1
Cajses 74 J.A.P. 17/7/63 i£g: 33 Sex; M
Pi; [gnosis! Carcinoma of oesophagus - middle third - with metastases in lymph
glands and brain; extensive local invasion. Anaplastic squamous call
carcinoma.
xdstory; 7-month history of increasing hoarseness, heartburn aid dysphagia.
Subsequently developed exertional dyspnoea, cough and ti^it:iess
around lower chest, laryngoscopy on 5 occasions between January and
June 1963 revealed oedema of larynx only and bronchoscopy was
negative also. Diagnosis missed until 15/7/63 when oesophagrscopy
revealed lesion at 27 cm. At this stage breathlessness was ioarked;
could only swallow fluids, appetite poor and weight decreasing.





(1) Symptomatic treatment: for hoarseness and heartburn
January to June 1963
(2) Repeated laryngoscopy and bronchoscopy: between January
June 1963
(3) Jesophagoscopy: carcinoma of the oesophagus at 27 cm.
15/7/63
(4) Tracheostomy: Under local anaesthesia 3/8/63
(5) Radiotherapy: 1,47Or to primary tumour area 13/8/63-2















(3-) Thiotepa; 60 mg, intrapleural
(l x 15 mg., 2 x 30 rag.)
(2) Cyclophosphamide; 1,000 rag. by continuous I.V. infusioi
24 hours 23/7/63
1,500 mg. by I.Y.I. 26/7/63-
(3 x 500 mg.)












Diagnosis repeatedly missed over a period of 6 months and c
already advanced when finally diagnosed. On admission, was
looking, cyanosed, grossly dyspnoeic with inspiratory stria
Severe respiratory distress was only partly relieved by tre
Small (L) pleural effusion. Tube feeding txiroughout. Slight
raent following intrapleural thiotepa and intravenous cyclop
but developed weakness of (R) hand and transient jaundice b
27/7/63 &nd 5/6/63. Started radiotherapy 13/8/63 but no eff
10 day course and finally unfit to attend. Thereafter devel
periods of extreme distress and agitation culminating in st















Mai-iced finger clubbing. (L) pleural effusion. (l<) lung coll
Invasion of (L) bronchus by tumour arising from middle thir
oesophagus. Tumour invading mediastinum and (L) hilum lymph
with massive haemorrhage into secondary in (L) parietal reg
brain. Death uue to respiratory embarrassment and cerebral





Re suit: .Although a large amount of cytotoxic drugs where administer
short period no significant benefit was obtained and the ai
pursued a relentless downhill course. 0 for lg months.
ed over a
sease













































diagnosis.- cAQCfMMj OF OCnHmoS.
TREATMENT TH'OT&A ' ; ,47Mf-AftWU.
CYUOMOVHtWOE ! / / /VJCCTIM
• /•/
3 tftT/KXr€t/ MOST^RQ : /V. (t/TCCTtW.
















700000 10000 100 _
180000 9000 90 _
160000 8000 80 _
140000 7000 70 _
170000 6000 60 _
100000 5000 50 _
80000 4000 40 _
60000 3000 30 _
40000 7000 20 _













Case Ho. 74: Carcinoma of Peso:;haras
Fig. Is Chest X-ray 5/3/63. Fig. 2: Chest X-ray 10/7/63.
Fig. 3: Chest X-ray 9/8/63. Fig. 2|.: Chest X-ray 12/8/63
Ta
GROUP N ; CARCINOMA OF STOMACH
ale Mte.
Ca R.B.H. 21/10/63 A^e: 42 Sex: M
Dii ignosis: Carcinoma of stomach with hepatic metastases and local recu
Anaplastic carcinoma of stomach.
rrence.
Hii itor.y: Partial gastrectomy for 20-year history of chronic duodenal
7/5/63 - in another hospital. Examination of stomach remnan
revealed a small pyloric carcinoma. Post-operative recovery
and convalescence interrupted by a subphrenic abscess. Ther
remained fit and well and at work until 21st October 1963 w
was re-admitted with a 3 week history of severe (r) upper a
pain, abdominal distension, nausea, heartburn and anorexia,
steady, Found to have ascites and massive hepatomegaly from
metastases. Transferred for further management. No previous
















at operation - in another hospital
7/5/63
(2) Abdominal paracentesis: Amounts of 2^-3? litres aspira
each of 6 occasions between 21,
and 12/11/63





(1) Thiotepa: 60 rag. intraperltoneally 21/10/63
(4 x 15 mg.)











Presented with massive hepatic deposits and ascites from ga
carcinoma 5§~ months after partial gastrectomy for chronic d
ulcer, at which operation carcinoma was not suspected. Desp
of cytotoxins, diuretics and low-salt diet continued to exp
severe upper abdominal pain, recurrent ascites, nausea and
Increasing naevi over upper trunk, progressive hepatic enlai
and venous dilatation over anterior abdominal wall. Progres










lg- litres of ascitic fluid. Mary small peritoneal deposits
throughout abdomen; omental masses. Large mass of tumour in
remnant, adherent to pancreas and transverse colon. Liver w:






Re jult: No benefit from cytotaxins either in controlling recurrent
or in affecting disease progress. Nausea and vomiting sever
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Ca se: 76 T.H. ll/LQ/64 Age: 58 Sex; M
Id; ignosis: Carcinoma of stomach with local invasion of liver and lymph
Histology of associated glands - replaced by adenocarcinoma
consistent with gastric primaiy.
glands.
Hi story: Admitted as a transfer from a medical ward with a 3 months
of anorexia, lassitude and loss of 3 st. in wei$rt. No vomi
bowels normal. Haemoglobin 50fc on admission to medical ward
previous history of note, but father believed to have died













(1) Laparotomy: Extensive, inoperable carcinoma of stomach
(L) lobe of liver with numerous involved g
around coeliac axis and in omentum. Biopsy
only. 12/l0/6t










(1) Thiocolciran: 350 mg. by I.V.I. 18/10/&.









Patient presented V7ith a typical history and tumour inopera
laparotomy. Commenced cytotoxLns I8/I0/64 with the hope of
able to carry out a "second-look" procedure. General condit
remained poor throughout ana persistently anaemic. No ben
cytotoxins, but side-effects not severe. Progressive deteri






in111 Died at home. Post-mortem not obtained.
.Re:suit: No benefit from cytotoxins over a period of 2% months. Mild
moderate side-effects only. 1-2 for 3 months.
to
Ta >le 14 c
Ca ie: 77 W.M. 14/10/64 Age: 64 Sex: M
Di ignosis: Carcinoma of the stomach with invasion of liver and regions
glands.
1 lymph
Hi story: 3 months history of dysphagia, epigastric pain, anorexia ar
diarrhoea. Had eaten no solid foods for 6 weeks. Loss of 1
weight over 2 months. No symptoms referable to other system
previous history of note but father probably died of c&rcin













(l) Laparotomy: Large carcinoma posterior wall fixed to (I








(1) Thiocolciran: 60 mg. by I.V.I. 23/10/64
(2 x 30 mg.)










Patient presenting with typical history of gastric carcinom
confirmed by barium meal, tnrge posterior wall lesion in st
just possibly reactable but considered suitable for chetaoth
second-look operation. Virtual collapse after first 2 injec
thiocolciran (epigastric pain on each occasion) and died 2'/











Resuit: Death almost certainly accelerated by cytotoxics although 1









Ca ges 78 I.M. 3/1/85 j^e: 89 Sex: F
Di agnosis: Carcinoma of stomach with involvement of regional lymph nod
Undifferentiated carcinoma of stomach.
es.
History: Anorexia, nausea and vomiting for 6 months with loss of 2-3
in weight over 1 year. One episode of diarrhoea lasting 2 v,
6 months previously. Diabetic for 1 year. No other signific
previous or family history. Confident clinical and radiolog











(1) Laparotomy: extensive, inoperable carcinoma of stomach
extensive lymph gland involvement. Biopsy
tumour only. 11/1/65










(1) Thiocolciran: 40 mg. by I.V.I. 16/1/65-
(2 x 20 rag.)










Carcinoma of stomach presenting with long history. Beyond a
of surgery when first seen. Immediate post-operative condit
but when chemotherapy was started on 5th post-operative day
developed severe watery diarrhoea, buccal ulceration and ag











Carcinoma of stomach with extensive spread to regional lymp
Chronic pyelonephritis and myocardial fibrosis. Pulmonary i




Re suit: Death almost certainly accelerated by cytotoxins to which s
side effects rapidly developed with minimal dosage.
0 for 2 weeks.
evere
Tal>le 14e
Ga ie: 79 R.C. 24-/3/65 i£e: 66 Sex: M
Di< ignosis: Carcinoma of stomach. Moderately differentiated adenocarcin
marked stomal reaction.
ma with
Hi! \toxy: First admitted to a medical ward in February 1965 with a 20'
history of intermittent episodes of epigastric pain and nau
Over previous 6 months these episodes had increased in freq
severity and were now associated with vomiting. During this
appetite decreased and lost 2 stones in weight. Investigati
medical ward did not establish a diagnosis and patient tran














(1) Laparotomy: Inoperable carcinoma of proximal stomach i
glands, pancreas and omentum. Biopsy only.
26/3/65
(2) Oesophagoscopy: 7/ith view to inserting Souttar's tube.
not feasible 22/6/65
(3) Analgesics and anti-emetics: intermittently throughout







(1) Thiocolciran: 390 mg. by I.V.I. 31/3/65-:









Diagnosis of carcinoma of stomach not established until die,
laparotomy 26/3/65. Tumour inoperable due to local invasion
fixation. Cytotoxic treatment started on 5th post-operative
Although thiocolciran injections produced epigastric pain,
and vomiting on almost every occasion, there was a short pe;
1 month between 20/4/65 and 20/5/65 when patient felt great:
improved. Thereafter general condition deteriorated, despit
continued treatment, with increasing epigastric pain and voi













Carcinoma of stomach invading the (L) lobe of liver and les
omentum associated with metastatic deposits in coeliac and





Res iult: Short period of subjective benefit from cytotoxins, but ovea
result was unsatisfactory. Marked pain in tumour from thioc
Terminal evidence of impending bone marrow depression.




Ca se: 80 B.C. 16/2/65 Age: 71 Sex: M
Ei ignosis: Carcinoma of stomach.
Hi story: Admitted as an emergency vdth a 2-week history of constant
dragging pain in (L) iliac fossa associated with excessive
flatulence, constipation and anorexia for 5 days. Ho releve
history. Clinical examination, barium enema and sigmoidoscc
failed to establish a diagnosis, but at diagnostic laparotc












(l) Laparotomy: Large carcinoma of pyloric region of stoma
Humerous small metastases throughout perit









(1) Thiocoleiran: 140 mg. by I.V.I. 7/3/65-]








Advanced carcinoma of stomach found at laparotomy for unexj
abdominal pain. Commenced cytotoxic therapy on 6th post-ope
day. No untoward effects, but felt slightly nauseated after
injection. Ho increase in pain in tumour area following in,
After 3 weeks'treatment was feeling well; weight steady. Re
well, apart from a few days of an influenzal illness, until
when his general condition began to deteriorate, began to











Died at home and no post-mortem obtained.
Resuit: Initially cytotoxins well tolerated and possibly of some b«
But over-all effect on disease course was minimal. 1-2 fc
nefit.
>r 2 months
T &~~ £ if
Ca; e; 81 P.D, 21/3/65 Age: 63 .Sex: M
Di* gnosis: Carcinoma of stomach, involving lower end of oesophagus - t
metastases. Adenocarcinoma of stomach.
epatic
■torys Admitted as an emergency on 23/3/65 with a Id story of sever
dysphagia for one week and several small haematemeses on ti
of admission. Patient had previously been investigated in
in IS63 for dysphagia, dyspepsia ana weight loss and was re£
peptic oesophagitis. His symptoms had. been increasing in £
over recent months and he was on the waiting list for opere
Investigations now confirmed the presence of a carcinoma of
















stomach involving lower oesophagus; hepatic metastases,
(2) Insertion of Souttar's tube: 30/5/65




(1) Thiocolciran: 150 me. by I.V.I. 16/4/65 - 10/5/65







Inoperable tumours of proximal stomach witb hepatic metastf
thoraco-laparotony 7/4/65. Commenced chemotherapy on the £
operative day without disturbance. One month later was eaf
normal diet without pain or discomfort and general conditic
good. Occasional dysphagia only, but feeling of nausea anc
for 2-3 days after thiocolciran injections. After a furthe
weeks dysphagia was again marked, but pain free and genera]
good. Thereafter dysphagia rapidly became complete, patier
further injections (attributing the dysphagia to their effe
Souttars' tube inserted 30/5/66 with relief of acute symptc
Patient remained reasonably well despite progressive anaeird

















Died at home - no post-mortem obtained.
i
j
Hei iult: Short, but definite response to cytotoxins. Return of dysj
after five weeks and thereafter patient x-efused further in,





Ca se: 82 A.W. 25/4/65 Age: 58 Sex: F
Li gnosis: (1) Carcinoma of stomach with advanced local spread.
(2) Carcinoma of (r) breast. I960.
Pulmonary metastases ? from breast lesion. Biopsy of abdomi
metastatic anaplastic carcinoma consistent with operative f
of carcinoma of stomach.
nal gland:
indings
Hi 3tor.y: Admitted to the ward 25/4/65 with a history of anorexia and
loss of 2 stones over previous 6 months; dysphagia and gnaw
epigastric pain for 2 months. Barium meal revealed a carcin
body of stomach. In 1942 had been diagnosed as having pernd
anaemia with regular follow-up thereafter. Above symptoms r
review 26/3/65. In addition, a Stage I carcinoma of (R) bre
treated by simple mastectomy and radiotherapy in i960. In 1
recurrent glands excised from (R) axilla but thereafter rem
until onset of abdominal symptoms in October 1964. When adm
















(1) Laparotomy: Infiltrating carcinoma of lesser curve of
Extensive local fixation. Biopsy of gland
28/4/65
(2) (R) simple mastectomy: 26/4/60
(3) Radiotherapy: (r) breast and shoulder regions - detail
known. 11/5/60-i
(4) Excision of metastatic glands (R) axilla: 8/2/62









(1) Thiocolciran: 210 mg. by I.V.I. 27/5/65-









At laparotomy, lesion in stomach considered primary but unce
deposits in lung were from stomach or breast. Cytotoxins st
27/5/65 in hope of controlling abdominal symptoms. Treatmen
continued far 4 months with 2-week interval between 15/7/65
2/8/65. During this period general condition remained fair,
appetite poor with occasional vomiting. Pain and nausea exp
after initial injections. Gained 6 lb. in weight between 27
19/8/65, but thereafter developed a persistent head cold, m
impairment and increasing pulmonary metastases. Treatment c












Lied at home. Post-mortem not obtained.
Re suit: Tumour activity possibly checked for 2 months but little ov
benefit. 1-2 for 4 months. Mild to moderate side effects -
pain and vomiting after injections; persistent coryza.
er-all
nausea,
GROUP 0 : CARCINOMA OF COLON AND RECTUM
Table 15a
Case: 83 J.N.S. 2i)/5/6l i£e: 32 Sex: M
Diagnosi s: Inoperable carcinoma of rectum. Biopsy of tumour.
History: First discovered to have a carcinoma of the rectum ins May 1961 when
he gave a 6 months history of increasing constipation, a feeling of
Incomplete defaecation and blood and mucus in the stools. Had lost
over 1 stone in weight and recently experienced occasional abdominal
distension and (L) sided sciatic pain. At laparotomy on 5/6/61 a
large, almost completely obstructing and irremovable carcinoma of
the rectum was found. N.B. At age of 9 had had sclerosing oil





(1) Laparotomy: inoperable cancer of rectum.
Permanent (L) iliac colostomy. 5/6/61
(2) Radiotherapy: 6.800r to pelvis 29/6/61-17/8/61
(3) Radiotherapy: 5.000r to pelvis 9/4/63-16/5/63
(4) Analgesics: Principally codeine for sciatic pain
Cytotoxi*
treatmentt:
(1) Thiocolciran: 210 mg. by I.V.I. 14/6/61-12/7/61
(2) Vinblastine sulphate: 60 rag. by I.V.I. 4/4/63-15/5/63
(3)Thiotepa: 60 mg;. by intra-rectal infusion 20/9/63
60 mg. by intra-rectal infusion 5/12/63
(15 mg. in 100 ml. saline
x 4 on each occasion)
(4) Cyclophosphamide: 2.000 mg. by I.V. drip 9/I/64-IOA/64
1,000 mg. by I.V.I. 14/1/64-18/1/64
(200 mg. x 5)





Inoperable carcinoma of rectum when first seen. "Yeated initially
with combination of cytotoxins and radiotherapy June 1961. Result of
therapy was good with sustained relief of symptoms and good general
health until January 1963 when clinical examination suggested
recrudescence of the tumour. Repeat rectal biopsy was carried out on
5/2/63 and confirmed active carcinoma. In view of patient's general
well-being;, nowever, and freedom from symptoms, no active treatment
was undertaken at this stage. By 28/3/63, however, increasing (L)
sided abdominal pain and (L) sided sciatica led to a further course
of radiotherapy and resumption of cytotoxins. Treatment resulted in
some improvement but was associated with listlessness, weight loss
and mild anorexia. 2 courses of intra-rectal thiotepa produced much
foul-smelling discharge from rectum and although temporary relief
was obtained general tendency was for increasing (L) low abdominal
pain and sciatica requiring analgesics. Commenced cyclophosphamide
In January 1964 and this produced considerable relief which was






Result: 2-3 for 2 years 10 months. Cytotoxins initially used in conjunction
with radiotherapy and combined result produced sustained objective
and subjective improvement for 18 months. Further symptomatic relief
was obtained by second course of combined radiotherapy and cyto¬
toxins. Cyclophosphamide alone producing good response.
— — ' - — »
Table 15b
Case: 84 I.L. 9/1V62 Age: 22 Sex: S
Liagnosi s: Carcinoma of sigmoid colon. Carcinomatosis peritonei,
secreting adenocarcinoma.
Mucus-
History: Laparotomy 3 years previously at another hospital for persistent
rectal bleeding. Laparotomy negative but polyp found on sigmoid¬
oscopy and removed. Well until June 1962 when she began to experience
colicky lower abdominal pain with the passage of fresh blood and
mucus in the stools. Subsequently developed diarrhoea with 3-4 loose
motions per day and lost 1 stone in v/eight. Investigations,
including sigmoidoscopy and barium enema were inconclusive.
Laparotomy on 3/10/62 in another hospital revealed carcinomatosis
peritonei with the primary tumour apparently arising in the sigmoid
colon. Transferred for further management. No other previous history




(1) Laparotomy: in another hospital. Carcinomatosis
peritonei. No operative procedure. 3/10/62
(2) Radiotherapy: l.OOOr to whole abdomen 10/12/62-17/12/62
(3) Blood transfusion: 3 pints whole blood 26/10/62





(1) Cyclophosphamide: 5.200 mg. by mouth 16/11/62-29/12/62
700 mg. by I.V.I. 3/1/63-6/1/63





Investigated for 3 months for symptoms of colicky abdominal pain,
diarrhoea with blood and mucus in stools, before diagnosis
established by laparotomy. InvLew of widespread nature of lesion
treatment was commenced with cytotoxins and prednisone. This
resulted in lessening of pain, diarrhoea and rectal discharge and
radiotherapy in the farm of an "abdominal bath" was commenced on
10/12/62. This resulted in nausea, vomiting and general distress
and was abandoned. Treatment with cytotoxins was resumed and the
patient was out of hospital for 2 wee*3. Thereafter developed
increasing abdominal distension, nausea and vomiting culminating in
complete obstruction on 30/12/62. Large tumour masses palpable in
abdomen. Perforated bowel and died on 7/1/63*
Luton sv
report:
Gross peripheral oedema. Widespread gas gangrene (positive cultures
from peritoneal fluid and subcutaneous tissues) from perforated




Initial response to cytotoxins was fair - some subjective relief of
symptoms. Subsequently cytotoxins of little effect but no definite
evidence of toxic effects. 0-1 for 6 weeks.
•
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Table 15c
Case: 85 A.M.T. 4/3/63 4ge: 52 Sex: W







First reported to own doctor in April 1962 with a 5 week history of
intermittent diarrhoea. Treated symptomatically and remained
relatively free of trouble until July 1962 when a further severe
bout of diarrhoea was experienced. Again symptoms relieved by
treatment with sulphonamides and patient continued until November
1962 when patient again reported with recurrence of diarrhoea,
blood and mucus in stools and rectal pain. Kxamination at another
hospital in December 1962 revealed the presence of an ulcerating,
encircling carcinoma of rectum at 10 cm. Defunctioning colostomy
carried out on 4/I/63 to empty colon but at laparotomy on 5/2/62
the tumour proved inoperable.
(l) Defunctioning colostomy: 4/1/63
(2) Laparotomy: inoperable carcinoma of rectum because
of local invasion 5/2/63
(3) Resuture of burst wound - on two occasions 6/2/63 and 14/2/63
- all above carried out at another hospital.
(4) Radiotherapy: 6,500r to pelvis 11/3/63-26/4/63
(5) Abdominoperineal excision of rectum:"
no glandular, hepatic or omentalmetastases 12/6/63
(6) Blood transfusion: total of 13 pints of whole
blood between 7/2/63 and 26/10/63
(7) Intero-caecostomy for small bowel obstruction 29/10/63
(l) ^annitol mustard: 500 mg. by I.V.I. 2/1/6>5A/63
(3 x l00 mg, 1 x 200 mg. as operation "cover")
2/2/63-13/2/63
II/6/63-I5/6/63
(2) Cyclophosphamide: 1,400 mg. by I.V.I.
(200 mg. x 7) as operation "cover"
(3) Mannitol mustard: 500 mg. by I.V.I.
(l6o mg. x 5) as operation "cover"
(4) Cyclophosphamide: 1,250 mg. by I.V. infusion 31/10/63-2/11/63
3,800 mg. by I.V.I. 6/ll/63-19A/64
2,700 mg. orally 9/12/6>25/1/64







One year delay before diagnosis of carcinoma of rectum made. At this
stage tumour was locally inoperable and a full therapeutic course of
radiotherapy was carried out. Recovery from exploratory laparotomy
had been complicated and a further 1 month's delay occurred before
radiotherapy commenced. Completed course of radiotherapy without
incident. General condition improved and local symptoms subsided.
Two months later abdominoperineal excision of the rectum was
successfully carried out under cytotoxic "cover". Good recovery
from this operation and home for 4 months. During this time,
however, there was a persistent discharge from a perineal sinus and
recurrent tumour nodules were present in the abdominal scar.
Readmitted 25/10/63 with small bowel obstruction. At laparotony
29/10/63 loops of small bowel were inextricably bound together by
recurrent tunour masses ana there was a large mass of recurrent
tumour in the pelvis. Ileo-caecostomy carried out and fair recovery.
Home for a further lraonth but readmitted 2/2/64 with rigors,
abdominal pain and vomiting and marked weight loss. Temporarily




Peritoneal cavity obliterated by adhesions and large quantities of
tumour tissue. Loculated intra-abdominal abscesses. Two small
surface metastases in liver only. Pancreas and abdominal lymph
glands invaded by tumour. Large tumour mass in wound and in pelvis.
No pulmonary metastases.
Result: Cytotoxins initially employed as operation "cover" and it is of
interest to note that at time of second operation (6 months after
transverse colostomy) there were no deposits in liver or glands.
Subsequently cytotoxins employed to control recurrent tumour but no
real evidence of benefit. 1-2 for 14 months.
■ *
Table 15a
Case: 86 E.H.W. 6/7/63 Age* 50 Sex: M
Diagnosis: Carcinoma of pelvi-rectal junction. Moderately well differentiated
adenocarcinoma.
History: First admitted to another hospital on 12/6/63 with a 3 week history
of constipation, generalised abdominal pains, mild anorexia and
vomiting. Treated by colonic lavage at that time but readmitted
2/7/63 with severe diarrhoea for 2 weeks (7-8 motions/day) and the
loss of l^- stones in weight. Had noted a little fresh blood and
mucus in stools. Now complained of listlessness and anorexia.
Barium enema now revealed a carcinoma of pelvi-rectal junction with




(1) Laparotomy and defunctioning colostomy: 15/7/63
Large tumour of pelvi-rectal junction with
fistula to jejunum. No other metastases.
Faecal laden colon.
(2) Abdamino-perineal excision of rectum:
Tumour and fistulous loop excised but tumour
tissue known to be left in pelvis. 14/9/63
(3) Blood transfusion: 12 pints of whole blood









(l) Cyclophosphamide: 1.500 mg. by I.V.I. 12/8/63-14/8/63
(3 x 500 mg.)
2,700 mg. by mouth 16/8/63-12/^/63(303 mg. x 3/week for 3 weeks;
900 mg. by I.V.I. I3/9/63-I5/9/63




Patient's general state on admission was poor. By attention to
diet, blood replacement and by establishing a defunctioning
colostomy, general condition rapidly improved. e!y 25/7/63 (3 weeks
after admission) was well, eating normally and gaining weight.
Discharged home 16/8/63 for period of convalescence. Readmitted
7/9/63 for elective abdomino-perineal excision of tumour and
fistula. Had remained well in the interval with further gain in
weight. Operation carried out 14/9/63 and recovery complicated only
by an infected haematoma in perineal wound, discharging
spontaneously. Discharged home 25/IO/63. At last review in
February 1964 was remaining well in all respects and free of






Result; CytotoxLns initially used in the hope of diminishing tumour activity-
end spread during the necessarily long wait between the first and
the definitive surgical procedures. After an initial course of I.V.
cyclophosphamide the drug was continued until the second operation
by mouth. Additional dose given intravenously over operation.
No toxic effects from drugs and at 5 months from operation was
remaining free of metastases. 2-3 for 6 months to date.
Table 15<8
Case; £ 7 A.W.S. 12/8/63 Me: 53 Sex; M
LiagnosL s; Carcinoma of caecum with extensive local spread.
History; Appendicectony and drainage of appendix abscess on 16/3/62 at
another hospital for a 10 day history of colicky lower abdominal
pain and anorexia. Following this operation patient continued to
experience intermittent (r) sided abdominal, pain which was twice
investigated with negative findings. Symptoms persisted and in
January 1963 barium enema revealed an irregular filling: defect in
caecum. ?inflammatory ?neoplastic. Laparotomy was carried out in
another hospital on 11/2/63 when a carcinoma of caecum with
advanced local spread found. Palliative (R) hemicolectomy carried
out and patient transferred for further management when recurrent
symptoms developed in July 1963.








in another hospital 16
(2) Laparotomy and palliative (R) hemicolectomy:
for large carcinoma of caecum with extensxve
local spread - also in another hospital 11,






(l) Cyclophosphamide: 3.000 mg. by I.V.I. I6A2/63-7/1/64
(9 x 200 mg., 3 x 400 mg.)
3,600 mg. by mouth 8/I/64-26/2/64




Carcinoma of caecum presenting as obstructive, acute appendicitis
and overlooked at operation. Continued symptoms finally led to
laparotomy in another hospital and to the diagnosis of locally
extensive tumour February 1963. When admitted here in August 1963
was complaining of pain in R.I.F., constipation and backache. Known
to have residual tumour in abdomen and a full course of radiotherapy
was therefore given in October 19&3. This course was completed
without incident but abdominal pain and backache persisted and, if
anything, were more severe. Bowels remained constipated. Liver first
palpable on 26/10/63 and noted to be jaundiced on 19/11/63. By
28/11/63 was experiencing considerable backache, wa3 listless and
anorexic and jaundice was marked. InvLew of pain, increasing
jaundice and good general state cytotoxins were commenced on
16/12/63 in hope of obtaining some symptomatic relief. By 23./12/63
backache was minimal and despite increasing jaundice he remained






Died at home and post-mortem not obtained.
Result: Cytotoxins anployed when patient already jaundiced in hope of
relieving severe abdominal and back pain. Despite increasing
jaundice and increasing hepatomegaly marked symptomatic relief was
obtained for 2^ months. No toxic effects from drugs.
Table 15J '
Case; 8£5 E.M.H. 17/10/63 Age: 39 Sex; F
Diagnosiss: Carcinoma of transverse colon with extensive hepatic metastases.
History; First admitted to another hospital on 12/9/63 with a 4 month history
of (R) subcostal pain, vomiting, weight loss and amenorrhoea. Bowels
regular but blood in motions. Examination at that time revealed a
greatly enlarged irregular liver and at laparotomy on 26/9/63 a
carcinoma of transverse colon with extensive hepatic metastases was
found. No operative procedure was undertaken and the patient





(1) Laparotomy: in another hospital. Carcinoma of
transverse colon with massive hepatic involvement.
No operative procedure and no biopsy. 26/9/63
(2) Blood transfusion: 3 pints of whole blood 19/10/63
(3) Antibiotics: (a) Sulphathalazole 17/10/63-28/10/63
(b) Crystamycin 17/10/63-28/10/63





(l) Cyclophosphamide: 200 mg. intraperitoneally 25/10/63
2,000 mg. by I.V.I. 26/10/63-4/11/63
(200 mg. x 10)




Disease already advanced by time of diagnosis. Patient ill, pyrexial
and with obvious weight loss. Examination revealed a moderate degree
of ascites and marked hepatomegaly. Anaemic. General condition
improved a little by 22/10/63 following blood transfusion and
antibiotics. Commenced chemotherapy 25/10/63 and although there was
a little improvement initially, progress was generally downhill with
recurrent ascites, weakness, anorexia, dyspnoea and finally death in
coma on 19/12/63 - 2 months after admission without leaving hospital,
Autopsy
report;
Confirmed extensive metastatic disease of liver from carcinoma of
colon. Ascites. No other metastases.
Result: No benefit from qytotoxins, but despite extensive hepatic
involvement toxic effects did not occur. 0-1 for 2 months.
Table 15 B
Case; 8! E.D. 12/12/63 Age: 35 Sex: F
Diagnosis: Recurrent carcinoma of rectum. Pulmonary metastases.
Hi story; Abdominoperineal excision of rectum at another hospital 2 years
previously for histologically proven carcinoma of reotum. Extremely
well until two months ago when she began to experience increasing
pain in perineum, particularly marked when sitting or walking and
not relieved by simple analgesics. When seen in October 19^3 in
another hospital symptoms thought due to coccyx, but excision
produced no relief. Subsequently nodules developed in posterior wall
of vagina. These were biopsied on 17/12/63 and found to be recurrent




(1) Abdominoperineal excision of rectum: in another hospital, 1961
(2) Biopsy of recurrent tumour nodules: 17/3/63
(3) Radiotherapy: 6.500r to pelvis 30/12/63-6/2/64
Cytotoxic
treatment:
(1) Vinblastine sulphate: 29 mg. by I.V.I. 21/12/63-7/2/64





Patient experiencing considerable pain in perineum at time of
admission; unable to sit or to walk comfortably and sleep greatly
disturbed. General health good; no respiratory symptoms. Commenced
radiotherapy combined with cytotoxic therapy on 30/12/63 and within
a few dpys pain decreased and sleeping improved. iy 3/2/64 was
entirely free of pain, posterior vaginal wall was less indurated and
nodular and general health was good. Started cyclophosphamide by
mouth on 27/2/64 in hope of controlling pulronary metastases since
these were apparently enlarging. Remained well and under continued




Result: Vinblastine used as an adjunct to radiotherapy for control of local
recurrence. Subsequently small oral dose of cyclophosphamide given
to control pulmonary metastases. Result difficult to assess but
patient remaining well and metastases not advancing rapidly after
6 months. 2-3 for 6 months to date.
Table 151L
Case: 9C P.W.N. Age: 44 Sex: M
Li a/mo si b: Carcinoma of rectum. Moderately well differentiated adenocarcinoma
of rectum with invasion of related lymph nodes.
History: 4 month history of rectal pain, diarrhoea and urgent desire to
defaecate. Occasional abdominal discomfort. No blood or mucus in
stools. General health good but steady loss of lj stcanes in weight
over 1 year. Patient had reported symptoms 3 weeks and again 5 weeks
after onset but was not examined and treated symptoraatically.





(1) Laparotomy and defunctioning colostomy: 18/12/63
extensive tumour completely occupying pelvis with hard,
fixed glands in root of mesentery; colon distended with faeces.
(2) Abdomino-perineel excision of rectum: 9/1/64
malignant tissue known to be left in pelvis and
in abdominal glands.
(3) Radiotherapy: 500r to abdomen 30/1/64-13/3/64
(D Blood transfusion: 6 pints whole blood 18/12/63-9/3/64




? (1) Cyclophosphamide: 2.800 mg. by I.V.I. 18/12/63-12/1/63
(14 x 200 mg.)
(2) Thiotepa: 15 mg. - local instillation in




Advanced carcinoma of rectum when first diagnosed. Two stage
abdomino-perineal excision of tumour but palliative only. Because
of delay between stages of operation cyclophosphamide was given
intravenous3y before and for a few days after the second stage in
the hope of reducing tumour activity and spread. Course of post¬
operative radiotherapy given to abdominal residual tumour. Course
completed without incident. Discharged home 13/3/64 well, with good
appetite, increasing weight and satisfactory colostomy action.





Result: Cyclophosphamide given because of delay between stages of operation
in hope of reducing tumour activity and spread. Thiotepa given as
"prophylactic" measure at time of second stage operation. Result of
cytotoxic therapy cannot be assessed, but no side effects accrued
and patient well 4 months post-operative3y
Ta Jle
Ca se: 91 R.&. 9/3/65 Aj?e: 59 Sex: M
Di ignosis: Carcinoma of colon with local invasion of abdominal wall ar
omentum. Moderately well-differentiated adenocarcinoma.
d
Hi stor.v: First admitted to ward 9/3/65 with 3-month history of abdorr
pain, anorexia and intermittent diarrhoea. No weight loss,
locally invasive carcinoma of transverse colon at laparotoir










(1) (R) hemicolectomy: Extensive tumour invading; abdominal
ileum and omentum with spread in tr
meso-colon towards pancreas. Exci
tumour judged at operation to be ir
17/3/65
(2) Blood transfusion: 1 litre whole blood 17/3/65









(1) Thiocolciran: 530 mg. by I.V.I. 26/3/65-2









In view of extensive nature of tumour and its incomplete re
cytotoxins were commenced in hope of obtaining additional p
It is to be noted that the early injections of thiocolciran
in moderately severe epigastric pain within half an hour of
injection. Pain usually subsided within 2-3 hours. No oth
effects. Remained well and on continued treatment 2/9/65 wb
haemoglobin fell to 5C% and transfusion was necessary. Low
haemoglobin had been associated with vomiting and nose blee
1 week. This was accepted as a suitable point to stop treat
Slow return to good health and at last review on 27/4/66 wa

















Re suit: Treatment commenced in hopes of delaying spread of tumour,
period of treatment before significant bone marrow depressi
developed. Treatment stopped after 6 months and patient rein





GROUP p : CARCINOMA of PANCREAS
ile 16a
Ca: ie: 92 F.H.R, 13/2/63 Age: 62 s^: F
Diagnosis: Carcinoma of pancreas with peritoneal and omental deposits
ascites. Mucin-secretin^ adenocarcinoma of pancreas.
ind
Ills tory: History of pain between shoulder blades, particularly after
for 3 months. Anorexia for 2 months and loss of 5 lb. in we:
Pain in (l) shoulder with radiation to (l) ear and (l) elbon
1 month. Epigastric pain for 2 weeks. Nausea but no vomiting
significant previous or family history. Examination on admi.
revealed a hard fixed gland in (L) side of neck, a (L) Horn<
syndrome and a palpable mass in (r) upper abdomen. Chest x-i















(1) Laparotomy: litres of bile-stained fluid. Extensive
carcinoma of pancreas, covering (r) poster:
abdominal wall, almost burying gallbladder
infiltrating the omenta widely. Numerous pc
nodules. Cholecyst-gastrostony and biopsy <
19/3/63
(2) Blood transfusion: 1 litre of whole blood 19/3/63










(1) I.Iarmitol mustard: 300 mg. by I.V.I, 22/2/63-i
(3 x 100 mg.)
(2) Cyclophosphamide: 600 mg. by I.V.I. 28/2/63-i
(6 x 100 mg.)
1,000 mg. by mouth 7/3/63-2;
(3) Vinblastine sulphate: 16 mg. by I.v.I. 29/2/63-]












Patient presenting with vague history and diagnosis of advar
carcinoma of pancreas only finally established at laparotorqj
after admission. Clinically the diagnosis of malignant disee
not, however, in doubt and with a positive gland biopsy cytc
therapy was commenced on 22/2/63. At this stage patient was
nauseated with continued back-pain. Within 2 weeks of start:
ment neck glands had considerably reduced in size and pressi
Symptoms less marked. A few days later became jaundiced, abc
distended and general condition deteriorated. Laparotomy to
jaundice. Immediate post-operative condition fair, but by 3:
operative day condition deteriorating and despite use of st«


















Re suit: Disease too advanced when patient first seen to allow of mu
benefit from therapy. Temporary relief of pressure symptoms
glands in neck but no overall effect on course of disease.




GROUP P : CARCINOMA OF PANCREAS
)le 16b (continued)
Ca se: 93 E.L. 1/12/64 Age: 48 Sex: F
Di gnosis: Carcinoma of pancreas with extensive local invasion and per
metastases.
it oneal
Hi story: Admitted to a medical ward in November 1964 with a 6-month
of anorexia, listlessness, lethargy, intermittent vomiting,
of 1 stone in weight. Had also experienced epigastric pain,
to meals, for 3 weeks, breathlessness and angina of effort,
investigation to be severely anaemic and thought to have a
of stomach. Hysterectomy 2 years previously for monorrhagia














satment: (2) Laparotomy: large, inoperable tumour of
pancreas infiltrating stomach and
liver. Gastroenterostomy and biopsy. 2/]





(l) Cyclophosphamide: l.OQOmg. by I.V. I. 7/12/64-










Presented with severe anaemia and large tumour mass produci
incomplete obstruction to stomach. Commenced chemotherapy 0
postoperative day. No untoward effects and discharged home
Remained on out-patient treatment and reasonably well for 3
despite steady increase in size of abdominal mass and raoder
of hair. By 1/4/64, however, general condition was deterior
she experienced intermittent vomiting and appetite decrease












Died at home - no post-mortem obtained.
He suit: Gastroenteroston\y was probably responsible for most of post
improvement, but it is significant that the patient remains
reasonably well, active and entirely pain-free despite a le
intra-abdominal neoplasm. Moderate alopecia from cyclophosp
starting after 1 month of treatment, reaching a peak after
and then regrcwing a little while on continued treatment.






Ta >le 16 c
Ca 3e: 94 J.K. 5/3/62 Age: 65 j3ex: M
Di ipnosis: Carcinoma of pancreas
A story: First presented in February 1962 with an 8 month history of
increasing epigastric pain, anorexia and weight loss. Thoug
have a duodenal ulcer but at laparotomy 6/3/62 an inoperabl
carcinoma of head of pancreas was discovered. Palliative ga
enterostoay. Remained well until Kay 1964 when returned, ag
increasing epigastric pain, anorexia, weight loss and steat
Obvious malignant mass in epigastrium, Assessed for cytotox
therapy Nov. 1964. Previous prostatectomy 1961. No other si














carcinoma head of pancreas 6/3/62
(2) Analgesics and anti-emetics: from May 1964
(3) Blood transfusion: 1 litre whole blood 31/12/64





(l) Cyclophosphamide: 4.650 mg. by mouth 26/11/64








2 years of good palliation from gastro-enterostony for carc
head of pancreas diagnosed at laparotomy 6/3/62. Returned i
1964 with increasing epigastric pain, anorexia and weight 1
Temporary benefit from oral pethidine and dianabol (anaboli
steroid), but symptoms severe and general condition poor by
1964. Then commenced treatment with cyclophosphamide but pa
remained severe, continued to have steatorrhoea and to lose*












Died at heme - post-mortem not obtained.
Re suit: No benefit from cytotoxins either on pain or course of disei
Evidence of increasing bone marrow depression terminally.
0-1 for 6 weeks only.
ase.
Tal >le 16d
Ca se: 95 J.T. I/13/64 Age: 59 Sex: M
Bi ignosis: Carcinoma of head of pancreas with extensive hepatic metast
Moderately differentiated adenocarcinoma.
ases.
Hi story: 2 year history of increasing central and lo?/er abdominal pa
particularly persistent and severe over 2 months prior to a
Occasional nausea and vomiting with anorexia and loss of 3
weight over 3 months. Discovered to have diabetes 6 months
admission but no other findings at that time - treated with













(1) Laparotony: Inoperable carcinoma head of pancreas with
extensive hepatic metastases. No procedure
2/12/64
(2) Cholecysto-.le.iunostony: for obstructive .iaundice
due to tumour 8/2/65
(3) Ferrous sulphate: 200 mg. t.i.d. from 17/2/65








(l) Cyclophosphamide: 1.200 mg. by I.V.I. 14/13/64
7,200 mg. orally 14/12/64










Good recovery from initial laparotony for advanced carcinomi
pancreas. Started chemotherapy 2 weeks after operation. 2 w
after starting therapy patient's pain decreased and appetit
improved. Thereafter remained well and pain-free for 1 mont
which time he returned to work. Then became progressively j
(although remaining pain-free) and palliative cholecysto-je
was carried out on 8/2/65. Again a good recovery, but gradu
developed ascites requiring repeated aspiration. Steady deti














Died at home - post-mortem not obtained.
Ressuit: Good initial response to cyclophosphamide with relief of pa
improvement in appetite. Improvement maintained for 1 month
thereafter, although pain-free, gradually deteriorated.




group q : malignant melanoma
3le 17a
Ca 3e: 96 R.G.C. 15/12/62 Age: 52 Bex: M
Bi ignosis: Malignant melanoma of (R) thigh with lymph gland metastases
Histology of primary and lymph glands (r; groin confirmed.
•
Hi story: First admitted to another hospital 30/11/62 with a 4 month
of increase in size and bleeding from a mole on medial aspe
thigh. He was noted to have enlarged glands in (R) groin at
time but there was no other evidence of spread and he was e
free of other symptoms. No previous or family history of no
for past 3 years had lived in Aden. Transferred for further












- in another hospital 5/12/62
(2) (a) Wide re-excision and skin grafting primary site
(b) Block dissection (r) groin





(1) Melphelan: 175 mg. by mouth 19/12/62









Presented with obvious malignant melanoma (R) thigh with me
in glands (R) groin. Initial excision of primary inadequate
excision with skin grafting carried out at same time as bio
dissection (r) groin. These last operations were carried ou
cytotoxic cover and, in the hopes of preventing further spr
delaying recurrence, cytotoxins were continued for 1 month
operatively. There was gross infection and wide breakdown 0
wound requiring a prolonged period for healing. Subsequent!
developed swelling of (r) leg subsiding with elastic bandag
Blood count depressed by cytotoxins and finally discharged
19/2/63. At this stage was fit and well. Remained well for
only and then developed a febrile illness with nausea, vomi



















Obese. Wound and graft intact and free of deposits. Large b
in posterior cranial fossa pushing cerebellar hemispheres u
brain. Clot semi-walled off and apparently arising from sma
aneurysm of (r) cerebellar artery. No evidence of metastase





Re salt: Cytotoxins given as operation "cover" and in hope of preven
delaying the appearance of recurrence. Moderate degree of b
marrow depression produced and considerable delay in wound
Although there is no direct proof the occurrence of a fatal





pas V- 97 M.S. 18/5/65 Age: 50 Sex: F
Dia snosis: Recurrent malignant melanoma of (L) leg. Histologically a
naevocarcinome...
typical
His tar.y: First seen with a view to cytotoxic therapy on 18/5/66 for
recurrent malignant melanoma of (L) leg. Patient had first
a growing black mark on (L) leg one year previously. Biop
that time, at another hospital, confirmed malignant melanom
wide excision with block dissection of inguinal glands was
out. Good recovery from operation, but was re-admitted to
hospital 6 months later with cellulitis of (L) leg. Resol
antibiotic therapy, but limb became lymphoedematous and was
to repeated mild episodes of cellulitis. Remained free of
recurrence of disease until end of April 1965 ana then rapi
developed nodules in area of extension and in (L) groin,















Inguinal elands: 19/5/62*. - in another hospital.
(2) Antibiotics: (a) 5-day course of orbenin for celluliti
leg 3-7/9/65
(b) Tetracycline 50 rag. 6-hourly
25/3/66-3/2/66
(3) Blood transfusion: 3 litres of whole blood
22/12/65 - 2/2/66







(1) Methotrexate: 277-5 mg. by mouth 4/6/65-13/12/65
(2) Melphalan: 720 rag. by mouth 4/6/65 - 13/12/65








When first seen on I8/5/65 there was extensive recurrent tu
(L) groin, in the fragted area (L) calf and a few small nod
elsewhere on (L) leg. No other known metastases. Commen
cytotoxic therapy 1//6/65 and after 10 days in-patient treat
was a moderate fall in platelet and white cell counts. Tr
was suspended for 2 weeks and then resumed as an out-patien
Remained reasonab3y well and active for 3 months, but then
condition began to slowly deteriorate and tumour masses to
in size and extent. Large gland masses now palpable above
ligament. Re-admitted to ward 21/12/65 for blood transfus
general condition poor and disease slowly spreading. Home
weeks and then re-admitted with large masses in (L) roin,
bleeding nodules in grafted area, swelling; end cellulitis c
leg. There was some improvement in condition of leg after























Died at home — no post-mortem obtained.
Re si ilt: Although on cytotoxic therapy for six months local disease i
extended to a final ugly fungating, bleeding state* It is
whether therapy was of ar^y benefit, apart from the first fe^







Cat s: 98 J.S. 13/7/65 A£gi 65 Sex: P
Dia gnosis: Malignant melanoma of (L) foot; skin and gland metastases.
Ulcerated malignant melanoma.
His ••i-fc»l First seen in mid-July 1965 with a history of painful swell
over instep of (L) foot present for three to four weeks,
had teen preceded by a blue discolouration of skin of (L) i
No other signiiicant history <W findings at this stage, but
to be noted that the (L) foot had been the site of a triple
arthrodesis forty years previously. Admitted to ward 25/7
excision and grafting of swelling (l) foot carried out 26/7














(2) Radiotherapy: palliative to (i.) groin 18/11/65 - 15
(3) Analgesics: Various at intervals throughout treatment






(1) Melphelan: 25 mg. by intra-arterial infusion 7/1/66
(2) 2-ethvl-hydrassine: 1G by intra-arterial infusion 24/1/
1G by intra arterial infusion 22/3/
1.8G by I.V.I. 26/3/66 - 12/5/66
3 x 400 mg,










Glands were first noted in (l) groin one month after excisi
and grafting of primary lesion on 26/7/65. By mid-October
glands in (L) groin were painful and numerous. . palliatl
course of radiotherapy was given between 18/11/65 and 15/12
with shrinkage of groin glands and moist desquamation of sl<
area treated. Before this course was completed, however,
recurrence was noted in grafted area (L) foot. Recurrence
rep idly painful and associated with skin metastases (L) foe
thigh. Good response to intra-arterial raelphelan given or
into (L) femoral artery. Fain much reduced and lesion les
Further arterial infusion with 2-ethyl-hydrazine on 24/3/66
little further benefit . Further nodules developed and re
lesion (l) foot increasing in size - considerable local pei
Transient relief only from further intravenous cytotoxin ar
























jle suit: Initial good response to intra-arterial cytotoxins, but sh<
lived. No significant aide-effects from treatment.
1-2 for 4 months.
irt
Ta
GROUP R : CARCINOMA OF UNKNOT.1N PRIMARY
ble L8a
jCa,ses 99 C.J.B. 22/3/63 Age: 46 Sex: M
Diadenosis: Carcinoma of unknown primary. Biopsy of umbilical mass - sq
cell carcinoma.
uamous
III story: First admitted to another hospital on 1/3/63 with a 3-month
of increasing indigestion and abdominal discomfort. Appetit
but progressive weight loss since onset of symptoms. Claime
in reasonably good general health. No bowel or urinary
Apart from one brief episode of abdominal pain and diarrhoe
7 months previously there was no significant past or family
Smoked 20/day. Biopsy of mass at umbilicus revealed a squan








Rrevious or (l) Biopsy of umbilical mass - at another hospital 3/3/63
/5/63catr
ncurrent
eatment: (2) Radiotherapy: 6.000r to abdominal tumour mass 2/4/63-£





(l) Cyclophosphamide: 1.200 mg. by I.V.I. 25/3/63-
4,300 mg. by mouth 1/4/63-*










Although symptoms were indefinite and patient claimed to fe
reasonably well, he presented the picture of advanced intra
abdominal malignant disease with ascites. Large masses of t
were palpable in the abdomen with a very large mass in lowe
and (R) abdomen. Liver also palpable. Histology - squamous-
carcinoma, primary unknown. Attempt to aspirate ascites pro
10 ml. of pseudo-mucinous material only. Commenced cyclopha
25/3/63 and in view of his good general state radiotherapy
started on 2/4/63» By 10/4/63 patient claimed to feel well
complaints of ai\> kind. Com: leted radiotherapy on 8/5/63 wi
mild diarrhoea and cystitis - no appreciable shrinkage of
mass. Losing a little more weight. Discharged 9/5/63 contin
cyclophosphamide as out-patient but stopped for 1 month fra
20/5/63. By 4/6/63 was remarkably well with good appetite,
improving and mass in abdomen reduced in size. Moderate def
of bone marrow requiring cessation of treatment 27/7/63. At





















Resuit: Cytotoxins used in conjunction with radiotherapy for contra
advance intra-abdominal malignancy of unknown origin. Despi
cachetic state on admission patient was alive, active and w




Case Mo. 99: Carcinoma of Unlmovm Primary




GROUP N s CARCINOMA OF UNKNOVSN PRIMARY
)le 18b (continued)
Ca 3e: 100 J.A. 29/8/63 Age: 24 Sex: M
PI a/mosis: Carcinoma of unknown origin with skin and glandular metasta
Neck gland biopsy - papillary carcinoma consistent with ori





Hi story: First reported 26/8/63 with a 4-dey history of painless swe
in (L) side of neck. Appetite, weight and general health no
No symptoms referable to other systems. Smoked 20/day. Tnve
for ? thyrotoxicosis aged 13, but negative findings. No oth
















(2) Radiotherapy: to (L) side of neck and
(L) axilla - dose not known 6/9/63-8
3,100r to dorsal spine and
(L) posterior chest wall 18/12/63
2,070r to (L) upper neck 31/12/63
(3) L-thyroxine: 0.1 mg. t.i.d. 16/9/63-
0.1 mg. b.i.d. 17/12/63
(4) Meprobamate: (tranquilliser)
400 mg. 6-hourly by mouth 29/12/63
(5) Pleural aspiration: 1.500 ml. 14/1/64





(2) Cyclophosphamide: 3.100 mg. by I.V.I. 3A/64-2
(3) Thiotepa: 30 mg. intrapleurally 14/1/64-
(4) 5-fluorouracil: 2.750 mg. by I.V.I. IO/2/64-










Rapid increase in size of masses (l) side of neck and (L) a
in the short time between onset of symptoms 24/8/63 and com
of treatment with radiotherapy 6/9/63. Radiotherapy produce
shrinkage of gland masses and at end of course patient clai
feel fit and well despite a loss of 10 lb. in weight. Disch
9/11/83 but readmitted 3 dty s later with severe epigastric
vomiting. Symptoms settled rapidly and there were no new cl
findings. 8y I8/H/63 was again complaining of low back and
pain. Had now lost a total of 16 lb. On 13/12/63 developed
pain between shoulder blades and nodules in (L) side of nec
axilla were enlarging. X-rays suggested a lesion about D
Backache increased and further radiotherapy given and L-try















Tal >ie 18b (ccmtinued)
extremely anxious and agitated and required regular sedatio
By I/I/64 general state was deteriorating, weight and appet
decreasing. Developed a (L) pleural effusion and cytotoxins
commenced at this time. Despite using a variety of cytotoxi
general condition deteriorated, disease fungated through sk












Died 21/2/64. Widespread tumour infiltration of skin of (L)
chest wall, (L) shoulder end (L) axilla with extensive supe
ulceration. Large necrotic tumour mass 6 cm. in diameter at
hilum invading pericardium. Numerous metastases (R) lung, p
and liver, lass of infiltrated glands around abdominal aort






Re suit: Marked but short-lived response to radiotherapy but no obvi
benefit from even large doses of cytotoxins used alone and
combination. Marked alopecia from cyclophosphamide.
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Case No. 100: Carcinoid of UrJ210.11 -/rirrury
Fig. 1: Chest X-ray 27/8/63. Fig. 2% Sr.at -ray 22/10/63.
Fig. 3: Chest X-ray 30/12/63. Fig. 4: Chest --ray 7/2/64*
Case No, 100.
Fig. 5: Chest X-ray 21/3/64. Fig. 6: Chest X-ray 11/2/6k.
Fig. 7: Tumour infiltration cf
skin of chest wall:
12/3/64 and L. axilla.
Tat le 19,5.
Ca; 101 J.McI. 29/12/64 Age: 54 Sex: F
Megnosis: Carcinoma of unknown origin vdth skeletal and glandular met
Undifferentiated carcinoma.
astases.
His itory: First seen in December 1964 with enlarged glands in (R) gro
obvious cause found on out-patient investigation end admitl
night for gland biopsy IO/2/65. At this stage glands were p
and patient had no other complaints. Histology of gland shoi
undifferentiated carcinoma. Readmitted i7/2/65 for further
investigation. No primary lesion could be detected, however
metastases present in dorsal spine and mandible. Now c amp la:
back pain and aching pain in (r) groin when standing. No re














(1) Radiotherapy: single palliative dose to mid-dorsal spoj
(R) groin glands 3/3/65







(l) Cyclophosphamide: 1.000 rag. by I.V. infusion over 24 h
14/3/65-1
800 mg. by i.V.I. 17/3/65-1










Primary lesion not detected despite prolonged, but not exhai
investigation. Because of pain in dorsal spine and commenci;
deterioration, single aose of X-rays given to aorsal spine 1
groin with some relief. Cytotoxins started 14/5/65 without
disturbance. No significant improvement in condition by dis<
on 6/4/65 end subsequently patient unable to attend as an 01











Died at home. Post-mortem not obtained.
Re alult: Little or no benefit obtained from relatively small dose of





Ca se: 102 J.W. 11/1/65 Age: 35 3ex: M
Bi w131
—
-s£i Carcinoma of unknown primary 'with peritoneal, lymph gland a
cutaneous deposits. Undifferentiated adenocarcinoma with ce





Hi story: Admitted as a transfer from a medical ward nere he had bee
admitted on 3/12/65 with a 5-month history of increasing (R
abdominal pain, nausea, weight loss, anorexia and constipat
Cause for symptoms not discovered in medical ward despite e
investigations. Malignant disease was, however, suspected a













(2) Laparotomy: widespread peritoneal and omental
deposits from undiscovered primary. Biopsy
of wall of transverse colon. i8/I/65
(3) Analgesics and anti-emetics:
intermittently throughout treatment






(1) Nitrogen mustard: 30 rag. by I.V.i. 22/1/65-









Patient presenting with widespread malignant disease from p
which remained undiscovered despite extensive investigation
laparotomy. Commenced cytotoxins 22/1/65 and by 15/2/65 co
was sufficiently improved to allow discharge home. Previous
abdominal pain less marked, glands in neck and skin nodules
9 lb. gain in weight. Readmitted 2/3/65 with severe dyspnoe
large (r) pleural effusion - aspirated. Benefit short lived
bilateral effusions required aspiration. Thereafter general
condition deteriorated and died in severe respiratory distr













Ided at home - post-mortem not obtained.
Re suit: Objective and subjective benefit from cytotoxins lasting 6
only. Nausea, vomiting and increased abdominal pain after i
injections of nitrogen mustard, but no other side effects.





GROUP $ : RETROPERITONEAL LEIOMYOSARCOMA
»le 13a
Ca £.: 103 S.L.P. 24/4/62 Age: 37 Sex: m
Li<gnosis: Retroperitoneal leiomyosarcoma
Hi itory: First reported 28/3/62 with a 3 month history of frequency
micturition, a feeling of incomplete emptying of bladder,
constipation and intermittent abdominal distension. Had bee
of a "lump" in abdomen for 2 months with anorexia and loss
weight over same period. L&parotony 10/4/62 in another hosp
revealed extensive, highly vascular and friable tissue mass
occupying pelvis and (r) lower abdomen, but no obvious primi
Biopsy - leiomyosarcoma. Transferred for further management
















(1) Laparotomy: large highly vascular tumour masses
in pelvis end (r) abdomen. Biopsy only.
No metastases. Carried out in another
hospital. 10/4/62
(2) Bona marrow extraction and storage: 30/4/62
(3) Radiotherapy: 6.500r to abdominal tumour
masses 3/5/62-2
(4) Blood transfusion: 1 litre of whole blood 12/4/62
(5) Laparotomy: findings as before but tumour
even more extensive. No metastases.
Biopsy only. 12/2/63






(1) Mannitol mustard: 300 mg. by I.V.I. 11/2/63-
(3 x 100 mg. over second ope
(2) Thiotepa: 10 mg. intraperitoneal at operation 12/2/63
(3) Mannitol mustard: 500 mg. by I.V. infusion 1/3/63-3
(50 mg./50Q ml./5-hourly)
2,900 mg. by mouth 8/3/63-1
(4) Cyclophosphamide: 1.200 mg. by I.V. infusion 11/9/63
3,000 mg. by I.V.I. 13/9/63-
















Diagnosis of retroperitoneal leiomyosarcoma established fol
laparotomy and biopsy when other investigations had been la
unhelpful. Tumour irremovable and a radical course of radio
was completed without incident between 3/5/62 and 26/6/62.
resulted in only slight shrinkage of tumour mass, but urina
bowel symptoms were partly relieved. Remained well and at w
6 months despite slow increase in size of tumour. Readraitte
31/1/63 with recurrent urinary and bowel symptoms and secon
operation carried out 12/2/63 in hope of doing something fu
Tumour even more extensive and friable than before and even
resulted in prolonged oozing from wound postoperatively. Fu
radiotherapy deemed unfeasible and since cytotoxin "cover"
used at second operation this treatment was continued. Defi
tumour shrinkage had occurred by the end of 1 month. Remain
reasonably well and at work for a further 7 months but was
(9/9/63) readmitted with increasing backache, constipation,
difficulty with micturition and weight loss. Further cytoto:
therapy produced only temporary relief and condition slowly






















Emaciated. Obvious protuberant mass in (R) lower abdomen,
throughout parenchyma of both lungs were small tumour nodul
5 mm, in diameter. .Arising from pelvis was a large necrotic
encephaloid tumour infiltrating bladder, rectum and colon,






Re]suit: Initial good response to radical radiotherapy alone and rem
maintained for 6 months. Further 7 months remission with ma
mustard but only slight benefit from addition of cyclophosp






group & : salivary gland tumours
ble 19 b
Ca se: 104 D.L.O. 7/1/63 Age: 42 Sex: M
Di agnosis: Mixed salivary tumour (r) parotid gland with pulmonary mete
Histology - typical "mixed" salivary tumour.
stases.
Hibtorj: Small swelling (r) sub-mandibular region excised locally 19
another hospital. Specimen not sent for histology. Swelling
in i960 and was re-excised in February of that year. Histol
showed a typical mixed salivary tumour and operation on thi
occasion was followed by a course of conventional voltage r
therapy. Remained well and free of recurrence until 21/12/6
reported with swelling in the irradiated area (R) sub-mandi
region. Examination confirmed local recurrence in an area c
radiotherapy scarring, and a solitary metastasis in upper z
(L) lung. General health otherwise exdellent, weight steady




















History - both operations carried out elsewhere. 195
(2) Radiotherapy: to (r) sub-mandibular area. Details not
(3) Radiotherapy: 5.500r to anterior (R) neck, anterior an






(1) Cyclophosphamide: 15.000 mg. by mouth 12A/63-
(2) Vinblastine sulphate: 172 mg. by I.V.I. 15/1/63-
(3) Cyclophosphamide: 2,000 rag. by I.V. infusion over 40 h
(10 x 200 mg. 4-hourly) 7/2/64-9











Malignant "mixed" salivary tumour appearing with local recu
and a solitary pulmonary metastasis 6 years after initial 1
excision and 2 years after excision of recurrence and radio
In view of previous radiotherapy and lung deposit, cytotoxic
was started on 12/1/63 using a combination of oral cyclopho
and intravenous vinblastine. Remained on this treatment for
during which time he remained fit and well and at work. Dur
period also the local recurrence and pulmonary metastasis r
almost static. ly 16/8/63 was experiencing neuralgic pains
side of face and it was decided to try further irradiation
recurrence and also to lung lesion. Completed radiotherapy
with relief of symptoms and virtual disappearance of lung 1
By 30/1/64, however, was again experiencing neuralgic pains
side of face and chest X-ray revealed multiple metastases t
out both lung fields. Further course of intravenous cycloph
with complete relief of facial pain within 5 days. Patient
























Re^ ••a Local recurrence and solitary lung metastasis remained stat
8 months of cytotoxic therapy. Subsequent flare-up of disea
radiotherapy. Further relief of symptoms from intravenous c
phosphamide given by continuous effusion. Remaining v/ell bu
slowly advancing disease at end of period of review.





Case Ho. 104: Salivary Gland Tumour
Pig. Is Recurrent tumour 7/1/63.
Pig. 2 s After cytotoxic therapy WW&b-
Ta
"OTHERS"
GROUP 3 : RHABDOMYOSARCOMA
ble 39c
Ca je: 105 J.S.W. 28/5/63 and 31/8/63 Age: 53 Sex : M
Dl gnosis: Rhabdomyosarcoma of (l) upper arm. Histology - typical apoe
of rhabdony0sarc orna.
arances
Hi steals first noted a small, painless swelling anterior aspect of (
ann in January 1963. First seen in another hospital I8/3/63
swelling was 1" in diameter. Excised under G.A. and on hist
found to be a rhabdomyosarcoma, No symptoms referable to ot















(2) ;ide excision of primary site and skin-grafting:
under cytotoxic cover 30/3
(3) Further wide excision of primary area and sacrifice
of anterior muscles: 18/8/63
(14.) Radiotherapy: 5 .000r to primary area
(R) upper arm 6/9/63-I
(5) Blood transfusion: 2 litres packed cells 21/8/63-
(6) Cardiac stimulants: Digoxin and quinine from 23/3/63





(1) Mannitol mustard: 1.000 mg. by I.V.I. 29/3/63-











Presented with small lesion on (r) upper arm which unexpect
proved to be a rhabdomyosarcoma. Primary area widely excise
30/3/63 under cytotoxic "cover" but skin grafts repeatedly
take, local recurrence occurred and further wide excision w
required I8/8/63 leaving a large granulating surface. At tY
a course of megavoltage radiotherapy was completed without
Marked pigmentation of arm, slow healing. By l/H/63, howev
forearm swollen and there was evidence of recurrent tumour,
metastases on X-rey of chest. Course of cyclophosphamide in
intravenously (R) ami produced same improvement and forequa
amputation was considered. Cardiac state, which had been pa
first anaesthetic, was now worse and required further treat
Forequarter amputation finally carried out on 4/12/63 but a
unfortunately coincided with severe fall in WBC to 700. Imtc
postoperative state critical with severe respiratory distre
tension pneumothorax, developed congestive cardiac failure
























Respiratory failure secondary to collapse of (R) lung and
myocardial infarct. Possibly an example of septicaemic shoe
small metastases posterior surface (R) lung but none elsewh
k, Two
ere.
Repult: Rapidly progressing sarcoma not influenced by any form of t
Cytotoxins of no benefit, produced severe bone marrow depre
probably resulted in graft failure and terminal septicaemia





Fig. 1: Chest X-ray 18/3/&3. Fig. 2: R. Upper arm 22/3/63•
Fig. 3: Chest X-ray 29/13/63. Fig. 4: Chest X-ray &12/63.
6 hours post-operation
Case No. 105
Fig. 5: Chest X-ray <3/13/63. Fig. 6: View of rhabdomyo-




group S : tumours of bone
d
Case: 106 m.m.H. 5/9/63 ££§: Sex: If
Diagnosis: Chondro-fibrosarcoma of left tibia.
History: 15 month history of progressive swelling over upper end of (L) tibia.
Initially pain free but increasing ache amounting, on occasion, to
gnawing pain over swelling for 6 months, talking with a limp.
General health otherwise excellent and no other symptoms. No relevant
past or family history.







t: (2) Radiotherapy: 6,200r to tumour (L) upper
tibia 9/
(3) (L) mid thigh amputation: 4/
(4) Physiotherapy:





(l) Mamitol mustard: 500 mg. by I.V.I. 1(








Clinically and radiologically, slowly growing malignant tumour of (L)
tibia. No other lesions. .After initial l,050r to tumour, drill biopsy
was carried out and confirmed diagnosis of chondro-fibrosarcoma.
Course of radiotherapy completed without incident. .After interval of
3 months, without appearance of metastases, a (L) mid thigh
amputation was carried out. Uncomplicated postoperative recovery, but
stump slow to heal. Remaining well and free of evidence of recurrence




Tiesult: Cytotoxin given as "cover" for drill biopsy and not possible to
assess result. No adverse effects other than area of induration at
site of cytotoxic injection (R) arm - no actual ulceration.
Case No, 106; Osteogenic Sarcoma of Jibia
Fig. 1: X-ray of Tumour. Fig. 2: Appearance of Affectec
Limb.




GROUP S : CEREBRAL TUMOURS
)le .19e
Ca se: 107 W.J.P. 9/4/62 and 13/10/63 Age: 39 Sex: M
Di) ignosis: Frontal astrocytoma, Grade III.
Hi story: First admitted to another hospital on 26/3/62 with a 15-mon
history of headaches, minimal paraesthesiae in (R) arm and
vomiting. Investigations confirmed presence of a space-occu
lesion (L) anterior tanporo-frontal region. (L) frontal-lot
29/3/62 established the lesion as a Grade III astrocytoma.
Uninterrupted postoperative recovery and transferred for fu





















(l) Cyclophosphamide: 800 mg. by I.V.I. 28/10/63








Following initial surgery and course of postoperative radio
patient remained remarkably well and at successive reviews
10/7/62 and 13/10/63 was judged free of recrudescence of di
Appetite, weight and general health excellent. Returned to
to driving a car. No detectable neurological defect or pers
change. Readmitted H/lO/63 with 6-dey history of recurrent
aches and occasional vomiting. Within a few days he was exp
frequent, severe frontal headaches, vomiting and demonstrat
episodes of bizarre behaviour. General state remained good
general deterioration in mental state with occasional lucid
Cyclophosphamide was started 28/10/63, but insufficient giv















Rei salt: Complete and prolonged remission from surgery and radiother
advanced cerebral tumour. Cytotoxins exhibited late in term









































































































































































































































































































































































40 patients(19female,21 )w retreatedithospently 45patients(17female,28 )weretre teditht oag tsincombina ion 7patients(4female,3)w retreatedithhrg ntsincombi ation 15patients(female,0l )w retre tedithfourorincombination
chemotherapyofcancer





























































































































































*1casewithHodgkin'sdiseaandarc nomaflu g +22patients(11female,l )subsequentlyreceivedcytotoxins asdjuvantther pyinditionoprophyl cticallynde includednbothgroups ^ 23patients(11female,2 )weretre t dbysurg ryan radiotherapyndrincludednbotgr ups



































































































































































































































































































35Patientsw regivencytotoxicagebyonroutely 55Patientsw regivencytotoxicage tbyt route 17Patientswefceg vencytotoxica ntsbythreormorrout s















































































11/1/62 20/2/62 27/6/62 11/1/64
0.5 0.7 0.5 0.6





7.4 6.8 6.0 6.3
4.9 4.3 4.1 4.1
2.4 2.5 1.9 2.2
1.7:1 1.6:1 2.1:1 1.9:1




(1)Vinblastine Sulphate:15/3/62 (2)Prednisone: 14/9/61 (Chlorambucil: 22/8/60)
2 (P.O.)
5/3/62 26/3/62 17/9/62 12/12/62 8/3/63 28/5/63 7/6/63
0.4 10.3 0.2 0.6 0.4 0.4








4.7 4.1 3.8 4.3
3.1 1.6 2.1 2.7
1.3:1 2.6:1 1.8:1 1.8:1
+++ +++




3.0 ^.1 3.8 2.7 2.9
(1)Mannitolustard: 9737^2 (2)Vinblastine Sulphate:I6/3/63 (3)NitrogenMustard: 2/4/63 (4)Cyclophosphamide: wSl (5)UracilMustard: 2/77^3
3
;(G-.R.)
10/7/62 27/8/62 28/5/63 5/9/63
0.6 0.4 0.4 0.5
6.7 4.0 9.8 10.6







6.5 6.3 6.4 5.3
3.9 4.0 4.0 3.7
2.6 2.3 2.4 1.6
1.8:1 1.8:1 1.7:1 2.3:1
















12.7 12.0 15.3 20.6
1 2 1 3
4 3 5 4
6.0 10 12
N
6.0 5.0 5.8 4.9 5.2
4.0 3.2 3.9 3.5 3.5
2.0 1.8 1.9 1.4 1.7




N N N N
17..,.192 N-(1)Vinblastine N-Sulphate:4/10/62 N6J+(2)NitrogenMustard: 4^3 N5.0(3)Mannitolustard: 11/1/63(4)Imuran:19/3/63








5 3 3 7
22 53 24 20
+ +
N.
6.6 6.4 7.4 6.6 6.0
4.5 4.1 4.8 4.5 4.0
2.1 2.3 2.6 2.1 2.0
2.0:1 1.8:1 1.8:1 2.1:1 2.0:1




N N N N N
N N N N N
6.0 4.8 4.3 3.8
(1)NitrogenMustard: 22/10/62 (2)Mannitolustard: 31/10/62
9/4/62 13/4/62 1/5/62 17/10/62 10/1/64
0.5 0.4 0.1 0.4 0.6
9.6 8.0 12.2 10 11
5 4
2 2 3







7.5 6.0 6.3 6.5
4,7 4.0 4.1 4.1
2.8 2.0 2.2 2.4
1.7:1 2.0:1 1.8:1 1.7:1
0.36 + + +
-.27 ++ ++ +
0.27 N N N
L.06 N N N
6.4 6.0 3.8





















Case No. 8 [A.W.)

















































rH <5 4.0 3.4 4.0 3.0 3.4


























































(1)Cyclophosphamide: ~ 28/10/63 (2)Vinblastine Sulphate:3Ql(/63
10 T.W.) 11 (L.T.)







4.5 3.3 3.3 14.0
2.1 3.4 3.1 2.8












22/11/63 28/13/63 2/12/63 12/12/63




1 3 4 4
36fco
4-2 ♦•8
>.1 i.2 5.8 5.5
3.0 14.3 2.3 2.8
2.1 1.9 3.5 2.7





















































































































































































































































































































































































































10/6/63 20/6/63 28/6/63 26/7/63 30/7/63
0.5 0.5 0.4 7.5 9.2
11.0 10.5 15.0 37.6 40.5




48 50 54 60
6.0 6.1 7.0 6.9 7.4
3.2 3.7 2.9 4.9 4.8
2.8 2.4 4.1 2.0 2.6
1.2:1 1.5:1 ia.3 2.5:1 1.8:1
0.25! 0.26 0.24
++ 1.0 1.20| 1.1010.62. 4N 0.35 0.76
N 0.80 0.67
4.0 6.3 6.2 6.8
(1)Mannitolustard: IWS3 (2)Cyclophosphamide:1
19 (A.FJ
27/5/63 3/7/63 28/7/63 25/8/63
0.3 0.5 0.5 0.4
7.7 8 21.6 23











































7.7 8.0 6.5 6.7 7.2 6.6 6.3 6.9 6.1 7.0 7.9 6.9
3.5 4.1 3.6 3.1 3.6 2.6 3.0 3.2 2.4 3.4 3.7 2.8
3.2 3.9 2.9 3.6 3.6 4.0 3.3 3.7 3.7 3.6 4.2 4.1
1.1:1 1:1 1.2:1 1:1.2 1:1 1:1.4 1:1.1 1:1.2 1:1.5 1:1 1:1.2 1:1.5
0.30 0.40 0.30 0.30 0.30 0.30 0.30 0.30 0.60 0.40 0.40 0.50
0.80 0.90 0.80 0.80 0.90 0.90 0.80 1.00 1.30 1.10 1.10 1.50
1.10 1.20 0.70 1.10 1.20 1.10 1.00 1.c 0.80 0.90 0.90 0.90




1.30- 1.60 1.20 1.50 1.00 1.30
3.7 5.0 4.0 2.9 4.0



























































































CytotoxicAgent(s) and DateofCommencem nt
23 (T.W.)
22/4/63 7/5/63 28/5/63 5/7/63
0.2 0.3 0.25 0.4
9.3 8.7 11.1 12
5 4 4 4
2
4 4 5
20 24 mt 28
6.9 6.7 5.4 5.2
4.4 3.8 3.4 2.6
2.5 2.9 2.0 2.6
1.9:1 1.2:1 1.6:1 1:1
0.16 0.25 0.10 0.12
0.96 1.15 0.91 1.10
0.50 0.88 0.50 0.82
0.80 0.57 0.54 0.66
6.4 6.8 7.0 6.3
(-01'hiotepa:20/4/63 (2)NitrogenMustard: 23/4/63 (3)Vinblastine Sulphate:23/5/63 (4)Cyclophosphamide: 30/5/63
24 (T.H.W.)
10/9/63 20/9/63 28/13/63 12/3/64
0.6 0.7 OA 0.5
8 7 3 6






5.8 5.9 6.1 6.0
3.2 3.6 3.3 3.1
2.6 2.3 2.8 2.9
1.2:1 1.5:1 1.1:1 1:1



























5.1 45 42.5 20.0 15.2 7.1 4.6 6.7




































































26/6/62 30/5/63 17/6/63 30/6/63
0.3 0.25 0.2 0.4
5 5.4 5.9 6
2 6 7 7
78 28 32
5.4 5.2 5.6 5.1
3.2 4.3 3.5 3.0
2.2 0.9 2.1 2.1
1.4:1 4.8:1 1.7:1 1.5:1
N
D D N
D D D D
4.8 5.2
1)Cyclophosphamide: 13/6/63 2)Prednisone: 24^762
27 (T.P.)
23/5/63 30/5/63 7/6/63 13/6/63 14/7/63
0.8 0.5 0.3 0.3 0.4
6.3 9.4 9.1 9.1 9.2







6.7 6.6 6.3 6.4
3.2 3.1 3.4 3.1
3.5 3.5 2.9 3.3
1:1 0.9:1 1.1:1 1:1
0.78 0.29 0.30 0.27




1.30 1.50 0.82 1.16
4.1 5.5 4.1 4.8

















































































































































9. 9*49. 9.5 w*h 7.*
10.
2.0 1.7 2.7 2.7 2.75 3.If 4.6




3.8 3.9 2.9 2.5 2.1 1.5 2.1
0.52J1.34 +++
i.oe






















































4/1/62 10/1/62 26/1/62 6/2/62 23/8/62 12/3/63 20/8/63
0.6 0.5 0.6 1.8 0.2 0.1
7.5
10
8 7 4.5 4.7 6.6
4 4 3 1 1 7
5 6 6 3 3
5









7.0 6.8 6.8 6.3 6.5 5.8
3.8 3.6 3.8 5.3 3.6 3.7
3.2 3.2 3.0 1.0 2.9 2.1
1.1:1 1.2:1 1.3:1 5:1 1.2:1 1.5:1
N 0.26 0.30 D 0.50 0.19
+
mm
0.90 1.0 N 0.72 0.50
N 0.98 0.80 D 0.87 0.89
N 0.89 0.90 D 0.72 0.50
mm
4.2 4.8 6.0 4.8 6.2












































































42.7 20.1 22.8 21
1 1 2 1 3 7 6
fa














6.6 7.8 7.0 7.4
11 4.2 3.7
«M
4.5 5.3 4.1 5.7
1? 2.1 3.3 2.1 2.5 2.9 1.7
—13—|2:1 1.1:1
mm







-L5-4 N 0.92 0.87 0.74 0.62
In N 0.73 0.52 1.02 0.4C
-12-jN 1.3* mm 0.52 1.0C 0.6]























23/4/63 25/6/63 27/l3/6j 15/3/63















6A 7.5 7.6 7.4
3.2 4.4 4.5 4.6
3.2 3.1 3.1 2.8
1:1 1.4:1 1.5:1 1.6:1
+ +
0.50 0.42
+ + 1.02 1.10
N N 0.8] 0.72





































































































































































(1)MannitolMustard: 27/11/43 (2)Cyclophosphamide: 16/12/63
45 (L.B.)
26/3/63 8/4/63 15/5/63 18/11/6;
0.8 0.9 0.92
■1.2C









10 12 8 12
+ +
mm
6.4 6.2 5.8 5.9
4.3 4.6 3.2 3.6
2.1 1.6 2.6 2.3











8.0 7.6 6.2 7.4


































N 0.20 0.30 0.20
N 0.60 0.60 0.80
N 1.00 0.80 0.70
mm
N 0.90 1.10 0.70
mm
4.2 3.3


















48 (A.W.) 49 (M.O.)
3/3/65 18/3/65 25/3/65 22/4/65 29/4/65 25/5/65 24/6/65 23/9/65 3/1/66 29/5/64 4/6/64 13/1/65 I8/3/65
50 (M.S.)
13/9/65 23/9/65 24/9/65 27/9/65 30/9/65 7/10/65 23/10/65 26/10/65
0.7 0.5 0.4 C.7 0.6 0.8 0.4 0.5
6










6.9 6.5 6.3 6.4 6.4 6.6 7.2 5.8 6.9 7.2 5.1 7.0 6.5 6.9 6.1 6.2 6.2 6.0 6.1 7.2 6.3
3.1 2.6 2.9 3.0 3.0 2.3 3.6 3.6 2.1 3.2 2.5 3.7 2.8 2.8 2.3 2.2 2.4 3.4 2.9
13
34156,7M
3.8 3.8 3.5 3.6 4.2 3.5 3.3 3.6 3.0 3.8 4.0 3.2 3.3 3.4 3.9 3.8 3.7 3.8 3.4
1:1.1 :1.4 s1.3 :1.2 :1.5 1.5
1:1 1:1 1:1.4 1:1.1 1*1.8 1.1:1 1:1.2 1:1.3 1:1.5 1:1.5 1:1.4 1:1.2 1:1.2
0.60 0.60 0.50 0.50 0.30 0.40 ++ ++ 0.60 0.80 0.20 0.30 0.30 0.20 0.40 0.40 0.20 0.40
1.00 1.00 1.00 1.70 0.70 0.90 ++ +♦ 1.60 1.60 0.90 0.80 0.80 1.60 1.00 1.10 2.20 0.90
N 1.00 1.00 0.90 1.00 0.80 1.00
V
N N 0.80 0.80 0.80 1.00 0.90 0.70 1.00 0.90 0.7ft 0.80
1.20 0.90 1.20 0.90 1.60 1.00
4.1 4.7 3.7 4.6 4.2 2.8 3.0 3.2
N N 0.80 0.80 1.30 1.30 1.40 1.40 1.40 1.40 1.70 1.30

















6.0 5.4 6.1 6.3 6.4
2.7 2.2 2.4 3.2 3.3
3.3 3.2 3.7 3.10| 3.1
1:1.2 1:1.3 1:1.4 1:1 1.1:1
0.50 0.40 0.50 0.40 ^0.4
0.80 0.09 1.00 0.90
0.80 0.90 1.00 0.80
1.2 1.0 1.20 1.00
(1)Thiotepn:12/8/Q (2)Cyclophoaphandte;


































6.1 6.2 6.5 6.4 6.3 5.9
2.9
••
4.0 4.3 3.8 3.1 3.3
3.2 2.2 2.2 2.6 3.2 2.6
1:1.1 1.9:1 2:1 1.5s 1:1 1.2:1
0.40 0.40 0.20 0.30 0.40 0.40
0.80 0.50 0.60 0,60 0.70 0.60
0.90
mm
0.60 0.80 0.60 1.00 0.90
1.20
«■>
0.70 0.60 1.10 1.10 0.80

















































































29/6/62 13/7/62 23/8/62 5/3/63
0,5 0.6 0.6 0.4
1
7.0 7.8 15 10.0









7.4 6.8 6.3 7.3
3.4 3.2 4.6 4.9
4.0 3.6 1.7 2.4
1:1.2 1:1.2 2.4:1 2:1
0.3" 0.3; o.u o.ii
1.2: 1.2( 0.8C l.OC
1.05 0.92 0,4' 0.5<
1.2* 1.2C OAC 0.5C
4.0 4.3 7.4 6.2
(lVThiocolciran: ' 9/7/^2 (2)Cyclophosphamide 5/11/82 (5}Vinblastine Sulphate:12/3/63
54 (A.E.)

















6.0 6.4 7.4 7.4
3.9 3.6 5.3 4.8
2.1 2.8 2.1 2.6
























































































7.1 6.8 7.3 6.2 6.5 6.4 6.4 6.4
3.3 2.4 3.3 2.4 3.1 2.6 3.3 2.7
3.7 4.4 4.0 4.8 3.4 3.8 3.1 3.7





0.60 0.80 0.70 0.90 0.70 0.90 0.70 1.00
0.80 0.80 1.00 0.80 0.80 3.80 3.90 0.70
2.20 2.50 2.00 1.80 1.60 1.70 1.40 1.60
2.8 3.8 3.7
UO
3.1 3.9 4.1 3.3
(1)Thiotepa:17/3/65 l2jCyclophosphamide: 24/6/65
58 (E.H.)
29/6/64 16/7/64 20/7/64 22/8/64 33/8/64 4/9/64
OA 0,3 0,5 1,0










6.0 5.4 5.2 5.2 5.2
3.5 2.5 2.5 2.2 2.0
2.5 '>.9 2.7 3.0 mm 3.2
1.4:1 1:1.2 1.1:1 1:1.4 1:1.4
0.40 0.50 0.50 0.40 0.50
0.90 i.10 0.90 1.00 1.00
3.70 3.70 3.70 3.80 3.70















































6.9 7.8 6.8 6.6
4.1 5.4 4.0 3.6
2.8 2.4 2.8 3.0
1.4:1 2.1:1 1.4:1 1.2:1
0.23 0.18 0.12 0.20
0.80 0.82 0.94 1.02
0.90 0.82 0.78 0.80
0.90 0.80 1.00 1.08
6.1 6.3 7.1 6.8








































































































































































































































































































































































































































































































































































































































































































6.4 6.0 6.6, 5.8 6.5 6.4 6.7 5.7 6.3 5.9 5.9 6.1 5.6 5.7 5.6 6.1 6.2 6.1 6.6
3.4 3.1 2.4 2.6 3.6 3.3 3.8 3.3 3.6 3.4 3.4 3.5 2.7 2.3 2.8 3.1 2.9 2.8 2.9
«•
3.0 2.9 4.2 3.2 2.9 3.1 2.9 2.4 2.7 2.5 2.5 2.6 2.9 3.4 2.8 3.0 3.3 3.3 3.7
1.1:1 1:1 1:1.8 1:1.2 1.2:1 1:1 1.3:1 1.3:1 1.3:1 1.4:1 1.4:1 1.4:1 1:1.1 1:1.4 1:1
1:1 1:1.1 1:1.1 1:1.3
0000000000000000000




0.90 0.90 1.10 1.00 1.00 0.90 0.90 0.80 0.80 1.00 0.80 0.90 0.80 1.00 1.10 1.30 1.20 1.10 0.80
1.00 0.80 1.20 0,80 0.80 1.10 1.00 0,70 0.80 0A0 0.70 0.60 0.70 0.80 0.70 0.60 0.70 0.80 0.90
1.20 0.90 1.60 1.0C 0,80 0.80 0,90 0.70 0.90 0.80 0.80 0.90 1,00 1.00 0.60 0,80 1.00 1.00 1,60
4.3 6.0 5.5 6,8 7-9 8.7 8.3 8.8 9.3 9.3 11,8 11.8 12.5 12.2 6.4 9.7 6.9 5.7
































































































Cytotoxic Agent(s) and Date of CommencmentHVO
TABLE25 GROUPL:ADRENAL
CARCINOMA








































































































































19/9/62 30/10/62 4/4/63 26/6/63
0.20 0.40 0.80 0.80
10.4 20.0 24 28
1 6 7 7
5 10
Ik 15
20 18 22 28
mm
N N
7.2 7.9 8.0 7.8
4.0 4.7 4.8 4.3
3.2 3.2 3.2 3.5
1.2:1 2.0:1 1.5:1 1.4:1
0.46 0.32 0.42 0.43
1.12 1.02 1.20 1.22
0.70 0.80 0.68 0.76
0.90 1.10 0.72 0.84
7,2 6.8 7.4 7.6
































































































































































































































































6.6 5.8 6.2 5.8 5.4 6.1
3.6 2.3 2.9 2.6 2.9 3.6
3.0 3.5 3.3 3.2 3.5 2.5
1.2:1 1:1.5 1:1.2 1:1.3 1:1.1 1.5:1
N 0.50 0.40 0.50 0.30 0.40
N 0.90 1.10 1.00 0.90 1.00
N 0.90 0.90 0.80 0.60 0.60
N 1.20 1.00 0.90 0.60 0.50
2.9 2.5 2.8 3.0 2.3 2.8
(l)Thiocolciranand Methotrexate: 33/3/65










6.0 5.9 5.6 5.3 6.0 5.3
3.2 3.7 3.5 3.2 2.7 2.4
2.8 2.2 2.1 2.1 3.3 2.9
1.1:1 1.5:1 1.5:1 1.5:1 1:1.2 1:1.1
0.40 0.20 0.30 0.10 0.50 0.30
0.90 0.90 0.90 1.00 1.10 1.30
0.60 0.50 0.50 0.60 0.80 0.90
0.90 0.60 0.40 0.40 0.90 0.50


































































































































































































































































































































CytotoxicAgent(s) and DateofCommencem nt
29/5/61 25/10/61 3/13/61 19/4/63 26/9/63 8/3/64
OA 0.4 0*6 0*3 0.3 0*3
8 10 8 11*3 9.0 9*0





6.2 6.3 6.9 7.4
4.1 4.5 3.5 4.8
2.1 i.a 3.4 2.6
1:1 2.5:1 1:1 1.9:1
N N 0.25 0.20
+
1.08 1.10
N N 1.10 0.60
N N
1.05 0.70
4.0 4.2 3.6 3.2




















17/12/62 8/3/63 I8/10/63 13/3/64
0.4 0.1 0.2 0.6
8.6 8.0 7.0 13.3
3 3 4 7
8 9 8 5
18
6.6 6.6 6.4 6.4
4.7 3.0 3.2 4.3
1.9 3.6 3.2 2.1
2.5:1 1:1.2 1:1 2:1
N 0.41 0A6 0.30
+
1.06 1.10 1.00
N 0.90 0.92 0.40
D 1.23 0.80 0.40
5.0 4.6 4.3 6.1



















































24/10/63 22/11/63 17/12/63 9/1/64
0.4 4.6 15.6 13.2
64.5 34.6 91.5 10.5
2 7.0 19 40




7.1 5.3 6.3 6.1
4.8 3.7 4.0 3.5
2.3 1.6 2.3 2.6







































































































6.5 6.4 6.2 7.0 6.7 6.6 6.5 5.7 6.8 6.6 6.2
-7
3.5 3.1 2.6 3.4 2.1 3.6 3.4 2.7 4.3 3.7 3.4
jn
mm
3.0 3.3 3.8 3.6 4.6 3.0 2.1 3.0 2.5 2.9 2.8 7-7
1.2:1 1:1 1:1.5 1:1 1.2:1 1.1:1 1:1.5 1:1.1 1.7:1 1.2:1 1.2:1
1Tt
+ 0.40 0.50 0.40 0.40 0.30 0.50 0.50 0.20 0.30 0.30
C\PA
N 0.90 1.00 1.10 1.10 0.70 1.00 0.80 1.00 0.90 0.60 A
N 0.80 0.90 0.90 1.20 0.80 0.80 0.60 0.60 0.80 0.80
inn
H 1.10 1.20 1.30 1.90 1.30 1.00 1.00 0.70 0.90 1.00
1fti
»•












































































(l)KannitolMustard: 22/2/h f2)Cyclophosphamide: 28/2/63 (3}Vinblastine Sulphate:29/2/63 (4)Thiotepa:19/3/63
93 (E.L.)
7/12/64 7/V65 23/1/65 18/2/65 13/3/65 15/4/65























































34/12/64 26/12/64 23/1/65 5/2/65 12/2/65
0.5 0.8 5.6 11.5 6.5





























16/2/65 22/2/65 8/V65 18/3/65 3/4/65




























































































(1)Riegyl-alaninc Mustard:19/12/62; (2)C.yclopho3phami; 22/12/62








7.5 6.7 7.3 6.5 6.0 6.6 6.4 5.6 5.2
4.2 4.0 3.9 3.6 3.1 3.6 3.4 3.4 2.5
3.3 3.7 3.4 2.9 2.9 3.0
mm
3.0 2.2 2.7
1.3:1 1:1 1.1:1 1.2:1 1:1 1.2:1 1.1:1 1.5:1 1:1
0.30 0.20 0.30 0.30 0.30 0.40 0.30 0.30 0.40
1.10 0.90 0.80 0.80 0.80 0.90
mm
0.80 0.70 0.90
1.00 0.90 1.10 0.70 0.80 0.80 1.00 0.80 0.80
1.00 0.70 1.10 1.00 1.10 0.90 0.80 0.50 0.70
3.2 3.0 3.4 2.4 3.9 4.2 3.0
(1)Methotrexate:SW(2)Phenyl-alanine: aatard:u/w(3 (3)2-2thyl-hydrasine:
23/13/65 3/3/66 10/1/66 13/3/66 24/1/66 25/3/66 7/3/66 a/3"
C.4
11
6.7 7.7 6.5 6.4 6.6 6.8 6.3
3.8 4.1 3.7 3.8 3.6 3.9 3.0
2.9 3.6 2.8 2.6 3.0 2.9 3.3
1.3:1 1.1:1 1.2:1 1.3:1 1.1:1 1.3:1 1:1.1
0.20 0.40 0.30 0.20 0.20 0.20 0.40
0.90 1.10 1.00 0.80 1.10 0.90 1.10
0.90 1.10 1.10 0.70 0.90 1.10 0.90
0.9 1.0 0.5 0.9 0.8 0.7 1.0
4.1
mm
4.1 2.8 3.8 4.9 3.6
(1)Phenyl-alanine *HI«■111-mmMIMIfc.vr~,n>mu mf< Mustard:7/3/(2)2-'thvl--h^drszinc:j
5/66




-•> 6.1 5.9 5.5
3.4 3.1 2.3




-0.-4^ 0.30 0.40 0.50
1.10 1.00 1.00
0.80 0.70 0.90




























































































(1)Vinblastine Sulphate:1/1/64 (2)Cyclophosphamide: 3/3/^4 (5)Thiotepa:14/1/64 (4)5-Fluouracil: 10/2/&,
101 (J«Mcl)
18/2/65 25/3/65 13/3/65 16/3/65 18/3/65 29/3/65

















2gl 0.60 2gl 2&























































































































(1)HannitolMustard: 11/2/63(2)Thiotepa: 1272763(3)Cyclophospharaicie: 11/9/63(4)Vinblastine Sulphate:1/10/63
104 (D.0.)
10/1/63 6/3/63 12/3/63 12/2/64




7 3 2 7
10
8
6.7 6.6 6.8 7.3
4.0 5.2 5.1 4.6
2.8 1.4 1.7 2.7
1.7:1 3.6:1 3:1 1.8:1
N N N 0.38
N N N 0.65
N N N 0.81
N D D 0.81
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*(a)SubjectiveRespons ;ympt maticimprove entmaintainedf rinimum periodof8w eks (b)O jectiveRespons :D fin ttum urregressionmaintainedforinimum periodof8w eks c)ObjectiveandSubjeResponse:Combinat onf( da ve d)Harmful;Deaththoug ttofjfnccelerateJbycytotoxics e)NoBenefit;sympt ma icimprovementri r v tmai tain dfo lessthan8weeks ;Nonerminimaltu ourregression :Insufficienttreatment
PATTERNSOF<*2GLOBULINNDURICCBYPRI CIPALTUMOURG OUPS
























































































































































































































































*Incompleteresultsin7Patient-. .J/ooft tal fromt talf107cases
T&Tff.Ti! 30
THE CHEEOTHERAIY OF CANCER




1. Gastro-intestinal 20 5
2. Bone Marrow 12 7
3. Integuments 14 14
4. Central Nervous System 3 4
5. Cardio-vascular System 10 3
6. Genito-urinary System 5 1
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ASSESSMENT OF RESPONSE TO TREMIISHT P?
PRINCIPAL TUMCUR GROUPS"
The benefits obtained by the use of cytotoxic drugs vary with
the nature and extent of the tumour, with the particular agent used
and, to a lesser extent, vdth the mode and route of administration
employed. The results obtained in this study largely accord with
22,23,24,37,40,41,46,78.
those reported by other workers.
1. Malignant Disorders of the Heticulo-endothelial System
3%qod-fprniry; Organ? {11+ feg.gsj
a) Hodgkinfe Disease (7 Cases)
Even with the 3raall numbers available, it is clear that
cytotoxic agents are of value in controlling the symptoms and
| progress of Hodgkinfe Disease. The alkylating agents, nitrogen
mustard, mannitol mustard and cyclophosphamide were found to be the
most useful in this condition. Vinblastine sulphate and, in one
case, uracil mustard have proved of benefit in producing further
remission when relapse occurs with other agents.
b) Lymphosarcoma (3 Cases)
Cyclophosphamide and vinblastine sulphate produced worth-
■
while remission in two of the three cases of lymphosarcoma but were
without effect in the third case. This virulent form of malignant
disease requires the application of all modalities of treatment of
which /
54.
which chemotherapy is perhaps the most important , Bvenso, prog¬
nosis remains uniformly bad.
c) Leukaemia (4 Cases)
Worthwhile remission was obtained in one case of acute
myeloid leukaemia using 6-mercapto-purine but in the remaining
three c&seSjOne of which was acute monocytic leukaemia, nitrogen
mustard and cyclophosphamide were used without effect.
In each of the above groups,the use of cortico-steroids has a
definite part to play in the control of symptoms and in the main¬
tenance of remission. They are of particular value in patients
who develop haemolytic anaemia or thrombocytocaenia. There is no
evidence, however, that they prolong life and the complications of
their use are considerable.
2. Carcinoma of the Lung (15 Cases)
Subjective and objective improvement v®.s obtained in approxi¬
mately 50 per cent of the cases of carcinoma of the lung treated
in this study. The principal agents used were cyclophosphamide
and nitrogen mustard. The greatest benefit was obtained in those
patients who had not received prior radiotherapy or in whom radio¬
therapy had been given a minimum of three months previously.
Remissions were usually short-lived, but in two cases the disease
was controlled for one year.
3. /
55
3. Carcinoma of Breast (22 Cases)
Cytotoxins have a definite part to play in the control of
advanced carcinoma of breast as confirmed by thi3 study. In
addition, carcinoma of breast lends itself to the prophylactic use
of cytotoxic drugs and although the patients in this series have
not been followed for a sufficient period of time, there is evi-
31,55,58,60
dence from other centres that definite benefit accrues from such
use. The agents mo3t useful have been cyclophosphamide, thiotepa
and vinblastine sulphate. The combination of cyclophosphamide
systemically and thiotepa intrapleurally or intraperitoneally is of
particular value. Cyclophosphamide and vinblastine have also
proved a satisfactory and effective combination. Some of the most
satisfactory and complete remissions were obtained in this group
and, in two cases, extended over a period of one year, .Approxi¬
mately 30 par cent of the patients obtain a good to excellent sub¬
jective and objective response and a further 10 per cent experience
subjective benefit. Two of the cases of carcinoma of the breast
in this series were considered to have been harmed in that their
deaths were probably accelerated by the use of cytotoxic drugs,
4. Malignant Tumours of the Genito-urimry system (18 Cases)
a) Carcinoma of Ovary (6 Cases)
Carcinoma of the ovary is particularly amenable to
cytotoxic /
56
cytotoxic therapy with agents such as cyclophosphamide and thiotepa.
In the six cases in this series, good tumour regression and pro¬
longed control were obtained in four. In the remaining two cases
slight subjective benefit was obtained in one end no effect in the
other.
b) Testicular Tumours (5 Gases)
Malignant disease of the testis, once it escapes the
control of surgery and radiotherapy, is only slightly influenced
by the use of cytotoxic agents including methotrexate, vinblastine
sulphate and cyclophosphamide. Transient subjective control was
obtained in two cases, but objective benefit was not evident.
c) Renal Carcinoma (5 Cases)
In the five cases of renal carcinoma treated, subjective
improvement was obtained in two cases with the use of cyclophos¬
phamide by intra-arterial injection. Objective improvement alone
was obtained in one case using intravenous cyclophosphamide.
•••
Marked resolution of pulmonary metastases was, however, accompanied
by the development of severe toxic effects and the patient remained
throughout her course in hospital (Case No. 65. Fig. 3).
d) Carcinoma of Bladder (l Case) and Trc-state (l Case)
No benefit was obtained in the one case of carcinoma of
the bladder using 5-fluouracil or in the one case of carcinoma of
the /
57.
the prostate with cyclophosphamide. In this last case severe
depression of the bone marrow occurred and accelerated the patient's
death,
5. Malignant Lesions of the G&3tro-intestinaI Tract (19 Cases)
The response of gastro-intestinal tumours to cytotoxic
therapy has been studied with particular interest. These tumours
are generally regarded as non-sensitive to radiotherapy and to
chemotherapy. Some benefit has, however, been obtained in 4°
per cent of the cases of gastro-intestinal malignancy treated in
this series. The principal cheaotherapeutic agents used were
methotrexate and thiocolciran in combination, and cyclophosphamide
alone or in combination with thiotepa or vinblastine.
5~Fluc|urj!jCil was not used in this series, but reports in the
literature suggest that this is the most satisfactory agent
available for treating tumours of the gastro-intestinal tract.
a) Carcinoma of Oesophagus (2 Cases)
No benefit was obtained in either of the two cases of
carcinoma of the oesophagus using cyclophosphamide.
b) Carcinoma of Stomach (8 Cases)
The response of gastric caroinoma to cytotoxic agents has
been poor, but subjective benefit lasting for periods of three to




c) Carcinoma of Colon and Rectum (9 Cases)
In carcinoma of the colon subjective benefit was obtained
in three cases and objective benefit in two, using combinations of
methotrexate and thiocolciran, cyclophosphamide and vinblastine
sulphate, or cyclophosphamide alone.
d) Carcinoma of Pancreas ( 4 Cases - Group ,P* included under
"Others" in principal tumour groups)
Four cases of carcinoma of the pancreas, included under
the Group headed "Others", were treated, one with a combination
of cyclophosphamide, vinblastine and mannitol mustard and three
with cyclophosphamide alone. Short-lived subjective benefit was
obtained in one case, but no benefit in the others.
6. Malignant Melanoma (5 Cases)
In the three cases of malignant melanoma in the series,
little or no benefit was obtained with the use of phenylalanine
mustard (melphelan) or 2-ethyl hyrazine. In one patient (Case No,
16) the prolonged use of melphelan is thought to have been a factor
precipitating a fatal subarachnoid haemorrhage.
7. Others (8 Cases)
Included under this heading are examples of bone, cerebral and
retro-peritoneal /
59.
retro-peritoneal tumours and cases of unknown primary origin.
These cases were mainly treated with cyclophosphamide alone or in
combination with vinblastine, thiotepa or mannitcl mustard. Sub¬
jective benefit was obtained in two of these cases and objective
benefit in one, but only one patient in the group survived far more
than a year from diagnosis.
In summary, it may be stated that cancer chemotherapy is of
definite benefit in malignant diseases of the reticulo-endothelial
system and blood-forming tissues, of the breast, ovary and lung.
It is of less value, but still has a useful part to play in the
management of tumours of the ©astro-intestinal and genito-urinaiy
tracts. Occasional benefit may be obtained in tumours of the
pancreas, in melanomas and in tumours of unknown origin. No benefit
derives from the use of cytotoxins in sarcomas and in tumours of the
oesophagus, adrenal gland and larynx.
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TABLE VII
CHEMOTHERAPY OF CANCER
MEANS USED OF ASSESSING- RESPONSE
!• Subjective Assessment
(a} Arrest of tumour growth
(b) Measurable decrease in size or volume





(e) Reduced pyrexia, bleeding or discharge







TOXIC SIDE-EFFECTS OF TREATMPHT
1. Castro-intestinal Tract
(a) Nausea and vomiting
(b) Diarrhoea
fc) Pain
(d) Bucco-labial ulceration and bleeding
("sore gums")








(a) Dry, scaly shin
fbJ Alopecia
(c) Ulceration at injection site
(d) Rashes
4. Central Nervous System
(a) Neuritis
b) Depression
c; Hallucinations and paranoia
5, Others
Lowering of host resistance to infection
(a) Respiratory infection
(b) Genito-urinaiy tract infection




The advent of effective chemotherapy has provided a further
approach to the management of malignant disease. Used alone, or as
an adjunct to surgery or irradiation, the agents at present availably
have much to offer. While principally indicated in the management
of the advanced case, cytotoxins may nop/ be employed to prevent or
control spread and recrudescence. % using combinations of drugs,
attacking different metabolic pathways v/ithin the cell, effectiveness
may be increased and toxicity reduced. Sophisticated techniques,
84 85
such as perfusion, alterations of oxygen tension or pH, and autologous
86
marrow infusion are of value in specialised units, but, in the
practical management of cancer, simplified, low-cost, out-patient
chemotherapy is the desired aim.
Objective means of assessing response are essential if results
obtained in different series are to be compared and observer bias is
to be eradicated. Biochemical changes in blood and urine, following
the exhibition of cytotoxic agents, constitute the most fruitful linb
of research and it should be possible to identify, at an early
stage, those patients being benefitted. Almost as important, is the
identification of those patients in whom continued use of cytotoxins
is unlikely to prove beneficial, so that treatment may be withdrawn
and hazards avoided.
The incidence and severity of toxic effects may also be reduced
by /
61.
by controlled maintenance therapy at sub-toxic dose levels. The
occurrence of these effects, however, will continue to limit the
application of cytotoxic agents and much research vrlll be required
I
before ideal agents become available.
The assessment of response to treatment, the incidence,
severity, significance and management of toxic effects, the sig¬
nificance of hepatic metastases in relation to response and toxicity
and the cause of death in treated patients, are considered the out¬
standing problems in cancer chemotherapy. These aspects constitute
the main points of this discussion.
62
DISCUSSION
a) The Assessment of Response to Treatment with Cytotoxic Agents
(Tables VII and 27).
The assessment of response to treatment constitutes one of the
most difficult aspects of canoer chemotherapy. 3o many problems are
involved in the management of patients with advanced malignant
' i
disease,that surmise,impression and observer bias cannot be entirely
eradicated from the assessment of a controversial treatment. The
mere placebo effect of an interested medical attendant, regularly
reviewing a patient with advanced cancer, may be considerable.
The physician may convey his own enthusiasm to the patient with the
result that the correct interpretation of symptoms and even of
clinical signs is delayed or avoided. Particular stress has
accordingly been placed, throughout this study, on achieving an
accurate and unbiased assessment of response to treatment. This
may be discussed under the two broad headings of Subjective Assess¬









a) Improved appetite and b) Improved well-being
Improvement in appetite and general well-being may represent no
more than the effect of such measures as bedrest, reassurance,
correction of anaemia, or intercurrent infection,or result from a
palliative surgical procedure. They are of little real value in
assessing response to cytotoxic therapy.
N
c) Reduction or loss of pain
'
The significance of reduction or loss of pain may be difficult
to determine and may equally well result from the use of simple
supportive measures such as rest, sedation and analgesia. If,
however, pain ha3 been severe and previously unrelieved by analgesics^
then relief following rapidly on the exhibition of cytotoxic drugs
may be reasonably ascribed to their effects.
d) Improved function
Improvement in function of an affected system, organ or limb,
for example, improvement in liver function, reduction of dyspnoea
following correction of a malignant pleural effusion,or return of
function in a limb by relief of tumour compression of nerve roots,
following cytotoxic therapy, is also difficult to assess. The
mere mechanical removal of fluid from the chest or abdomen may be
| sufficient to account for any improvement which ensues, while




While subjective improvement following the exhibition of cyto¬
toxic agents has been carefully noted throughout this study, little
significance can be attached to the findings recorded {Table No.27j
II. OBJECTIVE ASSESSMENT
a) Arrest of tumour growth.
b) Measurable decrease in size or volume of a tumour or its
metastases.
c) Biochemical changes: significance of changes in^ 2
globulin and serum uric acid.
d) Weight gain.
e) Reduced pyrexia, bleeding or discharge.
f) Morphological changes in tumours.
The only acceptable means of assessing tumour response to cyto¬
toxic drugs are objective and include a) the demonstration of arrest
of a tumour or its metastases when, previously, growth had been rapid
and obviousj b) a decrease in size or volume of a tumour or its
metastases on direct measurement car on serial X-ray examination.
The results detailed in Table 27 fulfil these criteria.and little
significance can be attached to published reports, unless the re¬
sults obtained are based on similar assessments.
c) Biochemical changes: the determination of biochemical changes
either in the blood or urine, e.g. changes in serum or urine uric
acid, in serum protein patterns or in certain serum enzymes,
constitutes /
65.
constitutes the most effective and most promising line of objective
assessment. Changes in plasma proteins, serum electrophoretic
patterns and serum uric acid levels, form an important aspect of
this study.
Significance of changes in 2 globulin and serum uric acid.
It is believed that a definite relationship exists between tumour
response and changes in the serum electrophoretic pattern and that
tumour breakdown results in measurable changes in serum uric acid
levels.
It can be seen from Table 28 that in 60^ of tho cases in this
'
series, the /, 2 globulin fraction of the serum electrophoretic
pattern was raised, often to a marked degree, when, the patient first
presented. If eases demonstrating advanced disease or metastases
were considered alone, then the percentage showing a raised 2
globulin fraction was 75.
From this table it can also be seen that the serum uric acid
was initially raised in 3Q& of the patients and could be further
altered by treatment with cytotoxic drugs.
The significance of these changes in the 2 globulin and uric
acid levels in relation to the chemotherapy of malignant disease has
79
already been made the subject of a separate study. The main con¬
clusions of this study were that changes in the./, 2 globulin fraction
of the serum electrophoretic pattern are a guide to tumour activity
following treatment with cytotoxic drugs. A persistently raised
level /
66
level suggests continued activity and a falling level, tumour
control. Changes in the serum uric acid level were similarly
considered to represent alterations in tumour breakdown.
Combining the changes in *L2 globulin and serum uric acid
levels, estimated before and at frequent intervals during the
administration of cytotoxic drugs, is considered a valuable ob¬
jective means of assessing tumour response. Furthermore, this
assessment can be made within two to three weeks of commencing
treatment in those cases in which response is likely to occur.
By this means the small percentage of patients with solid tumours
likely to be improved by continued cytotoxic therapy can be identi¬
fied and the remainder spared the potential hazards of treatment
which will not be beneficial. This work remains incomplete and
continued studies are necessary.
d) .Veight gain
One of the most sensitive indices of active malignant disease
is anorexia. Loss of appetite results in loss of weight and while
improvement in appetite may result from a number of other factors,
as discussed above, positive gain in weight may he regarded as an
objective indication of improvement. Patients in this study have
accordingly been weighed before and at intervals during treatment
and gain in weight included under "Objective benefit" in Table 27.
e) Reduced pyrexia, bleeding or discharge
If/
67.
If infection can be excluded, then reduction of pyrexia,
bleeding or discharge from a tumour may also be regarded as ob¬
jective evidence of response. Their importance in this context is,
however, largely confined to the assessment of response in malig-
riant disorders of the reticulo-endothelial system and blood-forming
organs.
76
f) Morphological changes in tumours following cytotoxic therapy
As detailed in an earlier section,this aspect of the study,
because of the difficulties involved in processing post-mortem
material and in getting a series of suitable biopsies for study,
was abandoned and it is hoped will be taken up in due course.
In the final assessment of tumour response to chemotherapy the
only criterion of success is the extent by which a patient's endurable j
and useful life may be prolonged. Less emphasis has been placed in
this study on the total duration of response or survival (Table 20)
than on the quality of response obtained over even short periods.
Little significance has been attached to the time spent as a hospital
in-patient. The aim of treatment has been to maintain the patient
on an out-patient regime and, whenever possible, to restore the
patient to normal activities. Such assessment requires repeated
out-patient review, the correction of associated conditions, such as
anaemia, intercurrent infection and intermittent bouts of vomiting
Or /
68
or diarrhoea and continuous reassurance. % those means, patients
have frequently remained at home and active when they would other¬
wise have been admitted to hospital for terminal care. In cancer
chemotherapy, the tumour being treated will, with few exceptions,
inevitably escape control within a matter of weeks or months.
It is believed by some that if remission is obtained treatment
should be stopped until relapse commences when a further course of
therapy is given in an attempt to achieve further remission. %
this means two, three or more courses of the same or of a different
agent may be employed at intervals of a few weeks to a few months.
Others believe that if remission is obtained, treatment should be
continued to prevent relapse and that maintencnce treatment with
a small dose is unlikely to produce severe toxic effects without
adequate warning. Both methods have been employed in this study
and the weight of evidence is in favour of a regime v?hich combines
an initial intensive intravenous, intra-arterial or intra-cavitary




b) THS TOXIC 3PE3CT5 OF CAKCBR ClfTlOTHir:: IUTIC AG3STS
(Pigs. 1-8) Tables VIII, 30 and 31.
The hazards associated with the administration of cytotoxic
drugs is the most important factor limiting their usefulness,while
the incidence and severity of the t oxic effects produced frequently
determine the total dosage and the duration of treatment. This
toxicity derives, not from an inherent property, but from the
similarity of their action on normal and malignant cells. The
principal toxic effects involve, therefore, the rapidly dividing
tissues such as those of the bone marrow, liver and gastro¬
intestinal tract. The minor qualitative differences which exist
between malignant and normal cells, cannot yet be exploited clini¬
cally and at this stage the occurrence of toxicity is inseparable
from the use of anti-cancer drugs.
filature and Incidence of Toxic effects
The toxio effects encountered in this study may be grouped
under five main headings as detailed in Table VII
1. Gastro-intestinal Tract
a. .Anorexia, nausea and vomiting.
b. Diarrhoea.
c. Pain.
d. Bucco-labial ulceration and bleeding.
Q. /
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e. Slou^iing of mucosa, f. Liver damage.
Disturbances of gastro-intestinal function are common during
treatment with cytotoxic drugs, particularly vath those of the
alkylating group. Although the effects produced are more severe
\vith some drugs, e.g. nitrogen mustard, than with others, e.g.
cyclophosphamide, the incidence and severity of these effects are
more closely related to duration of treatment and total dosage than
to the agents themselves.
Anorexia and nausea were experienced at some stage by most of
the patients in the study. Usually mild and of short duration,
these symptoms were readily controlled by anti-enetics and did not
necessitateohanges in treatment. Vomiting, which could be directly
attributed to cytotoxins, occurred in twenty-four patients (23, ).
In three cases it was mild to moderate and required temporary
reduction in dosage only; in the remaining twenty-one cases
vomiting was of sufficient severity to warrant cessation or pro¬
longed reduction in dosage, during maintenance therapy. Prom the
patient's point of view,nausea and vomiting are among the most
distressing of the effects produced by anti-cancer drugs. While
patients may remain unconcerned by low white cell or platelet counts
they are often reluctant to continue with treatment producing nausea,
loss of appetite and vomiting.
Diarrhoea,directly attributably to anti-cancer drugs,has occurred
in 7 (6$) of the patients studied. In 6 it was considered severe
and /
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and required cessation of treatment; in the remaining case treatment
was continued, but ?dth a lower dose. This side effect was most
commonly seen in association with drugs of the antimetabolite group.
The agents particularly associated with diarrhoea were Thiocolciran,
5-fluorouracil and Methotrexate. As might be expected, diarrhoea
occurred most frequently in those patients with primary gastro¬
intestinal tumours.
Severe pain at the site of the primary tumour or a large
metastasis was experienced in 9 patients (3,,) following intravenous
or intra-arterial injection of cytotoxins. In 6 cases the pain was
mild to moderate and could be controlled by simple analgesics, in
the remaining three cases it was severe, associated with marked pallor,
near collapse and only incompletely relieved by pethidine or mor¬
phine. The pain usually commenced within twenty minutes to one
hour of the injection, persisted for two to six hours and then
gradually subsided.
Severe bucco-labial ulceration and bleeding occurred in 6 (5/0
of the patients treated and, in each case was associated with the
use of Methotrexate. This distressing toxic effect was only seen
when the total white cell and platelet counts were depressed. The
occurrence of bucco-labial ulceration in the patients under study
has been regarded as an indication to reduce or temporarily stop
treatment, but in three cases treatment was subsequently resumed
without further incident. Most commonly, the lesions developed
along /
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along the line of lip closure in the bucco-labial sulcus or on the
edges and under surface of the tongue. The invariable complaint
of the patients was "soreness of the mouth" and in three cases was
of sufficient severity to prevent ingestion of food or fluids.
Sloughing of the mucosa of the gastro-intestinal tract is a
severe effect of certain drugs of the antimetabolite group,
particularly Methotrexate. This is an extreme manifestation of
the toxic effects of anti-cancer drugs on the gastro-intestinal
tract and was seen in only two cases in this series. Mucosal
destruction in these two cases was associated with profuse
diarrhoea, dehydration, severe electrolyte imbalance, profound
collapse and death. At post-mortem the appearances of the small
bowel were similar to those of a necrotising enteritis. Bacterio¬
logical culture of the stools was negative in both cases, but it
is believed that they represent examples of superinfection following
depression of the body defence mechanisms by cytotoxic drug.
It is possible that some of the other cases of diarrhoea seen in
this series were milder farms of gastro-intestinal mucosal damage,








The effects of cytotoxic agents on the bone marrow and peri¬
pheral blood picture have been studied in detail by a number of
workers. In this study, examination of the bone marrow was carried
out in 82 (80?Q patients and of the peripheral blood in all patients
prior to commencing treatment and at intervals thereafter. The
changes occurring in the marrow and peripheral blood were noted and
the incidence and severity of toxic depression recorded (see Table 3lJ)
In 12 (ll?o) cases, most of whom received cytotoxins as a
prophylactic measure only, the bone marrow showed little or no change
and this was reflected by persistently normal peripheral blood counts
The principal finding in 80j£ of cases was a depression of all the
blood forming elements of the marrow and in these cases the peripheral
blood picture showed varying degrees of anaemia, leucopenia or
thrombocytopenia. These changes were most frequently associated
with the alkylating agents, but the antimetabolites were, by their
nature, more specifically effective against the white cell series.
Within these groups, certain agents are more toxic to one cell series
than to others. For example, cyclophosphamide affects the white
cell series without affecting the thrombocytes to the same degree.
Myleran shows a selective destruction of the nyeloid series as com¬
pered with the lymphoid series and is therefore of value in the
treatment of chronic myeloid leukaemia.
The effects of cytotoxic agents on the blood-forming organs are
largely a function of dose and duration of treatment. In three
ease^/
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cases (77, 78 and 7°), however, an apparent sensitivity developed
so that severe depression of all cell series was produced with even
small amounts of drug. Complete bone marrow failure, although
uncommon, may therefore occur in the very early stages of treatment,
and be associated vath pancytopenia and a rapid downhill course.
It may also develop as a terminal event following prolonged cyto¬
toxic therapy as in cases 31 and 71 and this stage is usually
associated with severe intercurrent Infection involving chest, skin
and intestine.
Frequent estimations of white cell count, differential white
cell count, platelet count and haemoglobin constitute the principal
means of controlling cytotoxic therapy. In the majority of cases
it is the effects on the bone marrow and peripheral blood which
ultimately limit the application, duration of treatment and dosage
of many of the cytotoxic agents. It is essential that frequent and
accurate counts are available whenever patients are being treated
with these drugs. If the development of toxic effects on the bone
marrow are detected at an early stage, their severity may be limited
by reducing the drug dosage or by temporarily withdrawing treatment.
Although the effects of the drug may continue for many days after
withdrawal, the bone marrow will usually recover within ten to thirty
days (see Graphs of Case 65) and thereafter treatment can be resumed
■
at the same or reduced dosage. For the purposes of this study, a
white cell count of 2,000 or below, a haemoglobin of 5Q or below,
and /
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and a platelet count of 50,000 or belor/ have been taken as the
levels at which drug therapy should be greatly reduced or withdrawn.
While patients nay remain active, out of hospital, and apparently
well with counts below these ranges, the risk of intercurrent
infection is extremely high and three deaths in the series occurred




b. Dry scaly skin.
c. Ulceration at injection site,
d. Hashes.
a. Aloppoift
Although less serious in their consequences, the toxic effects
of anti-cancer drugs on the skin and its appendages are a frequent
concern to the patient. The most important of these effects is
alopecia which may occur with any of the drugs, but is most commonly
associated with alkylating agents such as thiotqpa and cyclophos¬
phamide. Hair loss may be any degree from mild to complete. It
appears to be a function of dosage and duration of treatment since,
cyclophosphamide, for example, if given in great enough dose far a
long enough period will produce alopecia in almost every patient.
This distressing side affect has been considered by some as a
serious /
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serious contra-indication to the use of anti-cancer drugs. It is
claimed that to add an embarrassing condition to the problems of a
patient dying of malignant disease is unjustified. A wig, however,
is a readily prescribed and easily fitted prosthesis. Even if
alopecia is marked, hair regrowth will usually occur within a period
of two to four months, despite the patient remaining on treatment.
Alopecia produced by anti-cancer drugs should be regarded in the
same light as major ablative surgery for such conditions as
osteogenic sarcoma which frequently require the fitting of a
complicated, cumbersome prosthesis.
Alopecia oocurred in 25 (24/5) of the patients under treatment
(14 female and 11 male) and in each case was associated with the
prolonged use of cyclophosphamide alone, or with cyclophosphamide
and thiotepa in combination. On one occasion a marked degree of
hair loss was associated with the use of thiocolciran, vinblastine
sulphate and a small amount of cyclophosphamide. In 8 (7/5) patients
hair loss was mild to moderate, and regrowth oocurred in all cases
within four months. In these patients treatment was continued
throughout but at a reduced dosage. Moderate to severe alopecia
occurred in a further 13 (12/5) patients and very severe or complete
hair loss in the remaining 4 (3.5/5) of cases. Many of the 25 pat¬
ients expressed concern when hair loss commenced, but marked distress
was only evident in two, while four patients remained unconcerned by
moderate to severe alopecia. As would be ejected, the females were
more perturbed by oven minimal hair loss than were the males.
Wigs /
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V/ig3 were provided for four patients in when epilation was severe
(Fig.2) but in three cases the prosthesis was discarded within
three months, while the fourth patient died before regrowth occurred.
In three cases alopecia occurred on two occasions, in associa¬
tion with courses of cyclophosphamide therapy separated by intervals
of 5 months, 8 months and 11 months. In each case hair loss was
more marked and occurred at an earlier stage on the second than on
the first occasion. In two cases the second episode of alopecia
was associated with the terminal stages of cancer and hair loss
was still marked at death.
b. Dry, scaly skin
The development of a dry scaly skin in association with
cytotoxic therapy was seen in 48 (4^) of tho patients treated.
In many of these the skin changes were considered to largely
reflect the nature and extent of the malignant process and to be
only partly attributable to the action of the drugs. Varying
degrees of brown pigmentation of the skin was also a common feature
and in only two cases could be ascribed to metastatic lesions in¬
volving the adrenal glands. Few patients complained of these skin
changes, but accepted them as part of their general illness.
o. Ulceration at injection site
An indolent ulcer at the site of intravenous injection occurred




with accidental extra-va3cular injection of an alkylating agent,
being used prophylactically. The agent concerned in one case
was mannitol mustard and the injection site was the dorsum of the
foot, the injection being given during the course of a general
anaesthetic. The ulcer failed to heal and excision and grafting
were ultimately required. In the second case nitrogen mustard
was used in an ante-cubital vein and produced a small shallow,
indolent ulcer which healed with conservative therapy over a
period of three months.
The avoidance of this troublesome complication requires con¬
tinuous care during the intravenous or intra-arterial injection of
cytotoxic drugs, particularly those of the alkylating group. If
the least pain is experienced at the injection site the injection
should be stopped and given elsewhere; when using agents such as
nitrogen mustard or mannitol mustard they must always be diluted
with sterile water or normal saline.
d. Rashes
Three patients in the series developed skin rashes considered
due to the administration of anti-cancer drugs. In two cases the
rash took the form of a generalised papular eruption most marked on
the face and forehead (Fig. 3 )• In both cases the underlying
disorder was Hodgkin's disease and drug being used was vinblastine
sulphate (velbe). In the third case, a patient with carcinoma of
the /
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the stomach, a haemorrhagic-purpuric rash, confined to the trunk
and upper arms developed in association with the use of metho¬
trexate (Pig. 4 ). The platelet count remained normal in this
case, but there was a severe depression of the white cell count
at the height of the rash. In all three cases the rash slowly
cleared follovang temporary cessation of treatment and did not
recur when treatment was resumed with reduced dosages.
Central Nervous System (Neuritis, depression, hallucinations and
paranoia)
Toxic effects on the central nervous system,directly attri¬
butable to the use of anti-cancer drugs,were uncommon in this study.
Two patients, one with lymphosarcoma. (Case No.23) and the other
with carcinoma of the lung (Case No.11), developed marked peripheral
neuritis while on treatment with cyclophosphamide. Neurological
changes are known, however, to occur as a feature of malignant
disease and the part therefore played by cytotoxics in these cases
is uncertain. Mild to moderate depression was a common symptom
among the patients under study. In many it resulted from failing
general health, from the patients increasing awareness of the true
situation and from the increasing limitations imposed on normal
activities by advancing malignant disease. In five cases (4.3/0,
however, endogenous depression developed at an early stage and was
of marked degree. Three of these patients were receiving vin¬
blastine sulphate (Cases No. 2, 53 and 72), one cyclophosphamide
(Case /
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(Case No. 17) and one phenylalanine (Case No. In all of these
patients depressive symptoms persisted while drug therapy was
maintained, but responded to the use of tranquilliser drugs and
the temporary cessation of treatment.
Hallucinations, resulting particularly from the use of vin¬
blastine sulphate were severe, in Cases No. 23, 25 and 65, and in
one preceded coma resulting from hyperuricaeniia (Case No, 25).,
In the other tv/o cases hallucinations occurred with the first few
doses of vinblastine sulphate, but coincided with a dramatic
improvement in general state and marked regression of the disease
process. One patient (Case No, 51) demonstrated severe paranoid
tendencies while on long term maintenance therapy with cyclophos¬
phamide and required temporary admission to a mental hospital.
These symptoms resolved spontaneously vdthin three weeks of dis¬
continuing cyclophosphamide and instituting therapy with chlor-
promazine. Mild paranoid states were evident in a further two
patients, one (Case No, 57) receiving a combination of cyclophos¬
phamide and thiotepa and one (Case No. 65) receiving vinblastine
sulphate. Psychiatric disturbances are common in patients suffer¬
ing from malignant disease, even when cytotoxins are not exhibited
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4« Buccal bleeding and ul¬
ceration: Methotrexate.
Fig. 5: Haemorrhagic rash -
Methotrexate (Case not in¬
cluded in series).
Fig. 6: Indolent induration at
site of injection of
vinblastine sulphate -
dorsum of hand.
Fig. 7: Radical mastectomy: in- Fig. 8: Same case: 6 weeks
fusion of cyolophospha- post—operation,
aide via internal mammary
artery: Case 42: 10 days
post-operation.
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1. Lowering of Host Resistance to Infection
Declining general health from progressive malignant disease is
frequently associated with an increased incidence of respiratory
tract, urinary tract, wound and skin infection. In patients
receiving cytotoxic drugs the effects on the blood-forming elements
and reticuloendothelial system are likely to increase the incidence
and severity of such infections. It is considered, however, that
the part played by low white blood countain producing infection has
been over-emphasised. Many patients in this series remained well
and active with total white cell counts below 3,CCG per cubic
millimetre. In three patients (Cases nos. 2, 27 and 31) with white
cell counts below 1,500 and exposed to a hospital environment for
long periods, ulceration and infection developed around the nose
and mouth and resisted attempts at healing until the peripheral
blood picture improved,
a. Respiratory Infection
The incidence of significant respiratory tract infection (6%)
was no higher in this group of patients than in a group of post¬
operative patients not receiving cytotoxic drugs. It was, however,
noted that many patients complained of persistent coryzal symptoms
which were often difficult to eradicate and one patient (Case No.9l)
experienced symptoms of chronic sinusitis for five months.
b. /
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b. Genito-urinarv Tract Infection
The incidence of urinary tract infection was found to be no
higher in patients treated with cytotoxic drugs than in control
patients. With the exception of haemorrhagic cystitis, seen
on three occasions (Cases Nos. 10, 67 and 99) in association with
cyclophosphamide therapy and resolving on cessation of drug therapy,
major infections of the genito-urinary tract wore not encountered
in this study. In the 22 cases in which the urine was examined
bacteriologically, pathogenic organisms were cultured in 9
The majority of these patients were symptomless and the urine was
rendered sterile by sulphonamide or antibiotic therapy. Two cases,
17 and 53, developed moderately severe non-haemorrhagic cystitis
v&th positive urine cultures. These were both associated with the
use of cyclophosphamide but responded to antibiotic therapy.
c. Wound Infection and Wound Healing
It has been stated that cytotoxins delay healing of wounds
and predispose to a high inoidence of wound infection. All wound
complications occurring in the series have been attributed to the
use of cytotoxins despite the possibility of other factors playing
a part. Three patients (Cases nos. 39, 42 and 86; demonstrated
delayed wound healing and one of these is illustrated (Figs 7 and 8
Case no. 42). The incidence of wound dehiscence does not appear
to be increased by treatment with anti-cancer drugs and occurred in
only /
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only two patients in the series. One of these, Case no. 56
had received cytotoxins for three weeks before operation, but the
second, Case no. 86, had received only one dose of aannitol mustard
prior to the episode of wound dehiscence. In the great majority
of cases primary, uncomplicated wound healing occurred despite
patients, in some cases, receiving cytotoxins, for many week3
prior to operation. If surgical technique is good,the occurrence
of these side effects should not influence the use of anti-cancer
drugs or the timing of a surgical operation.
d. Gram-negative Septicaemia
An E-coli septicaemia was established as the cause of death
in two of the patients (Cases nos. 3° and 102) dying in hospital.
In these two cases the E-coli septicaemia was the final event in a
terminal illness. In three cases (32, 77 and 78) overwhelming
clinical infection developed within a short time of commencing
cytotoxic therapy but bacteriological proof of Gram-negative
septicaemia was lacking. Septicaemia was believed to be the final
event in a further four patients (Case nos. 2, 3> 96 and 100) in or
approaching the terminal stages of their disease, but blood cultures
were again negative. In all cases the onset of clinical septicaemia
was preceded by moderate to severe depression of bone marrow function.
It is believed that overwhelming Gram-negative infection is an
important cause of death in patients receiving cytotoxic therapy
and will be further discussed in a later section.
2. /
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"Suppression of Immunity" '
The possibility that cytotoxic drugs may act in a harmful
manner by suppressing the "immunity mechanisms" of the host has
been investigated by a number of workers both in the experimental
animal and, on a much smaller scale, in the human patient. The
anti-cancer drugs, cyclophosphamide and irauran are employed in
renal homotransplantation to suppress the antigen-antibody re-
actions involved in host rejection of a transplant. These drugs
must similarly suppress antibody mechanisms in those patients
being treated for cancer. If it is accepted that a host-tumour
relationship exists and that this relationship may be adversely
affected by suppression of host resistance, then, from the above
analogy, it is clear that certain cytotoxic agents may actually
favour the growth and spread of tumours. In the experimental
animal it has been shovm that pre-treatment with, or con-current
administration of, nitrogen mustard will suppress the antibody
response to typhoid antigen in the rabbit (Spier, l%-7). Philips
81
et al. (1947) found antibody response to a booster dose of antigen
! ' ■' .
in previously immunised goats was delayed in onset or decreased in
'
extent after pre-treatment with nitrogen mustard. Preston and
/ ^ N 82others (1960) found that there was no suitable reduction in the
natural resistance to the development of lymphosarcoma in rats when
treated with nitrogen mustard, but there was considerable depression
of/
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of this resistance with steroids, cyclophosphamides and
5-fluouracil. Similar results have been obtained by other workers,
using a wide variety of experimental animals including goats and
chickens, the most marked effects being obtained with such agents
as 6-mecapto-purine, cyclophosphamide, nitrogen mustard and
5-fluouracil. In eight patients with advanced malignant disease
Woodruff and Nolan (1965) showed that injections of homologous
splenic cells produoed detectable tumour regression in one case;
again suggesting the presence of an immune mechanism. Particular
note was taken throughout this study of any feature or event
which might suggest the existence of, or changes in, tumour-host
resistance. In this context, it was noted that within a short
time of commencing cytotoxic therapy six patients demonstrated
rapid and widespread dissemination of a previously slowly-grovdng
■
tumour. This suggests a possible break-down in host immunity
mechanisms in favour of the tumour. Proof of this is, however,
lacking and further study, of the problem is required. It was also
noted that many patients remained well and active with normal
appetite and increasing weight, despite a steadily growing and
progressively disseminating tumour. This commensal-like relation¬
ship between host and tumour suggests suppression of defence
mechanisms .the normal functioning of which might be responsible for
some of the features of the "cancer illness." Tumour growth




burden of maintaining active resistance and reserves are utilised
for other purposes. If this hypothesis is tenable, then much of
the negative nitrogen balance, the increasing weight loss,
toxaemia and the feeling of general malaise associated with cancer
may represent the toll of host resistance. „ final point of
interest is that in some cases the bulk of tumour found at post-
i i
mortem wa3 of a degree quite unsuspected clinically. Compared
with the post-mortem findings in a small group of comparable
patients by age and tumour type the increased bulk of tumour in
patients receiving anti-cancer drugs suggests that this feature is
of significance. It may again indicate a lowering of the host
resistance, favouring rapid growth of the widespread primary
tumour and the development of widespread metastases.
Incidence of Toxic Sffect3
The incidence of toxic effects, in relation to nature and
duration of drug treatment, in the patients studied is detailed
in Table 31.
The Significance of Toxic Effects
It has been repeatedly stated that anti-canccr drugs must be
given to "toxic levels" in order to produce clinical effect. The
development of toxic side-effects, however, implies impairment of
the patient's condition, the development of unpleasant symptoms, a
reduction /
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reduction in appetite, food intake and disturbances of fluid and
electrolyte balance from vomiting and diarrhoea. It is manifest >
therefore ,that the occurrence of toxic effects detracts from
the principle aim of treatment. This aim should be the production
of maximal palliation of the disease and its affects «ri.th minimal
distress to the patient. If tumour-host resistance is depressed
by cytotoxic therapy ,then it is again evident that more harm than
good may ensue by continuing treatment to toxic levels. The
belief that anti-cancer drugs must be given to toxic levels before
olinical response is produced ore-supposes that these represent
the most effective therapeutic levels. I believe that a good
response may be obtained *>d.th sub-toxic levels of a drug iin the
same proportion of patients as would be obtained with levels pro¬
ducing severe side-effects. As indicated by this study, only
20 to 30 per cant of patients treated will achieve significant
benefit from the use of cytotoxins. It is clearly undesirable to
subject the remaining to 80 per cent of pationt3 to the hazards
of high dosage therapy viien there is no possibility of benefit
being produoed. Throughout this study «n attempt has been made to
relate response to toxic effects and to obtain support for the
hypothesis that toxic levels are unnecessary to produce clinical
benefit. The incidence and severity of side-effects are closely
related to the agent used, the total dose given and the duration
of treatment. In some cases, however, they develop acutely and
closely /
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close: y mimic a hypersensitivity reaction. Severe and often fatal
effects may therefore appear within a short time of commencing
treatment, or may only develop after a prolonged period of
treatment during which the patient receives a large dose of
cytotoxins. This study has shown that sub-toxic levels of anti¬
cancer drugs are compatible with a good and sustained clinical
response, but it is equally clear that the most dramatic results
occurred in those cases receiving a large amount of drug over a
short period of time and who survived the development of severe
toxic effects such as bone marrow depression, vomiting, epigastric
pain and buccal ulceration. In some of these patients marked
tumour regression occurred and persisted for periods of up to six
months, during which small doses of maintenance therapy were con-
tinued. The distress occasioned by the occurrence of toxic
effects ,together with the period of in-patient treatment required
for their control, further support the belief that therapy should
aim at sub-toxic levels ao that the patient may remain active and
.
reasonably well while receiving treatment for an inevitably fatal
condition. Cancer chemotherapy should not be employed to pro¬
long a miserable existence.
■
IV Mechanisms of Production of Toxic Side Kffects
These may be summarised as follows
1. Direct irritant action on cells and tissues.
2. /
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2. Central effects on brain-stem centres.
3. Depression or inactivation of cell enzymes systems -
"cytotoxic" action.
4. Inhibition or antagonism of co-enzymes and other essential
metabolites in cellular metabolism.
5. Effects resulting from presence of breakdown products in
blood and urine.
6. Effects of action on specific cells, e.g. small lympho¬
cytes.
■
1. Direct Irritant Action
■
Certain of the cytotoxic agents, particularly those belonging
to the alkylating group, have a powerful irritant or vesicant
action on tissues. This is well demonstrated when even a small
amount of an e ant such as nitrogen mustard or mannitol mustard,
escapes into the tissues during an intravenous or intra-arterial
injection. An area of induration develops around the injection
site and extends into the surrounding tissues one or two centi¬
metres (Fig. 6 ), The centre of this area becomes necrotic and
breaks down to leave a shallow, indolent ulcer which may take many
weeks to heal. The irritant nature of these agents is also demon¬
strated by the frequency of superficial vein thrombosis following
the single injection of a large dose or repeated use of the same
j vein . Direct irritant action probably explains many cases of
J nausea /
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nausea, vomiting and diarrhoea associated with the use of cyto¬
toxic drugs. This is most likely to occur when the drugs are
administered by mouth.
2. Central Effects
Central effects on brain-stem centres probably account for
such features as nausea, vomiting and anorexia which occur almost
invariably on commencing cytotoxic therapy by whatever route.
The exact mechanism of these effects is unknown, but is possibly
related to changes in cellular tonicity.
3* Direct Toxio Action on Cell-enzyme Systems
Many of the toxio effects of anti-cancer drugs are due to
their action as non-specific cell-poisons Resulting in depression,
inactivation or destruction of cell enzyme systems and ultimately
to disruption of cellular metabolism. This "cytotoxic"action is
particularly marked on the nucleic acids and their precursors so
that the vital processes of cell division and reproduction are
disrupted and the cell destroyed. The wide distribution of cyto¬
toxic agents in all tissues accounts for many of the effects, such
as depression of bone marrow function, hair loss, disturbance of
cerebral function and ulceration of epithelial surfaces, which
accompany their use.




normal cells are mainly of a quantitative nature and only a few
minor differences have so far been discovered between the two types
of cell. It is unlikely, therefore, that drugs will be readily
discovered that will be effective against malignant ceils and
leave normal cells unharmed. The effects of cytotoxic agents on
normal cell3 will continue, therefore, to limit their usefulness f
but with further research it is to be hoped that exploitable dif¬
ferences between malignant and normal cells will progressively
emerge.
4. Inhibition or Antagonism of Essential Metabolites
The inhibition or antagonism of co-enzymes and certain metab¬
olites, essential to the economy of the cell, is the mechanism of
action of the antimetabolite group of agent3. They are particu¬
larly active against the rapidly dividing cells of the bone marrow
and gastro-intestinal mucosa and the development of severe toxic
effects is readily understood. Employed as effective agents in
the management of disorders of the reticuloendothelial system and
blood-forming organs, the margin between therapeutic and toxic
levels is small and limits dosage and duration of their adminis¬
tration.
5. Breakdown Products in Blood and Urine
The destruction of rapidly dividing cells results in an excess
of /
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of metabolic breakdown products, particularly potassium, uric acid
and amino acids, in the blood and urine. The use of cytotoxio
agents in highly sensitive tumours, for example, in lympho¬
sarcoma, may precipitate a state of acute mental confusion
■
associated with drowsiness and, in some cases, acute renal failure
from hyperuricaemia and the deposition of uric acid crystals in
the renal tubules. It is possible that less marked degrees of
cerebral disturbance, malaise and depression may result from the
presence of excess breakdown products, particularly potassium and
oertain amino-acids in the circulation. It has been noted in
this study that patients receiving a single large dose or infusion
of a cytotoxic agent have occasionally demonstrated such effects
and that in some of these the serum uric acid has reached levels
of two or three times normal.
6. Effects on Specific Cells
Many of the effects cxf cytotoxic drugs on the bone marrow-
may be explained on the basis of non-specific cell-poisoning,
but certain agents such as Busulphan (myleran) and chlorambucil
(leukeron) are particularly effective against specific cell lines
in the myeloid and lyaphdd series respectively.
If suppression of "immunity mechanisms" by cytotoxic drugs is
accepted, then it is possible that part of this effect results from




reticuloendothelial system. This is a problem which is currently
being studied by other workers and has not been elaborated in this
study.
In the lowering of resistance to infection, direct toxic
effects on cell metabolism in respiratory and genito-urinary
epithelium may play a part. It is also possible that the lowering
of mucosal resistance in such sites as the alimentary tract may
allow the ingress of viruses and other organisms which would
normally fail to cross cell barriers. This may account for the
few cases of influenzal-like illness, gastroenteritis and myo¬
carditis occurring in association with the use of cytotoxic drugs.
Ultimately, the effects of all tho anti-cancer drugs are demon-
strated on the metabolism of normal and malignant cells and it is
the balance required between therapeutic and toxic dose levels
which renders their use hazardous and demands repeated monitoring of
the peripheral blood count, liver function tests, protein and uric
acid patterns and reassessment of the olinical state.
V Management of Toxic Side Sffects
In the management of toxic effects resulting from the treatment
of cancer by drug3, two main measures may be applied. In the first
of these,an attempt is made to eradicate or minimise the incidence
and severity of side effects and, in the second, measures are
undertaken to control or combate the effects produced.
1. /
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1, Measures to Eradicate or Linimiae the Incidence and Severity
of Topd-o, Effecta.
a) Small-dose re/dme
The simplest measure is the use of small doses at repeated
intervals over short periods of time so that side effects are un¬
likely to develop. The therapeutic dose of many cytotoxic agents
is*however»very close, or even equal, to the toxic do3Q and good
results will seldom be obtained by using the drugs in this manner.
b) Reduction of dosage
A more effective means is the reduction of dosage as soon
as toxic effects, such as depression of white cell count, hair loss
or oral ulceration, first appear. Ifcr this means a good thera¬
peutic response may be obtained and the severity of the side effects
reduced. In some cases it is necessary to completely withdraw
treatment and resume, with smaller doses of the same drugs, when
toxic effects have subsided. Alternatively, treatment may be re¬
sumed with another agent of a related or different group. It has
been shown in this study, that further treatment can safely be given,
even after the development of severe toxic effects and that the
use of cytotoxic drugs in short intensive courses separated by
intervals of a few weeks or few months is an important means of
reducing the incidence and severity of such effects.
c) /
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c) Use of drug combinations
The use of two or more drugs in combination allows each
drug to be given in a smaller dose than would be effective if used
singly. Used in this manner*side effects of the individual drugs
may be minimised or eradicated. In this study the use of drug
combinations ha3 been particularly exploited and it can be seen
from Table 31 that the incidence of toxic effects in these cases
is less than when treatment has been maintained on a single drug.
A less effective means of reducing the incidence of toxic effects
is to stop treatment with one drug before signs of toxicity appear
and to oontinue treatment with another closely related agent.
The actions of similar drugs may, however, be 3ummated and while
the occurrence of side effects is occasionally delayed they are
not prevented.
d) Single dose infusion technique
Of less significance than depression of bone marrow
function or suppression of immunity, the occurrence of nausea,
vomiting, anorexia and diarrhoea frequently cause more distress
and disturbance to the patient. In an attempt to minimise these
effects the administration of a single large amount of drug,by
continuous intravenous infusion ovar a period of 24 to 36 hours *
has been undertaken in a number of patients in this series. During
the course of the infusion small regular doses of phenobarbitone or
chlorpromasine /
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jhlorpromazine have been given to produce a sedative-anti-eaetic
affect. There is some evidence that chlorproaazine may also act
as an un-coupling agent, permitting more effective action of such
87
irugs as cycloohosphaaide. It is therefore the anti-emetic of
» »
choice.
It has been found that the incidence and severity of nausea and
vomiting has been greatly reduced by the use of this technique and,
in mary cases they did not occur at all. Following a single dose
infusion, treatment has been resumed on an out- ;atient basis using
intermittent intravenous injection or oral maintenance therapy. The
dose given can then be maintained at subtcxic levels although the
accumulative effects of treatment over many months may result in a
slow,progressive depression of bone marrow function, loss of hair,
the development of a dry, scaly skin and other effects. Of all the
measures applied to reduce the incidence and severity of side
effects thi3 is at the same time the simplest and most effective.
It does, however, require that the patient should occupy a hospital
bed for a minimum period of 24 to 48 hours ^but even in a busy sur¬
gical unit this can usually be arranged.
e) Use of antagonists
The toxic effects of a few agents may be minimised by
using the drug in combination with its antagonist."52"Ke best known
example of such use is folinic acid (citro vorum factor) in
combination /
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combination with the folic acid antagonist methotrexate. Dy
saturating the normal tissues with folic aci~ it is hoped that
the effects of methotrexate on the normal cell vail be minimised
$
while its action on the malignant cell remains unaffected. This
technique has been widely used by other workers,but its efficacy
is doubtful and it has not been employed in this study.
f) Protection of bone marrow
Of the many toxic effects produced by using anti-cancer
drugs those on the bone marrow are possibly the most significant
and most serious. Any measure which will protect the bone marrow
is, therefore, of value. In this study this has been attempted
in a few cases by extraction of the bone marrow and replacing it
at some stage following the administration of cytotoxic agents.
There are two principal ways in which this technique was carried
out. a) In the first the bone marrow was extracted, stored at
4° C. for 24 hours, then immediately replaced by intravenous
infusion. During the period of 24 hours between extraction and
replacement, a single large dose of a cytotoxic drug is given by
continuous infusion. Thi3 technique was carried out in 5 patients
vdth no serious consequences and in 3 with obvious benefit from
reduction in incidence and severity of side effects. In the second
method bone marrow was extracted, concentrated, sealed in 20ml.
ampoules and a total cell count carried out. The marrow was then
cooled /
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cooled in step-wise manner to minus 79° C. and stored at this temp¬
erature. The marrow can be maintained in a viable state for up to
three months at this temperature. Chemotherapy was then adminis¬
tered parenterally or by mouth over a period of weeks or months
until toxic effects appeared^when the patient's bone marrow was
taken out of storage, rewarmed and replaced. In those cases in
which toxic effects did not develop within the period of marrow
viability, the marrow was used for homologous transfusion in any
genotypically related patients demonstrating severe effects. This
technique of marrow extraction and storage was employed in 12 cases,
but autologous marrow was replaced in only 3 cores and homologous
marrow in 2 cases.
With the use of autologous marrow, replaced after twenty-four
hours storage, no adverse reactions were observed. In one case of
autologous marrow replacement after a period of two months' storage
the patient (Case No. 31) complained of mild headache, slight
sweating and precordial discomfort but no other significant effects.
In two cases receiving homologous marrow replacement after periods
of ten and twelve weeks' storage, sweating, precordial discomfort
and pyrexia developed. In one of these the symptoms were sufficient¬
ly severe to abandon the infusion after 200 ml, had been replaced.
The techniques of bone mrvo. extraction, storage and replace¬
ment are detailed in appendix II I,but no obvious benefits accrued
from this method and because of the time, C03t, and hazards involved,
its /
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its use was ultimately abandoned.
Autologous Splenic Tissue
Injection of autologous splenio tissue has been employed by
Woodruff and Nolan (1965) as a means of obtaining regression in
cases of advanced malignant disease. On the basis that the spleen
may be the site of anti-tumour antibodies, this would seem a
rational method of reducing the incidence and severity of toxio
effects. This technique has not, however, been employed in the
study and its indications would appear limited.
2. Measures for the Control of Existing Side Effects
Many supportive measures may be employed to control the side
effects of cytotoxic therapy.
a) Antibiotics
The use of appropriate antibiotics to treat chest or urine
infections, wound infections, and skin lesions has an obvious place.
b) Haematinios
The control of anaemia by haematinics, including iron,
vitamin and folic acid, is essential.
°) Blood transfusion
The timely use of blood transfusion nay x»estore not only
the /
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the haemoglobin level but also a degree of vigour and vitality
beyond that which might be expected. The discriminate use of
blood transfusion may also allow continued treatment when bone
marrow depression, low peripheral blood counts and a poor general
state would otherwise require its withdrawal,
d) Nutritional factors
Protein supplements, vitamins and a high calorie diet
are readily prescribed and the patient should, be encouraged to
continue their use.
e) Short in-patient periods
If toxic effects are severe, then a few days in hospital,
during which intravenous therapy, blood transfusion and appropriate
sedation are employed, will do much to alleviate distress and
restore the patient to a state where out-patient treatment may be
continued.
f) Anti-emetics and analgesics
Anti-emetics such as ohlorpromazine, promazine and
stemetil| analgesics such as aspirin, codeine and periston, and
gastro-intestinal sedatives such i s nacton and probanthine all play




The proper use of supportive measures in the control of
the effects produced by anti-cancer drugs offers a wide scope
for the considerate praotice of good medical care.
Much can, therefore, be done to reduce the incidence and
severity of toxic effects and to relieve the distress and
discomfort occasioned by those that develop. It remains the
responsibility of the physician, however, to ensure that the
most effective agent with the least likelihood of producing
severe or irreversible damage is being used, in a suitable dose,
by the most appropriate route. /
c) Significance of Hepatic Metastases
Forty-two patients (4©?o) in this series were known or believed
to have metastases in the liver. The significance of hepatic
metastases in relation to cancer chemotherapy, requires further con¬
sideration.
It has been stated that jaundice or extensive hepatic metastases
contra-indioate /
102.
contra-in&ioate the use of cytotoxic agents. In that they act on all
'
rapidly dividing cells, the effect of cytotoxins on the remaining
liver parenchyma in these cases, is likely to precipitate hepatic
failure. It can be seen from the results of the liver function tests,
Table 25, however, that only a few cases in this study demonstrated
evidence of impaired hepatic function following the use of cytotoxic
drugs, even in large doses over long periods of time. Three cases
were jaundiced prior to commencing cytotoxic therapy. In two of
these the condition rapidly deteriorated, but in the third, reduction
in size and tenderness of palpable liver metastases, was associated
with resolution of the jaundice.
It must, however, be accepted that when marked impairment of
liver function results from the presence of extensive metastases,
j
cytotoxic agents are unlikely to produce benefit and they may pre¬
cipitate hepatic failure. Such cases, are usually in the terminal
stages of their illness and should not be considered far cytotoxic
therapy.
The presence of hepatic metastases has been said to increase the
incidence and severity of toxic effects due to the inability of the
liver to metabolise the drugs or to remove excess breakdown pro¬
ducts from the blood. From details contained in Tables 1-19 and
Table 31 it can be seen, however, that there is no increase in the
incidence or severity of toxic effects in patients with metastases




develop toxic effects at any stage. This merely confirms that,
providing the stress is not too severe or prolonged, the presence of
even a small amount of functioning hepatic tissue is a, equate for
most metabolic purposes.
Finally, the changes occurring in the 2 globulin fraction of
the serum electrophoretic pattern have been attributed to changes
in hepatic function and to the presence of hepatic metastases. It
can be seen from Table 29 that the presence of hepatic metastases
is not directly related to changes in the ,/JZ. globulin level. A
point of interest arising from Tables 28 and 29 is the correlation
between the presence of metastases in the liver and simultaneously
elevated levels in all three; liver function tests, 2 globulin
and serum uric acid levels.
The significance of hepatic metastases may be summarised as
follows:- when present to an extent causing severe impairment of
hepatic function, they are usually related to an advanced stage of
the disease and cytotoxic agents should not be exhibited. When
present in lesser degree, cytotoxins may be safely used without
causing further impairment of hepatic function. The influence of
hepatic metastases and impaired hepatic function on the patterns of
the
t j 2 globulin is uncertain but does not appear to be direct.
There is no increase in the incidence or severity of side effects
in those patients with hepatic metastases compared to those without.
Causes of Death /
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Causes of Death
Seventy-eight patients (76)) of total series) died during the
course of this study. In 42 of these (5*$ of those dying) post¬
mortem examination was carried out. The principal cause of death
recorde&was "Progress of Disease" and 46 of the 76 patients (59a»)
died from the direct effects of primary or metastatic malignant
disease. A further 16 patients (20))) died from cardio-respiratory
failure - mostly bronchopneumonia accelerating an otherwise inevit¬
able end.
The remaining 16 cases (20))) died at a stage in the progress of
their disease when cancer was not the immediate cause of death. In
some of these, death was sudden and occurred unexpectedly when the
prognosis was otherwise in terms of several months. Gram negative
septicaemia was considered the possible cause of death in 8 of these
16 cases and in two was established by blood culture. The remaining
patients (8 of 78) were positively harmed by the use of anti-cancer
drugs and died from haemorrhage, complete bone marrow failure or
renal failure. It must be accepted, therefore, that the use of
cytotoxic agents vdll be associated with an accelerated death in a
small percentage of the patients treated. Preventable deaths,
however, must be avoided when dealing with cancer as with any other
oondition. While the majority of cases died as a direct result of
their disease, it is essential that effective supportive therapy is
administered to prevent deaths from other causes, at a stage when the
patient remains otherwise well and active.
ASPECTS OF CANCER CHMOTHERAFY
SECTION VII
CONCLUSIONS
Fiages 105 - 108.
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CONCLUSIONS
The results of treating malignant disease by chemical means
leave much to be desired. The agents at present available, if
administered in adequate dosage, with careful attention to the avoid¬
ance of toxic effects and to the correction of associated disorders,
will produce worthwhile benefit in 20-30# of the oases treated.
Occasionally a dramatic result is obtained which provides encourage¬
ment to continue.
Effectiveness may be improved and toxicity reduced by using
cytotoxic agents in combination and by delivering them in high local
concentration to the tumour. A few agents, e.g. 5-fluor©uracil, are
best given in intermittent courses, but the majority are best admin¬
istered by an initial in-patient intravenous, intra-arterial or
intra-cavitary course, followed by out-patient oral or intravenous
maintenance therapy.
The prevention of tumour spread and implantation is an important
indication for the use of cytotoxins, but the principal aim of
cancer chemotherapy must remain the control of distressing symptoms
resulting from advanced malignant disease. To protract a miserable
existence is unjustifiable. These agents should never be used for
this purpose, nor exploited in terminal patients. A few cases of
prolonged remission are reported, but in the majority of cases re¬
mission lasts a few months at the most before the disease pursues an
unrelenting course. Once tumour remission has been obtained and
recrudescence /
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recrudescence occurs, it is unlikely that a further gcod response
will be obtained by using another agent of the sane or different
group.
Cancer chemotherapy is of definite benefit in malignant diseases
of the retieulo-ondothelial and haemopoietic systems and of the breast
ovary and lung. Less benefit is obtained in tumours of the gastro¬
intestinal and genito-urinary tracts, but chemotherapy still has a
useful part to play in their management. Occasional benefit may
derive from the use of cytotoxic agents in cancer of the pancreas
and testis, and in malignant melanomas, but they are of no value in
oesophageal, laryngeal and adrenal carcinomas.
Sophisticated techniques, such as arterial perfusion and autolo-
gous bone marrow replacement, play little part in the over all use of
cheraotherapeutic agents in the management of malignant disease. This
study is an attempt to demonstrate the value of cancer chemotherapy,
practiced largely on an out-patient basis, using simplified techniques
and avoiding the cost of expensive equipment and prolonged periods of
hospital treatment.
Assessment of response is one of the most difficult aspects of
treating cancer by drugs. It requires objective unbiased means of
measuring change in size or activity of a tumour or its metastases and
the determination of biochemical changes in blood and urine appears
the most fruitful line for further research. In the final assessment
of response to chemotherapy, quality of life is of more importance
than length of survival and the only criterion of success is the
extent /
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extent by whioh a patient's endurable and useful life is prolonged.
The incidence and severity of toxic effects remains the limiting
faotor in the application of oheoical agents to the management of
malignant disease. It is, however, considered that they can be pre¬
vented, minimised or controlled by using sub-toxic dose levels and by
meticulous attention to supportive therapy. Toxicity is not an accu¬
rate index of therapeutic activity and the occurrence of severe toxic
effects detracts from the principal aim of cancer chemotherapy. The
development of mild to moderate bone-narrow depression i3 not necessa¬
rily an indication to cease treatment and, in some cases, treatment
may be safely resumed even after the occurrence of severe toxic
effects.
The possibility that cytotoxic agents may produce harmful sup¬
pression of body "defence mechanisms", requires further research,
but this aotion may also permit a commensal-like relationship to exist
between tumour and host. The tumour continues to grow and to metas-
"? / .. .
tasise, but the patient remains active and apparently well for many
weeks or months.
When present in sufficient degree to cause severe impairment of
function, hepatic metastases are usually associated with an advanced
stage of the disease and cytotoxic agents should not be employed. If
there is little or no impairment of liver function, the presence of
<
metastases does not contra-indicate their use and they are unlikely to
produce a higher incidence of toxic effects.
The management of advanced cancer requires close co-operation
between /
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between general practitioner, surgeon, radiotherapist and. physician.
Patient and relatives must bear the immensity of the human problems
involved and require every assistance. The place of chemotherapy in
this pattern, is in the control of the disease when other modalities
of treatment are no longer effective or cannot be employed. Its use
requires specialised knowledge of the agents available, the methods
and routes of administration, dosages and toxic effects.
The ideal agents have not yet been found, but chemotherapy offers
an avenue for at least the symptomatic relief of certain malignant
conditions. The patient should not be allowed to die of intercurrent
infection or toxic effects simply because the underlying disease is
cancer. The opportunity to remain active and at home, the control
of pain, bleeding, discharge and other distressing symptoms and the
moral-lifting affect of an interested medical attendant, justify the
continued use of chemotherapy in canoer.
The approach to the future is beautifully defined in the words
of Gordon Gordon-Taylor:-
" *the vision splendid,' which for us is that
long desired day, perhaps not too far distant, \dien in
the cure of cancer gross mechanical destruction and cruel
mutilation of human tissues 3hall no longer be required,
nor the scorching methods and machinery of Hephaestus the
blacksmith god, or Prometheus who stole fire from heaven!
"When the biologist shall know the laws that govern cell-
growth with a knowledge akin in its sweep and accuracy to
that of the astronomer," he will then have a power denied
to those who scan the stars in the firmament, and that









A total of 107 cases (62 male and 45 female),with histologically
proven malignant disease and all receiving cytotoxic therapy were
studied.
A brief review of the history of cancer chemotherapy is given >
together with a detailed account of the principal agents currently
available, methods and routes of administration, means of assessing
response to treatment and the necessary routines of investigation.
The results obtained are presented,mainly in tabular form.
Assessment of response, incidence, severity, significance, mechanisms
and management of toxic effects, the significance of hepatic metas¬
tases and causes of death in relation to oancer chemotherapy, are
discussed in detail.








The care of cancer patients can never be the responsibility of
one individual or of one discipline. It would be impossible to nam®
the many people to whom I owe a debt for the final preparation of
■
this manuscript.
I am, however, particularly indebted to the Director General of
Medical Services, Royal Mr Force, to Air Vice Marshal Sir Peter
Dixon (retired), Consultant in Surgery and to ay foamier colleagues
in the Royal Air Farce Medical Branch for the initial stimulus to
study the problems of cancer chemotherapy and for permission to draw
freely on my eacperiaroeswhile serving as a Surgical Specialist at the
Royal Air Force Hospital, Uxbridge, Middlesex.
.
My immediate debt is to Sir John Bruce, Regius Professor of
Clinical Surgery in the University of Edinburgh y/ho has constantly
encouraged my endeavours and has allowed me to study all cases ad¬
mitted to his charge in the Rcyal Infirmary of Edinburgh. In this
context I would like to espress ay gratitude to senior colleagues in
the Department of Clinical Surgery, in other units in the Royal
Infirmary and in other local hospitals for case material included.
% limited knowledge of Radiotherapy and Ra&Lotherapeutic
techniques was gained at the clinics of Sir Brian '.Tindoyer at the




The filial burden has been borne by the secretarial staff
(Mrs W. Thomson, Mrs K. Robertson, Miss J. Ross, Miss R. Sutherland
and Mrs H. Cockburn) and the technical staff (Mr IT. Samuel,
Mr A. Patterson, Mr D. Dirom and Mr C. Thomson) of the Department
of Clinical Surgery. To these I owe a lasting gratitude.




1. Cooper, Sir Astl^y (1825), "Lectures on the Principles and
Practice of Surgery',' 2, 193.
2. Knock, F.E. (1964). Surg. Gynec. Obstet.. 119. 1091
3. Spier, C.L. (1947). Rroc, Soc. exp. Biol.. 64. 259.
4. V/alshe, V/.H. (I846). "The Nature and Treatment of Cancer,"
London, 193-220.
5. Ravdin, R.G. and EUdLns, W.L. (1962), Surg. Clin. N, Amer..
itO, 1641.
6. Osier, Sir Y/illiam (1958). Ann, roy. Coll. Surg. Engl..
6, 430.
7. Cushing, H. (i960). Ann, roy. Coll. Surg. Engl.. 4. 259.
8. Heller, J.R. (1962). Bull. N.Y. Acad. Med.. 38. 348.
9. Haagensen, C.D. (1933). Amer. J. Cancer. 18. 42.
10. Guthrie, D. (1945). "A History of Medicine," Edinburgh:
Thomas Nelson.
11. Stone, W.S. (1916). N.Y. med. Record. 90. 628.
12. Y/alker, J. (1948), Brit, med. Bull.. 5. 361.
13. Stftrck, C. (1762). "Essay on the Medicinal Nature of
Hemlock," Edinburgh,
14. Haddow, A. (1947). Brit, med. Bull., 2$., 417.
15. Haddow, A, (1963). "The Contribution of Chemistry to
Cancer Research: in Chemistry in the Service of Medicine,"
London: Pitman.
16. Blair Bell, W., Woolfenden, H.F., Williams, W.R., Cunningham,!.
and Herd, S.B, (1926). Lancet. 1, 537.
17. Dobson, J. (1959). Ann, roy. Coll. Surg, Engl... 25. 176.
18. Adair, F.E. and Bagg, H.J. (1931). Ann. Surg., 190.
19./
19. Oilman, A, and Philips, F.S. (1946), Science. 103. 409.
20. Gilman, A, (1963). Amer, J, Surg.. 105. 574.
21. Ehoads, C.P, (1946). J. Amer. med. Ass.. 131. 656,
22. Goodman, L»S,, Wintrobe, M.M., Dameshek, W», Goodman, M.J,,
Gilinan, A. and McLennan, M.T. (1946), J. Amer. med. Ass.
132. 126.
23. Rhoads, C,P,, Kamofsky, D.A,, Burchenal, J.H, and
Craver, L.F. (1950), 'Iran3. Ass. Amer. Phvcns. 63. 136,
24. Farber, S,, Toch, R., Sears, E.M. and Finkel, D. (1956).
"Advances in Chemotherapy of Cancer in Man. In
Greenstein, J.P. and Haddon, A. (eds): Advances in
Cancer Research," vol. 4, New Yorkj Academic Press.
25. Bavies, A. (1964), "The Use of Cytotoxic Agents in
Surgery in Recent Advances in Surgery," 6th ed.,
p. 64. London: Selsyn Taylor.
26. Waksnan, S.A. and Woodruff, H.B. (1940). Proc. Soc. exn.
Biol.. Jj£, 609.
27. Johnson, I.S., Wright, H.F. and Svoboda, G.H.(l959).
J. Lab, clin. Med,. 54. 830,
28. Rose, F.L., Hendry, J.A. and V.alpole, A.L. (1950).
Nature. 165. 993.
29. MacGregor, A.B. (1966). Med. Hist.. X, 374.
30. Hertz, R., Bergenstal, D.M., Lipgett, M.B., Price, E.B.
and Hilbish, T.F, (1959). J. Amer. aed. Ass. 168. 845.
31. Watne, A. (1962). iiaisJLSaJLuilSS., j£2, Part 2, 2133.
32. Parker, S.W.L. (1867). "The Modern Treatment of Cancerous
Disease by Caustics or Enucleation," London: John
Churchill and Sons.
33. Sykes, M.P., Philips, F.S. and Kamofsky, D.A. (1956).
Med. Clin. N. Amer.. 40. 837.
34. Heidelberger, C. et al. (1957). Nature. 179. 663.
35. Dobson, L. (1962). Amer. J. Surg*. 104. 143.
36. Y/eiss, A.J. and Jackson, L. (1961). Amer. J. Gastroent..
J55, i38.
37. Tan, L.T.C., Dargeion, H.W. and Burchenal, J.H. (1959).
Pediatrics. 24. 544.
38. Huggins, C.B. (1956). Cancer Res.. 16. 825.
39. Golomb, F.M. (1963). Amer. J, Surg.. 105. 579.
40. Weisberger, A.S. (1958). Ann. N«Y. Acad. Sci,. 68. 1091.
41. Rundles, R.W., Laszlo, J., Garrison, F.E. and Hobson, J.B.
(1962). Cancer Chemother. Rep.. JL6, 407.
42. Arnold, H. and Bourseaux, F. (1958). Angew. Cheraie. 70. 539
43. Creech, 0. and Krementz, E.T, (1964). J. Amer. med. Ass..
188. 855.
44. Bergel, F, and Stock, J.A. (1953). "Cytotoxic Alpha
Amino Acids and Peptides," Thirty-first Annual Report
of the British Empire Cancer Campaign, JS1, 6,
45. Larionov, L.F., Sckodinskaja, E.N., Troosheikina, V.I.,
Khokhlov, A.S., Vasina, 0.S, and Novidova, M.A. (1955).
Lancet. 2, I69.
46. Sellei, C. and Eckharots, S, (1958). Ann. II.Y. Acad. Scl..
68, 1164.
47. Rundles, R.W.. et aL. (1959). Amer. J. Med.. 27 . 424.
48. Everett, J.L., Roberts, J.R. and Ross, W.C.J. (1953).
J, Chem. Soc.. 2386.
49. Schell, R.F. and Hall, B.E. (1958). Surg. Gynec. Obstet..
106. 459.
50. Shay, H,, Zarafonetis, C,, Smith, N,, Woldow, I. and Sun, D.C
(1953). .■.Arch, intern. Med., 92. 628.
51. Li, M.C., Hertz, R, and Spencer, D.B. (1956). Proc. Soc.
exp. xiiol.. jd . 361.
52./
52. Sullivan, R.D., Miller, E. and Sikes, M.P. (1959)•
Cancer. 12. 1248,
53. Duff, J.K., Sullivan, R.D., Miller, E., Ulm, A.H.,
Clarkson, B.D, and Clifford, P. (1961), Canoer. 14. 744#
54. Thomson, J.W.W., Wilken, B.J, and MacGregor, A.B, (1966).
Ninth International Cancer Congress - Tokyo, p. 449.
55. Mrazek, R., Economov, S. McDonald, G.O., Slaughter, D.P,
and Cole, W.H. (1959). Ann, Surg.. 150 . 745.
56. Cruz, E.P., McDonald, G.O. and Cole, W.H. (1956). Surgery.
291.
57. Roberts, S.S., Watne, A.L., Mc&rew, E.A., Mc&rath, R.&.,
Nands, S. and Cole, W.H. (1958). Surg. Forum. 8, 14i>.
58. Watne, A.L., Moore, &.E., Nadler, S. and Ross, C.A. (1962).
N.Y. J. Med.. 62 (21) 3387.
59. Quo, M,, OkajJima, K., Sakakibara, N. and Karaeyana, H. (1961).
J. Jap. Rract. Surg.. 22 (6), 26.
60. Mrazek, R,, Economov, S,, McDonald,.G.O., Slaughter, D.P.
and Cole, W.H. (1964). Univ. Intern. Contra. Cancer
Acta.. 20. 5U.
61. Engell, H.C. (1955)* Acta, chir. Scand., suppl. 201.
62. Moore, G.E.. et al. (1957). Ann. Surg.. 146. 580.
63. Henne, H.P. (1962). Zbl. Chir.. 87 (34), 3469.
64. Denk, W», Karrer, K. and Wurnig, P. (1964). Acta. XX. 64.
65. Moore, G.E., Ross, A. and Stiver, R.B. (1963). Amer. J.
Surg., 2S&, 591.
66. Schlosser, J.V., Ryan, A.P. and Krementfc, E.T. (1961).
Proc. Amer. Ass, Cancer Res.. JS, 266.
67. Goldin, A. and Mantel, N, (1957). Cancer Res.. 17. 635.
68. Boyland, E. (1963). Proc. roy. Soc, Med.. 56. 640.
69./
69. Burchenal, J.H. (1964). Acta. XX. 33.
70. Wilken, B.J. and Thomson, J.W.W. (1966). Brit. J. Surg..
10.
71. Bierman, H.R., Byron, R.L. and Kelly, K.H. (1951).
Cancer Res.. 11. 236,
72. Irvine, V/.T. (1962). "Regional and Total Body Perfusion
of Malignant Tumours with Cytotoxic Drugs in Modern
Trends in Surgery," 1st ed., p.164. London: Butterworthn.
73. Golomb, M., Salmons, P. and Wright, J.C. (1964). J. Amer.
med. Ass.. 118. 225.
74. Stehlin, J.S., et al. (i960). Arch. Surg.. 80. 934.
75. Mckenzie-Pratt, R. and Betteridge, T.J. (1962). Pfroc. roy.
Soc. Med..J£, 921.
76. Presnov, M.A. (1964). Acta. XX. 126.
77. Green, H.N., Wakefield, J. and Li.tlewood, G. (1957).
Brit, med. J.. 2, 779.
78. Vaitkevicius, V.K., Talley, R.W., Brennan, M.J. and Kelly, J.31.
(1961). J. Michigan med. Soc.. 60. 492.
79. Wilken, B.J. (1965). "Protein and Uric Acid Patterns in
Malignant Disease," Edin. Univ. Library.
80. Sunderman, F.W. (1964). Amer, J. Clin. Path.. 42. 1.
81. Philips, F.S., Hopkins, F.H. and Freeman, M. (1947).
J. Immunol.. 55. 289.
82. Preston, F.W., Jackson, E.L., Henegar, G. ana Schrek, R.
(I960). Ann. Surg.. 152. 594.
83. Schwarts, R., Stack, J. and Dameshek, W. (1958). Proc. Soc.
exp. Biol.. 22»
84. Kreraentz, E.T. and Knudson, L. (1961). Surgery. 50. 26.
85. White, L.P. (i960). Science. 151. 1041.
86. Costakel, 0. (1964). Acta. XX. 54.
87. Bacigalupo, G. (1964). Acta. XX. 52.
ASPECTS Off CMGSR CMEMOTHEfciFY
SECTION XI
APPENDICES
APPENDIX It ABBREVIATIONS USED THROUSIOOT.
APPENDIX II: NORMAL VALUES OP LIVER FUNCTION
TESTS, FROTE3NS, SERUM ELECTRO¬
PHORESIS AND URIC ACID.
APPENDIX III: TECHNIQUES OP BONE MARROW EXTRACTION,
STORAGE AND REPLACEMENT.
APPENDIX IV: COMPLETE LET OP TABLES,
APPENDIX I
ABBREVIATIONS USED THROUGHOUT
A. Cancer Chemotherapeutic Agents
1. Nitrogen Mustard ». ,, •• .. •• N. .
2. Cyclophosphamide .. .. .. •• .. C. .
3. Phenyl-Alanine Mustard .. .* «. P.
(Melphelan)
4* Mannitol Mustard .. .. .. .. .. D.
(Degranol)
5. Uracil Mustard ,, .. M •• •• U.
6. Chlorambucil „ •• •• •• .. Cl.
(Leukeran)
7. Tri-Ethylene-Thiophosphoramide .. Th.
(Thiotepa)
8. Ethoglucid .« .. .. .. .. E.
(Epo^yl)
9. Busulphan .. .. .. ♦, .. My.
(jflyleran)
10. Methotrexate .. M.
11. 6-Wercapto-Purine M.P.
12. 5-Eluouracil .. •• .• .. .. F.
13. Vinblastine Sulphate .. .. ». .. V.
14. 2-Etlyl-f^ydrazine .. .. .. E.H.
13. Thiocolciran Tc.
16. Imuran .. .• .. .. .. I.
B. Systems
1. Cardiovascular System .. .. .. C.V.S.
2. Respiratory System .. .• .. .. R.S.
3. Castro-Intestinal Systen/Tract .. C.I.S/T.
4. Gastro-Urinary Systern/Tract ,, .. G-.U.S/T,
5. Reticuloendothelial System .. ., R.E.S.
C. Others
1. Post-Mortem .. .. .. ,. .. P.M.
2. Intravenous Injection .. .. .. I.V.I.
3. Tntre—Musc'ulsr Injection «, ». ,, T.M.T,
APPENDIX II
NORMAL VAUUKS OF LTVIlt FUNCTION TESTS. PROTPINS.
SEBUM llKCTROTHOIfcSIS AND URIC ACID




















< 1£$ after 30 minutes
< yji after 45 minutes
* Local Laboratory Values


















1* After ounderman (1964): results = mean - standard deviatii
2* After Albert Recht (1959): results = "X" - x standard .
deviation
3* Serum Uric Acid
Mean Value = 3*7 tag/100 ial»+
Range = 1*0-5*0 mg/100 ml*
+After Jamieson and Kay, 1965*
an
APPENDIX III
Techniques of Bone-Marrow Extraction. Storage and Replacement
(a) Bone-Marrow Extraction.- With the patient
anaesthetised, bone-marrow was extracted from sternum,
anterior and posterior iliac spines and from the sacrum
by multiple punctures using a wide bore aspirating needle.
The needle w&a connected through a three-way valve to a
suction machine through-a collecting bottle and a bottle
of sterile tissue culture fluid. By this technique
quantities of 400-600 ml. of marrow could be obtained which,
when separated from the tissue culture fluid and concentrated,
yielded between 50 and 70 ml. of marrow concentrate.
(b) Bone-marrow storage and replacement.- The
extracted mar-row was first separated from tissue culture
fluid and concentrated to a volume of 50 to 70 ml. Small
amounts of heparin were added during extraction to avoid
clotting. The marrow was then gradually cooled over a
period of two hours to a temperature of -79°C, a temperature
achieved by freezing with carbon dioxide snow. A small
amount of the marrow was extracted for subsequent genotyping
and the remainder held at a low temperature until required.
In those cases in which the marrow was to be replaced after
twenty-four hours, the extracted specimen was again
concentrated, but was rapidly cooled to 4°0 and held at this
temperature for the required period.
Whei/
When required for replacement the marrow was reconstituted
with normal saline 200-^00 ml. and slowly infused over a period
of two to four hours using a wide bare needle in a large vein.
The patient was carefully observed for the occurrence of
t
reactions during and for twenty-four hours after the infusion.
Although the benefits of long-term marrow storage appeared
minimal and the: technique was largely abandoned, the value
of replacement after twenty-four hour storage was felt to
warrant its continued use in selected cases.
APPENDIX IV
CHEMOTHERAPY OF CANCER
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